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UPDATE STATEMENT 
A Toxicological Profile for Barium and Barium Compounds, Draft for Public Comment was released in 
September 2005.  This edition supersedes any previously released draft or final profile.   
Toxicological profiles are revised and republished as necessary.  For information regarding the update 
status of previously released profiles, contact ATSDR at: 
Agency for Toxic Substances and Disease Registry  
Division of Toxicology and Environmental Medicine/Applied Toxicology Branch 
1600 Clifton Road NE 
Mailstop F-32 
Atlanta, Georgia 30333 
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FOREWORD
This toxicological profile is prepared in accordance with guidelines developed by the Agency for 
Toxic Substances and Disease Registry (ATSDR) and the Environmental Protection Agency (EPA).  The 
original guidelines were published in the Federal Register on April 17, 1987. Each profile will be revised 
and republished as necessary. 
The ATSDR toxicological profile succinctly characterizes the toxicologic and adverse health 
effects information for the hazardous substance described therein.  Each peer-reviewed profile identifies 
and reviews the key literature that describes a hazardous substance's toxicologic properties.  Other 
pertinent literature is also presented, but is described in less detail than the key studies.  The profile is not 
intended to be an exhaustive document; however, more comprehensive sources of specialty information 
are referenced. 
The focus of the profiles is on health and toxicologic information; therefore, each toxicological 
profile begins with a public health statement that describes, in nontechnical language, a substance's 
relevant toxicological properties. Following the public health statement is information concerning levels 
of significant human exposure and, where known, significant health effects.  The adequacy of information 
to determine a substance's health effects is described in a health effects summary.  Data needs that are of 
significance to protection of public health are identified by ATSDR and EPA.  
Each profile includes the following: 
(A) The examination, summary, and interpretation of available toxicologic information and 
epidemiologic evaluations on a hazardous substance to ascertain the levels of significant 
human exposure for the substance and the associated acute, subacute, and chronic health 
effects; 
(B) A determination of whether adequate information on the health effects of each substance is 
available or in the process of development to determine levels of exposure that present a 
significant risk to human health of acute, subacute, and chronic health effects; and 
(C) Where appropriate, identification of toxicologic testing needed to identify the types or levels 
of exposure that may present significant risk of adverse health effects in humans. 
The principal audiences for the toxicological profiles are health professionals at the Federal, State, 
and local levels; interested private sector organizations and groups; and members of the public.   
This profile reflects ATSDR’s assessment of all relevant toxicologic testing and information that 
has been peer-reviewed. Staff of the Centers for Disease Control and Prevention and other Federal 
scientists have also reviewed the profile. In addition, this profile has been peer-reviewed by a 
nongovernmental panel and is being made available for public review.  Final responsibility for the 
contents and views expressed in this toxicological profile resides with ATSDR. 
 vi 
The toxicological profiles are developed in response to the Superfund Amendments and 
Reauthorization Act (SARA) of 1986 (Public Law 99-499) which amended the Comprehensive 
Environmental Response, Compensation, and Liability Act of 1980 (CERCLA or Superfund).  This 
public law directed ATSDR to prepare toxicological profiles for hazardous substances most commonly 
found at facilities on the CERCLA National Priorities List and that pose the most significant potential 
threat to human health, as determined by ATSDR and the EPA.  The availability of the revised priority 
list of 275 hazardous substances was announced in the Federal Register on December 7, 2005 (70 FR 
72840). For prior versions of the list of substances, see Federal Register notices dated April 17, 1987 
(52 FR 12866); October 20, 1988 (53 FR 41280); October 26, 1989 (54 FR 43619); October 17, 1990 (55 
FR 42067); October 17, 1991 (56 FR 52166); October 28, 1992 (57 FR 48801);  February 28, 1994 (59 
FR 9486); April 29, 1996 (61 FR 18744); November 17, 1997 (62 FR 61332); October 21, 1999 (64 FR 
56792); October 25, 2001 (66 FR 54014); and  November 7, 2003 (68 FR 63098). Section 104(i)(3) of 
CERCLA, as amended, directs the Administrator of ATSDR to prepare a toxicological profile for each 
substance on the list. 
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QUICK REFERENCE FOR HEALTH CARE PROVIDERS 
Toxicological Profiles are a unique compilation of toxicological information on a given hazardous 
substance. Each profile reflects a comprehensive and extensive evaluation, summary, and interpretation 
of available toxicologic and epidemiologic information on a substance.  Health care providers treating 
patients potentially exposed to hazardous substances will find the following information helpful for fast 
answers to often-asked questions. 
Primary Chapters/Sections of Interest 
Chapter 1: Public Health Statement: The Public Health Statement can be a useful tool for educating 
patients about possible exposure to a hazardous substance.  It explains a substance’s relevant 
toxicologic properties in a nontechnical, question-and-answer format, and it includes a review of 
the general health effects observed following exposure. 
Chapter 2: Relevance to Public Health: The Relevance to Public Health Section evaluates, interprets, 
and assesses the significance of toxicity data to human health. 
Chapter 3: Health Effects: Specific health effects of a given hazardous compound are reported by type 
of health effect (death, systemic, immunologic, reproductive), by route of exposure, and by length 
of exposure (acute, intermediate, and chronic).  In addition, both human and animal studies are 
reported in this section. 
NOTE: Not all health effects reported in this section are necessarily observed in the clinical 
setting. Please refer to the Public Health Statement to identify general health effects observed 
following exposure. 
Pediatrics: Four new sections have been added to each Toxicological Profile to address child health 
issues: 
Section 1.6 How Can (Chemical X) Affect Children? 
Section 1.7 How Can Families Reduce the Risk of Exposure to (Chemical X)? 
Section 3.7 Children’s Susceptibility 
Section 6.6 Exposures of Children 
Other Sections of Interest: 
Section 3.8 Biomarkers of Exposure and Effect 
Section 3.11 Methods for Reducing Toxic Effects 
ATSDR Information Center  
Phone:  1-800-CDC-INFO (800-232-4636) or 1-888-232-6348 (TTY)   Fax: (770) 488-4178 
E-mail: cdcinfo@cdc.gov Internet: http://www.atsdr.cdc.gov 
The following additional material can be ordered through the ATSDR Information Center: 
Case Studies in Environmental Medicine: Taking an Exposure History—The importance of taking an 
exposure history and how to conduct one are described, and an example of a thorough exposure 
history is provided.  Other case studies of interest include Reproductive and Developmental 
Hazards; Skin Lesions and Environmental Exposures; Cholinesterase-Inhibiting Pesticide 
Toxicity; and numerous chemical-specific case studies. 
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Managing Hazardous Materials Incidents is a three-volume set of recommendations for on-scene 
(prehospital) and hospital medical management of patients exposed during a hazardous materials 
incident. Volumes I and II are planning guides to assist first responders and hospital emergency 
department personnel in planning for incidents that involve hazardous materials.  Volume III— 
Medical Management Guidelines for Acute Chemical Exposures—is a guide for health care 
professionals treating patients exposed to hazardous materials. 
Fact Sheets (ToxFAQs) provide answers to frequently asked questions about toxic substances. 
Other Agencies and Organizations 
The National Center for Environmental Health (NCEH) focuses on preventing or controlling disease, 
injury, and disability related to the interactions between people and their environment outside the 
workplace. Contact: NCEH, Mailstop F-29, 4770 Buford Highway, NE, Atlanta, 
GA 30341-3724 • Phone: 770-488-7000 • FAX: 770-488-7015. 
The National Institute for Occupational Safety and Health (NIOSH) conducts research on occupational 
diseases and injuries, responds to requests for assistance by investigating problems of health and 
safety in the workplace, recommends standards to the Occupational Safety and Health 
Administration (OSHA) and the Mine Safety and Health Administration (MSHA), and trains 
professionals in occupational safety and health.  Contact: NIOSH, 200 Independence Avenue, 
SW, Washington, DC 20201 • Phone: 800-356-4674 or NIOSH Technical Information Branch, 
Robert A. Taft Laboratory, Mailstop C-19, 4676 Columbia Parkway, Cincinnati, OH 45226-1998 
• Phone: 800-35-NIOSH. 
The National Institute of Environmental Health Sciences (NIEHS) is the principal federal agency for 
biomedical research on the effects of chemical, physical, and biologic environmental agents on 
human health and well-being.  Contact:  NIEHS, PO Box 12233, 104 T.W. Alexander Drive, 
Research Triangle Park, NC 27709 • Phone: 919-541-3212. 
Referrals 
The Association of Occupational and Environmental Clinics (AOEC) has developed a network of clinics 
in the United States to provide expertise in occupational and environmental issues.  Contact: 
AOEC, 1010 Vermont Avenue, NW, #513, Washington, DC 20005 • Phone:  202-347-4976 
• FAX: 202-347-4950 • e-mail: AOEC@AOEC.ORG • Web Page:  http://www.aoec.org/. 
The American College of Occupational and Environmental Medicine (ACOEM) is an association of 
physicians and other health care providers specializing in the field of occupational and 
environmental medicine.  Contact: ACOEM, 25 Northwest Point Boulevard, Suite 700, Elk 
Grove Village, IL 60007-1030 • Phone:  847-818-1800 • FAX:  847-818-9266. 
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chapter of each profile for consistency and accuracy in interpreting health effects and classifying 
end points. 
2.  Minimal Risk Level Review. The Minimal Risk Level Workgroup considers issues relevant to 
substance-specific Minimal Risk Levels (MRLs), reviews the health effects database of each 
profile, and makes recommendations for derivation of MRLs. 
3. Data Needs Review.  The Applied Toxicology Branch reviews data needs sections to assure 
consistency across profiles and adherence to instructions in the Guidance. 
4. Green Border Review.  Green Border review assures the consistency with ATSDR policy. 
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PEER REVIEW 
A peer review panel was assembled for barium and barium.  The panel consisted of the following 
members: 
1.  Michael Dourson, Ph.D., DABT, Toxicological Excellence for Risk Assessment, Cincinnati, 
Ohio; 
2.  Ernest Foulkes, Ph.D., University of Cincinnati, Cincinnati, Ohio; and 
3. Richard Leggett, Ph.D., Private Consultant, Knoxville, Tennessee. 
These experts collectively have knowledge of barium and barium compound's physical and chemical 
properties, toxicokinetics, key health end points, mechanisms of action, human and animal exposure, and 
quantification of risk to humans.  All reviewers were selected in conformity with the conditions for peer 
review specified in Section 104(I)(13) of the Comprehensive Environmental Response, Compensation, 
and Liability Act, as amended. 
Scientists from the Agency for Toxic Substances and Disease Registry (ATSDR) have reviewed the peer 
reviewers' comments and determined which comments will be included in the profile.  A listing of the 
peer reviewers' comments not incorporated in the profile, with a brief explanation of the rationale for their 
exclusion, exists as part of the administrative record for this compound.   
The citation of the peer review panel should not be understood to imply its approval of the profile's final 
content. The responsibility for the content of this profile lies with the ATSDR. 
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1 BARIUM AND BARIUM COMPOUNDS 
1. PUBLIC HEALTH STATEMENT 
This public health statement tells you about barium and barium compounds and the effects of 
exposure to these chemicals.   
The Environmental Protection Agency (EPA) identifies the most serious hazardous waste sites in 
the nation. These sites are then placed on the National Priorities List (NPL) and are targeted for 
long-term federal clean-up activities.  Barium and barium compounds have been found in at least 
798 of the 1,684 current or former NPL sites; however, the total number of NPL sites evaluated 
for these substances is not known. This information is important because these sites may be 
sources of exposure and exposure to this substance may harm you. 
When a substance is released either from a large area, such as an industrial plant, or from a 
container, such as a drum or bottle, it enters the environment. Such a release does not always 
lead to exposure. You can be exposed to a substance only when you come in contact with it.  
You may be exposed by breathing, eating, or drinking the substance, or by skin contact. 
If you are exposed to barium and barium compounds, many factors will determine whether you 
will be harmed. These factors include the dose (how much), the duration (how long), and how 
you come in contact with them.  You must also consider any other chemicals you are exposed to 
and your age, sex, diet, family traits, lifestyle, and state of health. 
1.1 WHAT IS BARIUM? 
Barium is a silvery-white metal that takes on a silver-yellow color when exposed to air.  Barium 
occurs in nature in many different forms called compounds.  These compounds are solids, 
existing as powders or crystals, and they do not burn well.  Two forms of barium, barium sulfate 
and barium carbonate, are often found in nature as underground ore deposits.  Barium is 
sometimes found naturally in drinking water and food.  Because certain barium compounds 
(barium sulfate and barium carbonate) do not mix well with water, the amount of barium usually 
found in drinking water is small.  Other barium compounds, such as barium chloride, barium 
nitrate, and barium hydroxide, are manufactured from barium sulfate.  Barium compounds such 
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as barium acetate, barium chloride, barium hydroxide, barium nitrate, and barium sulfide 
dissolve more easily in water than barium sulfate and barium carbonate, but because they are not 
commonly found in nature, they do not typically end up in drinking water unless the water is 
contaminated by barium compounds that are released from waste sites. 
Barium and barium compounds are used for many important purposes.  Barium sulfate ore is 
mined and used in several industries.  It is used mostly by the oil and gas industries to make 
drilling muds.  Drilling muds make it easier to drill through rock by keeping the drill bit 
lubricated. Barium sulfate is also used to make paints, bricks, tiles, glass, rubber, and other 
barium compounds.  Some barium compounds, such as barium carbonate, barium chloride, and 
barium hydroxide, are used to make ceramics, insect and rat poisons, and additives for oils and 
fuels; in the treatment of boiler water; in the production of barium greases; as a component in 
sealants, paper manufacturing, and sugar refining; in animal and vegetable oil refining; and in the 
protection of objects made of limestone from deterioration.  Barium sulfate is sometimes used by 
doctors to perform medical tests and take x-ray photographs of the stomach and intestines. 
More information on the chemical and physical properties and use of barium is found in 
Chapters 4 and 5. 
1.2 WHAT HAPPENS TO BARIUM WHEN IT ENTERS THE ENVIRONMENT? 
The length of time that barium will last in air, land, water, or sediments following release of 
barium into these media depends on the form of barium released.  Barium compounds that do not 
dissolve well in water, such as barium sulfate and barium carbonate, can persist for a long time 
in the environment.  Barium compounds, such as barium chloride, barium nitrate, or barium 
hydroxide, that dissolve easily in water usually do not last in these forms for a long time in the 
environment.  The barium in these compounds that is dissolved in water quickly combines with 
sulfate or carbonate that are naturally found in water and become the longer lasting forms 
(barium sulfate and barium carbonate).  Barium sulfate and barium carbonate are the barium 
compounds most commonly found in the soil and water.  If barium sulfate and barium carbonate 
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are released onto land, they will combine with particles of soil.  More information on the 
environmental fate of barium is found in Chapter 6. 
1.3 HOW MIGHT I BE EXPOSED TO BARIUM? 
Background levels of barium in the environment are very low.  The air that most people breathe 
contains about 0.0015 parts of barium per billion parts of air (ppb).  The air around factories that 
release barium compounds into the air has about 0.33 ppb or less of barium.  Most surface water 
and public water supplies contain on average 0.030 parts of barium per million parts of water 
(ppm) or less, but can average as high as 0.30 ppm in some regions of the United States.  In some 
areas that have underground water wells, drinking water may contain more barium than the 
2 ppm limit set by EPA.  The highest amount measured from these water wells has been 10 ppm.  
The amount of barium found in soil ranges from about 15 to 3,500 ppm.  Some foods, such as 
Brazil nuts, seaweed, fish, and certain plants, may contain high amounts of barium.  The amount 
of barium found in food and water usually is not high enough to be a health concern.  However, 
information is still being collected to determine if long-term exposure to low levels of barium 
causes any health problems. 
People with the greatest known risk of exposure to high levels of barium are those working in 
industries that make or use barium compounds.  Most of these exposed persons breathe air that 
contains barium sulfate or barium carbonate.  Sometimes they are exposed to one of the more 
harmful barium compounds (for example, barium chloride or barium hydroxide) by breathing the 
dust from these compounds or by getting them on their skin.  Barium carbonate can be harmful if 
accidentally eaten because it will dissolve in the acids within the stomach unlike barium sulfate, 
which will not dissolve in the stomach.  Many hazardous waste sites contain barium compounds, 
and these sites may be a source of exposure for people living and working near them.  Exposure 
near hazardous waste sites may occur by breathing dust, eating soil or plants, or drinking water 
that is polluted with barium.  People near these sites may also get soil or water that contains 
barium on their skin.  More information on how you might be exposed to barium is found in 
Chapter 6. 
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1.4 HOW CAN BARIUM ENTER AND LEAVE MY BODY? 
Barium enters your body when you breathe air, eat food, or drink water containing barium.  It 
may also enter your body to a small extent when you have direct skin contact with barium 
compounds.  The amount of barium that enters the bloodstream after you breathe, eat, or drink it 
depends on the barium compound.  Some barium compounds that are soluble, such as barium 
chloride, can enter bloodstream more easily than insoluble barium compounds such as barium 
sulfate. Some barium compounds (for example, barium chloride) can enter your body through 
your skin, but this is very rare and usually occurs in industrial accidents at factories where they 
make or use barium compounds.  Barium at hazardous waste sites may enter your body if you 
breathe dust, eat soil or plants, or drink water polluted with barium from this area.   
Barium that enters your body by breathing, eating, or drinking is removed mainly in feces and 
urine. Most of the barium that enters your body is removed within 1–2 weeks.  Most of the small 
amount of barium that stays in your body goes into the bones and teeth.  More information on 
how barium enters and leaves your body is found in Chapter 3. 
1.5 HOW CAN BARIUM AFFECT MY HEALTH? 
Scientists use many tests to protect the public from harmful effects of toxic chemicals and to find 
ways for treating persons who have been harmed. 
One way to learn whether a chemical will harm people is to determine how the body absorbs, 
uses, and releases the chemical.  For some chemicals, animal testing may be necessary.  Animal 
testing may also help identify health effects such as cancer or birth defects.  Without laboratory 
animals, scientists would lose a basic method for getting information needed to make wise 
decisions that protect public health.  Scientists have the responsibility to treat research animals 
with care and compassion.  Scientists must comply with strict animal care guidelines because 
laws today protect the welfare of research animals. 
The health effects associated with exposure to different barium compounds depend on how well 
the specific barium compound dissolves in water or in the stomach.  For example, barium sulfate 
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does not easily dissolve in water and causes few harmful health effects.  Doctors sometimes give 
barium sulfate orally or by placing it directly in the rectum of patients for purposes of making x-
rays of the stomach or intestines.  The use of this particular barium compound in this type of 
medical test is not harmful to people.  Barium compounds such as barium acetate, barium 
chloride, barium hydroxide, barium nitrate, and barium sulfide that dissolve in water can cause 
harmful health effects. Barium carbonate does not dissolve in water, but does dissolve in the 
stomach; it can also cause harmful health effects.   
Eating or drinking very large amounts of barium compounds that dissolve in water or in the 
stomach can cause changes in heart rhythm or paralysis in humans.  Some people who did not 
seek medical treatment soon after eating or drinking a very large amount of barium have died.  
Some people who eat or drink somewhat smaller amounts of barium for a short period may 
experience vomiting, abdominal cramps, diarrhea, difficulties in breathing, increased or 
decreased blood pressure, numbness around the face, and muscle weakness.  One study showed 
that people who drank water containing as much as 10 ppm of barium for 4 weeks did not have 
increased blood pressure or abnormal heart rhythms.  The health effects of barium have been 
studied more often in experimental animals than in humans.  Rats that ate or drank barium over 
short periods had swelling and irritation of the intestines, changes in organ weights, decreased 
body weight, and increased numbers of deaths.  Rats and mice that drank barium over long 
periods had damage to the kidneys, decreases in body weight, and decreased survival.  We have 
no information about the ability of barium to affect reproduction in humans; a study in 
experimental animals did not find reproductive effects.   
Some studies of humans and experimental animals exposed to barium in the air have reported 
damage to the lungs, but other studies have not found these effects.  We have no reliable 
information about the health effects in humans or experimental animals that are exposed to 
barium by direct skin contact. 
Barium has not been shown to cause cancer in humans or in experimental animals drinking 
barium in water.  The Department of Health and Human Services and the International Agency 
for Research on Cancer have not classified barium as to its carcinogenicity.  The EPA has 
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determined that barium is not likely to be carcinogenic to humans following ingestion and that 
there is insufficient information to determine whether it will be carcinogenic to humans 
following inhalation exposure. 
More information on the health effects of barium can be found in Chapter 3. 
1.6 HOW CAN BARIUM AFFECT CHILDREN? 
This section discusses potential health effects in humans from exposures during the period from 
conception to maturity at 18 years of age.  
We do not know whether children will be more or less sensitive than adults to barium toxicity.  
A study in rats that swallowed barium found a decrease in newborn body weight; we do not 
know if a similar effect would be seen in humans. 
1.7 HOW CAN FAMILIES REDUCE THE RISK OF EXPOSURE TO BARIUM? 
If your doctor finds that you have been exposed to substantial amounts of barium, ask whether 
your children might also have been exposed.  Your doctor might need to ask your state health 
department to investigate. 
The greatest potential source of barium exposure is through food and drinking water.  However, 
the amount of barium in foods and drinking water are typically too low to be of concern.  
1.8 IS THERE A MEDICAL TEST TO DETERMINE WHETHER I HAVE BEEN 
EXPOSED TO BARIUM? 
There is no routine medical test to determine whether you have been exposed to barium.  Doctors 
can measure barium in body tissues and fluids, such as bones, blood, urine, and feces, using very 
complex instruments.  These tests cannot be used to predict the extent of the exposure or 
potential health effects. This is normally done only for cases of severe barium poisoning and for 
medical research.   
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More information on testing for barium exposure is found in Chapters 3 and 7. 
1.9 WHAT RECOMMENDATIONS HAS THE FEDERAL GOVERNMENT MADE TO 
PROTECT HUMAN HEALTH? 
The federal government develops regulations and recommendations to protect public health.  
Regulations can be enforced by law. The EPA, the Occupational Safety and Health 
Administration (OSHA), and the Food and Drug Administration (FDA) are some federal 
agencies that develop regulations for toxic substances.  Recommendations provide valuable 
guidelines to protect public health, but cannot be enforced by law.  The Agency for Toxic 
Substances and Disease Registry (ATSDR) and the National Institute for Occupational Safety 
and Health (NIOSH) are two federal organizations that develop recommendations for toxic 
substances. 
Regulations and recommendations can be expressed as “not-to-exceed” levels, that is, levels of a 
toxic substance in air, water, soil, or food that do not exceed a critical value that is usually based 
on levels that affect animals; they are then adjusted to levels that will help protect humans.  
Sometimes these not-to-exceed levels differ among federal organizations because they used 
different exposure times (an 8-hour workday or a 24-hour day), different animal studies, or other 
factors. 
Recommendations and regulations are also updated periodically as more information becomes 
available. For the most current information, check with the federal agency or organization that 
provides it. Some regulations and recommendations for barium include the following: 
The EPA has determined that drinking water should not contain more than 2.0 milligrams (mg) 
barium per liter (L) of water (2.0 mg/L).   
OSHA has a legally enforceable occupational exposure limit of 0.5 mg of soluble barium 
compounds per cubic meter (m3) of air averaged over an 8-hour work day.  The OSHA 8-hour 
exposure limit for barium sulfate dust in air is 15 mg/m3 for total dust.  NIOSH considers 
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exposure to barium chloride levels of 50 mg/m3 and higher as immediately dangerous to life or 
health. 
More information on government regulations can be found in Chapter 8. 
1.10 WHERE CAN I GET MORE INFORMATION? 
If you have any more questions or concerns, please contact your community or state health or 
environmental quality department, or contact ATSDR at the address and phone number below. 
ATSDR can also tell you the location of occupational and environmental health clinics.  These 
clinics specialize in recognizing, evaluating, and treating illnesses that result from exposure to 
hazardous substances. 
Toxicological profiles are also available on-line at www.atsdr.cdc.gov and on CD-ROM. You 
may request a copy of the ATSDR ToxProfilesTM CD-ROM by calling the toll-free information 
and technical assistance number at 1-800-CDCINFO (1-800-232-4636), by e-mail at 
cdcinfo@cdc.gov, or by writing to: 
Agency for Toxic Substances and Disease Registry 
  Division of Toxicology and Environmental Medicine 
1600 Clifton Road NE 
  Mailstop F-32 
  Atlanta, GA 30333 
  Fax: 1-770-488-4178 
Organizations for-profit may request copies of final Toxicological Profiles from the following: 
National Technical Information Service (NTIS) 
5285 Port Royal Road 
  Springfield, VA 22161 
  Phone: 1-800-553-6847 or 1-703-605-6000 
  Web site: http://www.ntis.gov/ 
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2.1 BACKGROUND AND ENVIRONMENTAL EXPOSURES TO BARIUM IN THE UNITED 
STATES 
Barium is an alkaline earth metal, principally found as barite (barium sulfate) and witherite (barium 
carbonate) ores. Barium and barium compounds have a variety of uses including as getters in electronic 
tubes (barium alloys), rodenticide (barium carbonate), colorant in paints (barium carbonate and barium 
sulfate), and x-ray contrast medium (barium sulfate).  Barium naturally occurs in food and groundwater.  
Barium concentrations in drinking water in the United States typically average 30 μg/L, but can average 
as high as 302 μg/L. However, individuals residing in certain regions of Kentucky, northern Illinois, New 
Mexico, and Pennsylvania who rely on groundwater for their source of drinking water may be exposed to 
barium concentrations as high as 10 times the maximum contaminant level (MCL) in drinking water of 
2.0 mg/L.  Low levels of barium are also found in ambient air; levels are typically less than 0.05 μg 
barium/m3. 
There is little quantitative information regarding the extent of barium absorption following inhalation, 
oral, or dermal exposure. Available evidence indicates that barium is absorbed to some extent following 
inhalation, oral, and dermal exposure; however, in some cases, absorption is expected to be limited.  For 
example, there is some evidence that gastrointestinal absorption of barium in humans is <5–30% of the 
administered dose.  The general population can be exposed to barium via inhalation, oral, or dermal 
exposure; under most circumstances, oral exposure would be the predominant route of exposure. 
2.2 SUMMARY OF HEALTH EFFECTS  
An important factor affecting the development of adverse health effects in humans is the solubility of the 
barium compound to which the individual is exposed.  Soluble barium compounds would generally be 
expected to be of greater health concern than insoluble barium compounds because of their greater 
potential for absorption.  The various barium compounds have different solubilities in water and body 
fluids and therefore serve as variable sources of the Ba2+ ion. The Ba2+ ion and the soluble compounds of 
barium (notably chloride, nitrate, hydroxide) are toxic to humans.  Although barium carbonate is 
relatively insoluble in water, it is toxic to humans because it is soluble in the gastrointestinal tract.  The 
insoluble compounds of barium (notably sulfate) are inefficient sources of Ba2+ ion and are therefore 
generally nontoxic to humans.  The insoluble, nontoxic nature of barium sulfate has made it practical to 
use this particular barium compound in medical applications as a contrast media for x-ray examination of 
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the gastrointestinal tract. Barium provides an opaque contrasting medium when ingested or given by 
enema prior to x-ray examination.  Under these routine medical situations, barium sulfate is generally 
safe. However, barium sulfate or other insoluble barium compounds may potentially be toxic when it is 
introduced into the gastrointestinal tract under conditions where there is colon cancer or perforations of 
the gastrointestinal tract and barium is able to enter the blood stream. 
There are a number of reports of serious health effects in individuals intentionally or accidentally exposed 
to barium carbonate or chloride.  The predominant effect is hypokalemia, which can result in ventricular 
tachycardia, hypertension and/or hypotension, muscle weakness, and paralysis.  Barium is a competitive 
potassium channel antagonist that blocks the passive efflux of intracellular potassium, resulting in a shift 
of potassium from extracellular to intracellular compartments.  The net result of this shift is a significant 
decrease in the potassium concentration in the blood plasma.  Although the case reports did not provide 
information on doses, it is likely that the doses were high.  In addition to the effects associated with 
hypokalemia, gastrointestinal effects such as vomiting, abdominal cramps, and watery diarrhea are 
typically reported shortly after ingestion.  Similar effects have been reported in cases of individuals 
exposed to very high concentrations of airborne barium; the effects include electrocardiogram (ECG) 
abnormalities, muscle weakness and paralysis, hypokalemia, and abdominal cramps, nausea, and 
vomiting. 
Several investigators have examined whether exposure to much lower doses of barium would adversely 
affect the cardiovascular system.  A population-based study found significant increases in the risk of 
death from cardiovascular disease among residents 65 years of age and older living in communities with 
high levels of barium in the drinking water.  However, these data cannot be used to establish a causal 
relationship because the study did not control for other cardiovascular risk factors or the use of water 
softeners, which would decrease barium levels and increase sodium levels.  Two other studies did not find 
alterations in blood pressure and cardiac rhythm.  In general, animal studies designed to assess 
cardiovascular function have not found significant alterations in blood pressure or ECG readings 
following low-dose oral exposure.  One study did find significant increases in blood pressure in rats 
exposed to 0.80 mg barium/kg/day.  However, the use of a low mineral diet with less than adequate levels 
of calcium may have influenced the study results.   
The available animal data provide strong evidence that the most sensitive adverse effect of barium is renal 
toxicity.  There are some reports of renal effects in case reports of individuals ingesting high doses of 
barium.  Nephropathy has been observed in rats and mice following long-term oral exposure to barium.  
11 BARIUM AND BARIUM COMPOUNDS 
2. RELEVANCE TO PUBLIC HEALTH 
In both species, there is a steep dose-response curve for the incidence of nephropathy.  For example, 
nephropathy was not observed in mice exposed to 205 mg barium/kg/day for an intermediate duration; at 
450 mg barium/kg/day, 95% of the animals exhibited mild to moderate nephropathy.  Data in mice also 
suggest that the severity and sensitivity to renal lesions is related to duration of exposure.  As noted 
previously, a 205 mg barium/kg/day dose is a no effect level in mice exposed to barium chloride for 
90 days; a 2-year exposure to 200 mg barium/kg/day resulted in moderate to marked nephropathy. 
The potential for barium to induce reproductive and developmental effects has not been well investigated.  
Decreases in the number of sperm and sperm quality and a shortened estrous cycle and morphological 
alterations in the ovaries were observed in rats exposed to 2.2 mg barium/m3 and higher in air for an 
intermediate duration.  Interpretation of these data is limited by the poor reporting of the study design and 
results, in particular, whether the incidence was significantly different from controls.  In general, oral 
exposure studies have not found morphological alterations in reproductive tissues of rats or mice exposed 
to 180 or 450 mg barium/kg/day, respectively, as barium chloride in drinking water for an intermediate 
duration.  Additionally, no significant alterations in reproductive performance was observed in rats or 
mice exposed to 200 mg barium/kg/day as barium chloride in drinking water.  Decreased pup birth weight 
and a nonsignificant decrease in litter size have been observed in the offspring of rats exposed to 
180/200 mg barium/kg/day as barium chloride in drinking water prior to mating. 
Several studies have examined the carcinogenic potential of barium following oral exposure and did not 
find significant increases in the tumor incidence.  No studies have adequately assessed the carcinogenicity 
of barium following inhalation exposure.  The Department of Health and Human Services (DHHS) and 
the International Agency for Research on Cancer (IARC) have not assessed the carcinogenicity of barium.  
The EPA has concluded that barium is not classifiable as to human carcinogenicity, Group D. However, 
under EPA’s revised guidelines for carcinogen risk assessment, barium is considered not likely to be 
carcinogenic to humans following oral exposure and its carcinogenic potential cannot be determined 
following inhalation exposure. 
2.3 MINIMAL RISK LEVELS (MRLs) 
Estimates of exposure levels posing minimal risk to humans (MRLs) have been made for barium.  An 
MRL is defined as an estimate of daily human exposure to a substance that is likely to be without an 
appreciable risk of adverse effects (noncarcinogenic) over a specified duration of exposure.  MRLs are 
derived when reliable and sufficient data exist to identify the target organ(s) of effect or the most sensitive 
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health effect(s) for a specific duration within a given route of exposure.  MRLs are based on 
noncancerous health effects only and do not consider carcinogenic effects.  MRLs can be derived for 
acute, intermediate, and chronic duration exposures for inhalation and oral routes.  Appropriate 
methodology does not exist to develop MRLs for dermal exposure. 
Although methods have been established to derive these levels (Barnes and Dourson 1988; EPA 1990), 
uncertainties are associated with these techniques.  Furthermore, ATSDR acknowledges additional 
uncertainties inherent in the application of the procedures to derive less than lifetime MRLs.  As an 
example, acute inhalation MRLs may not be protective for health effects that are delayed in development 
or are acquired following repeated acute insults, such as hypersensitivity reactions, asthma, or chronic 
bronchitis. As these kinds of health effects data become available and methods to assess levels of 
significant human exposure improve, these MRLs will be revised. 
Inhalation MRLs 
No acute-, intermediate-, or chronic-duration inhalation MRLs were derived for barium because studies 
evaluating the effects of barium in humans and animals following acute, intermediate, and chronic 
inhalation exposure were inadequate for establishing the exposure concentrations associated with adverse 
health effects. Five reports of occupational exposure to barium have been identified.  In one study (Doig 
1976), a benign pneumoconiosis was observed in several workers exposed to barium sulfate; two other 
studies did not find barium-related alterations in the respiratory tract of workers exposed to barium sulfate 
(Seaton et al. 1986) or barium carbonate (Essing et al. 1976).  Other effects reported in the occupational 
exposure studies were an increase in blood pressure (Essing et al. 1976), gastrointestinal distress, muscle 
weakness and paralysis, absence of deep tendon reflex, and decreased serum potassium levels in a worker 
exposed to barium carbonate powder (Shankle and Keane 1988).  A fifth study did not find alterations in 
plasma potassium levels in welders using barium-containing electrodes (Zschiesche et al. 1992). 
Interpretation of these studies is limited by the small number of subjects, possible lack of a control group, 
and/or the lack of quantitative exposure information.   
Three animal studies evaluating the toxicity of inhaled barium have also been identified.  Two of the 
studies reported adverse respiratory tract effects including lung lesions (perivascular and peribronchial 
sclerosis and focal thickening of the intraalveolar septa) in rats exposed to 3.6 mg barium/m3 as barium 
carbonate dust 4 hours/day, 6 days/week for 4 months (Tarasenko et al. 1977) and bronchoconstriction in 
guinea pigs exposed to 0.06 mg barium/m3/minute as barium chloride for an unspecified amount of time 
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(Hicks et al. 1986).  The third study (Cullen et al. 2000) did not find histological alterations in the lungs 
of rats exposed to 44.1 mg barium/m3 as barium sulfate for 7 hours/day, 5 days/week for 119 days.  
Increases in blood pressure were observed in the Tarasenko et al. (1977) and Hicks et al. (1986) studies.  
Tarasenko et al. (1977) also reported hematological, reproductive, and developmental effects in rats 
exposed to barium carbonate dust.  None of these studies provide a suitable basis for an inhalation MRL.  
The Tarasenko et al. (1977) studies are limited by poor reporting of the study design and results, lack of 
incidence data, and lack of statistical analysis for many of the end points.  The Hicks et al. (1986) study 
did not report the frequency or length of exposure, the number of animals used was not clearly reported, 
and it does not appear that control animals were used.  Although the Cullen et al. (2000) study was well 
reported and designed, it only examined the respiratory tract and did not identify an adverse effect level.  
Oral exposure studies identify the kidney as the most sensitive target of toxicity; this end point was not 
evaluated in the Cullen et al. (2000) study.   
Oral MRLs 
There are numerous case reports of individuals intentionally or accidentally ingesting unreported but 
presumably high doses of barium (Das and Singh 1970; Deng et al. 1991; Diengott et al. 1964; Downs et 
al. 1995; Gould et al. 1973; Jha et al. 1993; Koch et al. 2003; Lewi and Bar-Khayim 1964; McNally 1925; 
Ogen et al. 1967; Phelan et al. 1984; Silva 2003; Talwar and Sharma 1979; Wetherill et al. 1981).  The 
consistently observed effects included abdominal distress (vomiting, abdominal cramping, and watery 
diarrhea), numbness around the face, muscle weakness, paralysis, and ventricular tachycardia.   
Information on the acute oral toxicity of barium is limited to two studies in rats conducted by Borzelleca 
et al. (1988).  A nonsignificant increase in mortality (3/20 females compared to 0/20 in controls) was 
found in rats receiving gavage doses of 198 mg barium/kg/day as barium chloride in water for 10 days.  In 
the other study conducted by this group, 15/20 animals died after a single dose of 198 mg barium/kg/day 
as barium chloride in water.  In the 10-day study, significant decreases in relative kidney weight 
(kidney:brain ratio) were observed in female rats administered 66–138 mg barium/kg/day and decreases 
in blood urea nitrogen (BUN) levels were observed in female rats dosed with 66–198 mg barium/kg/day 
and male rats dosed with 198 mg barium/kg/day.  The magnitude of change in BUN levels was small (less 
than 15%) and was not dose-related; the decrease in BUN was not considered to be biologically 
significant. Additionally, BUN levels are typically increased in response to kidney damage.  Significant 
decreases in absolute ovary weight and relative ovary weight (ovary:brain ratio) were observed at 198 mg 
barium/kg/day in the 10-day study.  The biological significance of this change in organ weight is 
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questionable; no gross alterations in the ovaries were observed in this study and no histological alterations 
were observed in rats or mice exposed to barium chloride for acute, intermediate, or chronic durations to 
barium doses as high as 180 mg barium/kg/day in rats (NTP 1994) and 495 mg barium/kg/day in mice 
(NTP 1994).   
The data are considered inadequate for derivation of an acute-duration oral MRL for barium.  The 
available animal studies (Borzelleca et al. 1988) have evaluated the toxicity of barium chloride in 
repeated dose studies; however, neither study identified a non-lethal biologically significant adverse 
effect level. Longer-term studies identify the kidney as the most sensitive target; however, it is not 
known if the kidney would also be the most sensitive target following acute-duration exposure.  Data in 
mice suggest that the severity and sensitivity to renal lesions are related to duration of exposure.  The 
intermediate-duration mouse study identified a NOAEL of 205 mg barium/kg/day; however; a 2-year 
exposure to 200 mg barium/kg/day resulted in moderate to marked nephropathy (NTP 1994).  Derivation 
of an MRL using the highest identified no-observed-adverse-effect level (NOAEL) is not recommended 
at this time because critical targets of toxicity and dose-response relationships have not been established 
for this exposure category.  The exposure levels are poorly characterized in the available reports of human 
poisonings, acute-duration animal studies have failed to identify the critical target of barium toxicity, and 
it is possible that the critical target (kidneys) following long-term exposure may not be a sensitive target 
following short-term exposure.  
•  An MRL of 0.2 mg barium/kg/day has been derived for intermediate-duration oral exposure (15– 
364 days) to barium. 
Information on the oral toxicity of barium in humans following intermediate-duration oral exposure is 
limited to an experimental study in which men were exposed to 0.1 or 0.2 mg barium/kg/day as barium 
chloride in drinking water for 4 weeks (Wones et al. 1990).  No significant alterations in blood pressure or 
ECG readings, relative to initial baseline measurements, were found.   
A number of animal studies have evaluated barium toxicity following intermediate-duration oral 
exposure. Several of these studies focused on the cardiovascular system or assessed cardiovascular 
function.  Perry et al. (1983, 1985, 1989) reported significant increases in blood pressure in rats 
administered 8.6 or 11 mg barium/kg/day as barium chloride in drinking water for 1 or 4 months, 
respectively. NTP (1994) and McCauley et al. (1985) did not find significant alterations in blood pressure 
or ECG readings in rats exposed to 150 or 180 mg barium/kg/day in drinking water for 13 or 16 weeks, 
respectively. The reason for the differences between the results from the Perry et al. (1983, 1985, 1989) 
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studies and the NTP (1994) and McCauley et al. (1985) studies is not known.  It is possible that the low-
mineral diet used in the Perry et al. (1983, 1985, 1989) studies influenced the results.  The calcium 
content of the rye-based diet was 3.8 mg/kg, which is lower than the concentration recommended for 
maintenance, growth, and reproduction of laboratory rats (NRC 1995b).   
The results of the McCauley et al. (1985) and NTP (1994) studies suggest that the kidney is the most 
sensitive target of toxicity in rats and mice.  In the McCauley et al. (1985) study, glomerular alterations 
consisting of fused podocytes and thickening of the capillary basement membrane were found in 
uninephrectomized Sprague Dawley rats, Dahl salt-sensitive rats, and Dahl salt-resistant rats exposed to 
150 mg barium/kg/day in drinking water for 16 weeks.  In the NTP (1994) 13-week rat study, significant 
increases in absolute and relative kidney weights were observed in female rats exposed to 115 or 180 mg 
barium/kg/day and in males exposed to 200 mg barium/kg/day.  At 200 and 180 mg barium/kg/day, 
minimal to mild dilatation of the proximal convoluted tubules of the outer medulla and renal cortex was 
observed in the males and females, respectively; an increase in mortality (30%) was also observed in the 
males exposed to 200 mg barium/kg/day.  In mice, mild to moderate nephropathy (characterized as tubule 
dilatation, regeneration, and atrophy) was observed in 100% of the males exposed to 450 mg 
barium/kg/day and 90% of the females exposed to 495 mg barium/kg/day; no renal lesions were observed 
at the next lowest dose level (205 and 200 mg barium/kg/day in males and females, respectively).  Other 
effects observed at the 450/495 mg barium/kg/day dose level included weight loss, spleen and thymus 
atrophy, and increased mortality (60% of the males and 70% of females died after 5 weeks of exposure).   
Other end points that have been examined in rats and mice include neurotoxicity, reproductive toxicity, 
and developmental toxicity. In male and female rats, slight decreases in undifferentiated motor activity 
were observed at 10 mg barium/kg/day and higher.  However, the difference between motor activity in the 
barium-exposed rats and the controls was less than 20% and was not considered to be biologically 
significant. At 180 mg barium/kg/day, the difference was 30% in the female rats, which was considered 
to be adverse. No significant alterations were found on the remaining neurobehavioral tests (grip 
strength, tail flick latency, startle response, and hindlimb foot splay).  In mice, a significant decrease in 
forelimb grip strength was observed in females exposed to 495 mg barium/kg/day; this may have been 
due to debilitation.  No other alterations in neurobehavioral performance were found.  No effects on 
reproductive tissues or reproductive performance were observed in rats or mice exposed to approximately 
200 mg barium/kg/day (Dietz et al. 1992; NTP 1994).  Pre-mating exposure of male and female rats to 
180/200 mg barium/kg/day resulted in decreased pup birth weight and a nonsignificant decrease in litter 
size; the NOAEL for these effects was 110/115 mg barium/kg/day (Dietz et al. 1992).  No developmental 
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effects were observed in mice exposed to 200 mg barium/kg/day (Dietz et al. 1992).  Another study 
(Tarasenko et al. 1977) also reported developmental effects (increased offspring mortality during the first 
2 months and disturbances in liver function) in an unspecified animal species; however, the lack of 
information on experimental methods, exposure conditions, and results limits the usefulness of this study 
for evaluating the potential of aluminum to induce developmental toxicity. 
Based on these data, the kidney appears to be the most sensitive target following intermediate-duration 
oral exposure to barium.  Three studies identified adverse effect levels for kidney effects:  (1) a lowest­
observed-adverse-effect level (LOAEL) of 150 mg barium/kg/day was identified in uninephrectomized 
and salt-sensitive and salt resistant rats (McCauley et al. 1985), (2) a LOAEL of 115 mg barium/kg/day 
was identified for increased kidney weight in rats; the NOAEL was 65 mg barium/kg/day (NTP 1994), 
and (3) a LOAEL of 450 mg barium/kg/day for nephropathy in mice; the NOAEL was 205 mg 
barium/kg/day (NTP 1994).  The NTP (1994) 13-week rat study, which identified the lowest LOAEL for 
a kidney effect, was selected as the basis of the intermediate-duration oral MRL; the change in kidney 
weight was considered an early indicator of potentially more serious effects in the kidney. 
In this study (NTP 1994), groups of 10 male and 10 female F344/N rats were administered 0, 125, 500, 
1,000, 2,000, or 4,000 ppm barium chloride dihydrate (0, 10, 30, 65, 110, and 200 mg barium/kg/day for 
males and 0, 10, 35, 65, 115, and 180 mg barium/kg/day for females) in drinking water for 90 days.  
Exposure-related deaths were observed during the last week of the study in 30% of the males and 10% of 
the females exposed to 200/180 mg barium/kg/day. Significant decreases in final body weights were 
observed in the 200 mg barium/kg/day males (13% lower than controls) and 180 mg barium/kg/day 
females (8% lower than controls); significant decreases in water consumption (approximately 30% lower 
than controls) were also observed at this dose level.  Significant increases in absolute and relative kidney 
weights were observed in females exposed to 115 or 180 mg barium/kg/day and increases in relative 
kidney weights were also observed in males at 200 mg barium/kg/day; an increase in relative kidney 
weight was also observed in the females exposed to 65 mg barium/kg/day;  The magnitude of the 
increases in relative kidney weights were 7, 14, and 19% in the females exposed to 65, 115, and 180 mg 
barium/kg/day and 12% in males exposed to 200 mg barium/kg/day.  Minimal to mild, focal to multifocal 
dilatation of the proximal renal cortex was observed in three male and three female rats in the 200/180 mg 
barium/kg/day group.  The small increase in relative kidney weight (7%) observed in the female rats 
exposed to 65 mg barium/kg/day was not considered biologically significant because it is not supported 
by an increase in histological alterations in the kidney at 65 or 115 mg barium/kg/day or in rats exposed 
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to 75 mg barium/kg/day for 2 years (NTP 1994).  Thus, this study identifies a NOAEL of 65 mg 
barium/kg/day and a LOAEL of 115 mg barium/kg/day. 
A NOAEL/LOAEL approach was used to derive the MRL because none of the available benchmark dose 
models provided an adequate fit to the absolute or relative kidney weight data.  Thus, the intermediate-
duration oral MRL of 0.2 mg barium/kg/day was calculated by dividing the NOAEL of 65 mg 
barium/kg/day by an uncertainty factor of 100 (10 to account for animal to human extrapolation and 
10 for human variability) and a modifying factor of 3.  The modifying factor of 3 was included to account 
for deficiencies in the oral toxicity database, particularly the need for an additional developmental toxicity 
study.  Decreases in pup birth weight and a nonstatistically significant decrease in live litter size were 
observed in the offspring of rats exposed to 180/200 mg Ba/kg/day as barium chloride in drinking water 
prior to mating (Dietz et al. 1992).  Maternal body weight gain and water consumption were not reported, 
thus it is not known if the decreases in pup body weight were secondary to maternal toxicity or direct 
effect on the fetus. No developmental effects were observed in mice at the highest dose tested (200 mg 
Ba/kg/day) (Dietz et al. 1992).  One other study examined the potential for developmental toxicity in 
orally exposed animals (Tarasenko et al. 1977).  However, because the study was poorly reported and no 
incidence data or statistical analysis were presented in the published paper, the reported findings of 
increased mortality and systemic toxicity in the offspring of an unspecified species orally exposed to 
barium during conception and pregnancy can not be adequately evaluated.  The Dietz et al. (1992) study 
was designed to be a mating trial and did not expose the animals during gestation; thus, database is 
lacking an adequate study to evaluate the potential for barium to induce developmental effects.  
•  An MRL of 0.2 mg barium/kg/day has been derived for chronic-duration oral exposure 
(>365 days) to barium. 
Several human and animal studies have examined the toxicity of barium following chronic-duration 
exposure. Two community-based studies have evaluated the possible association between elevated levels 
of barium in drinking water and increased risk of cardiovascular disease.  No significant alterations in 
blood pressure measurements or increases in the prevalence of hypertension, heart disease, or stroke were 
found among residents of two communities with elevated (0.2 mg barium/kg/day) or low 
(0.003 mg barium/kg/day) levels of barium in drinking water (Brenniman and Levy 1985; Brenniman et 
al. 1979a, 1981).  In the second study, significantly higher mortality rates, particularly among individuals 
65 years of age and older, for cardiovascular disease and heart disease (arteriosclerosis) were found in a 
community with elevated barium drinking water levels (0.06–0.3 mg barium/kg/day) as compared to a 
community with low barium levels (0.006 mg barium/kg/day) (Brenniman and Levy 1985; Brenniman et 
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al. 1979a, 1981).  A common limitation of both studies is the lack of information on tap water 
consumption, actual barium intakes, and duration of exposure.  Additionally, the second study did not 
control for a number of potential confounding variables, particularly the use of water softeners, which 
would have resulted in a decrease in barium levels in the drinking water and an increase in sodium levels.  
Significant increases in blood pressure were observed in rats exposed to 0.8 mg barium/kg/day as barium 
chloride in drinking water for 16 months (Perry et al. 1983, 1985, 1989); the NOAEL for this effect was 
0.17 mg barium/kg/day.  At higher doses (7.2 mg barium/kg/day), depressed rates of cardiac contraction, 
reduced cardiac electrical conductivity, and decreased cardiac ATP levels were observed.  As noted in the 
discussion of the intermediate-duration oral MRL, interpretation of the results of this study is limited due 
to the low mineral diet, which may have supplied inadequate levels of calcium.  No adverse effects were 
observed in rats exposed to 60 mg barium/kg/day as barium chloride in drinking water for 2 years (NTP 
1994), 15 mg barium/kg/day to an unspecified barium compound in drinking water for 68 weeks 
(McCauley et al. 1985), or 0.7 mg barium/kg/day as barium acetate in drinking water for a lifetime 
(Schroeder and Mitchener 1975a). In mice exposed to barium chloride in drinking water for 2 years, 
marked renal nephropathy was observed at 160 mg barium/kg/day; the increased incidence of 
nephropathy in the next lowest dose group (75 mg barium/kg/day) was not statistically significant.  Other 
adverse effects observed at 160 mg barium/kg/day included weight loss and increased mortality (NTP 
1994). 
As with intermediate-duration exposure, the animal data provide suggestive evidence that the kidney is 
the most sensitive target of toxicity.  A serious LOAEL of 160 mg barium/kg/day was identified for 
nephropathy in mice (NTP 1994); the NOAEL identified in this study is 75 mg/kg/day.  Although no 
kidney lesions were observed in rats exposed to doses as high as 60 mg barium/kg/day (NTP 1994), the 
doses utilized in the study may not have been high enough to cause kidney damage.  Biologically 
significant kidney alterations were observed at 115 mg barium/kg/day and higher in rats exposed for an 
intermediate duration (NTP 1994).  The chronic-duration mouse study (NTP 1994) was selected as the 
basis of the chronic-duration MRL for barium. 
In this study (NTP 1994), groups of 60 male and 60 female B6C3F1 mice were exposed to 0, 500, 1,250, 
or 2,500 ppm barium chloride dehydrate (0, 30, 75, and 160 mg barium/kg/day for males and 0, 40, 90, 
and 200 mg barium/kg/day for females) in drinking water for 2 years.  Increased mortality attributed to 
renal lesions was observed in the 160/200 mg/kg/day group.  Decreased body weights (<7%) were 
observed in the barium-exposed mice.  The investigators noted that a moderate to marked weight loss was 
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observed in animals dying early.  No significant alterations in hematology or clinical chemistry 
parameters were observed.  A significant increase in the incidence of nephropathy was observed in male 
and female mice exposed to 160/200 mg/kg/day.  The nephropathy was characterized by extensive 
regeneration of cortical and medullary tubule epithelium, tubule dilatation, hyaline cast formation, 
multifocal interstitial fibrosis, and glomerulosclerosis in some kidneys.  The average severity of the 
nephropathy was 3.6 (moderate to marked) for both the males and females in the 160/200 mg/kg/day 
group. 
A benchmark analysis of the incidence data for nephropathy in mice was conducted; details of this 
analysis are presented in Appendix A.  A benchmark dose (BMD) of 80.06 mg barium/kg/day, which 
corresponds to a 5% increase in the incidence of nephropathy was calculated; the 95% lower confidence 
limit on the BMD (BMDL) was 61.13 mg barium/kg/day.  The BMDL05 was selected as the point of 
departure for deriving the chronic-duration oral MRL.  The dose corresponding to a predicted 5% 
incidence was selected over the typically 10% incidence as a precaution due to the severity of the 
observed effects (moderate to marked severity nephropathy), which resulted in marked weight loss and 
increased mortality.  Thus, the chronic-duration oral MRL of 0.2 mg barium/kg/day is based on the 
BMDL05 of 61 mg barium/kg/day in male mice and an uncertainty factor of 100 (10 to account for animal 
to human extrapolation and 10 for human variability) and a modifying factor of 3.  The modifying factor 
of 3 was included to account for deficiencies in the oral toxicity database, particularly the need for an 
additional developmental toxicity study.  Decreases in pup birth weight and a nonstatistically significant 
decrease in live litter size were observed in the offspring of rats exposed to 180/200 mg Ba/kg/day as 
barium chloride in drinking water prior to mating (Dietz et al. 1992).  Maternal body weight gain and 
water consumption were not reported, thus it is not known if the decreases in pup body weight were 
secondary to maternal toxicity or direct effect on the fetus.  No developmental effects were observed in 
mice at the highest dose tested (200 mg Ba/kg/day) (Dietz et al. 1992).  One other study examined the 
potential for developmental toxicity in orally exposed animals (Tarasenko et al. 1977).  However, because 
the study was poorly reported and no incidence data or statistical analysis were presented in the published 
paper, the reported findings of increased mortality and systemic toxicity in the offspring of an unspecified 
species orally exposed to barium during conception and pregnancy can not be adequately evaluated.  The 
Dietz et al. (1992) study was designed to be a mating trial and did not expose the animals during 
gestation; thus, database is lacking an adequate study to evaluate the potential for barium to induce 
developmental effects.  
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3.1 INTRODUCTION 
The primary purpose of this chapter is to provide public health officials, physicians, toxicologists, and 
other interested individuals and groups with an overall perspective on the toxicology of barium.  It 
contains descriptions and evaluations of toxicological studies and epidemiological investigations and 
provides conclusions, where possible, on the relevance of toxicity and toxicokinetic data to public health. 
A glossary and list of acronyms, abbreviations, and symbols can be found at the end of this profile. 
When evaluating the health effects of barium compounds, it is important to keep in mind that different 
barium compounds have different solubilities in water and body fluids and therefore serve as variable 
sources of the Ba2+ ion.  The Ba2+ ion and the soluble compounds of barium (notably chloride, nitrate, and 
hydroxide) are generally highly toxic to humans and experimental animals.  The insoluble barium 
compounds (notably sulfate) are inefficient sources of the Ba2+ ion and therefore are generally nontoxic.  
Although barium carbonate is insoluble in water, barium ions would be released from ingested barium 
carbonate in the acid milieu of the stomach.  Throughout the following section (3.2), the health effects by 
route of exposure of both soluble and insoluble barium compounds are discussed. 
3.2 DISCUSSION OF HEALTH EFFECTS BY ROUTE OF EXPOSURE  
To help public health professionals and others address the needs of persons living or working near 
hazardous waste sites, the information in this section is organized first by route of exposure (inhalation, 
oral, and dermal) and then by health effect (death, systemic, immunological, neurological, reproductive, 
developmental, genotoxic, and carcinogenic effects).  These data are discussed in terms of three exposure 
periods: acute (14 days or less), intermediate (15–364 days), and chronic (365 days or more). 
Levels of significant exposure for each route and duration are presented in tables and illustrated in 
figures. The points in the figures showing no-observed-adverse-effect levels (NOAELs) or lowest­
observed-adverse-effect levels (LOAELs) reflect the actual doses (levels of exposure) used in the studies. 
LOAELs have been classified into "less serious" or "serious" effects.  "Serious" effects are those that 
evoke failure in a biological system and can lead to morbidity or mortality (e.g., acute respiratory distress 
or death). "Less serious" effects are those that are not expected to cause significant dysfunction or death, 
or those whose significance to the organism is not entirely clear.  ATSDR acknowledges that a 
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considerable amount of judgment may be required in establishing whether an end point should be 
classified as a NOAEL, "less serious" LOAEL, or "serious" LOAEL, and that in some cases, there will be 
insufficient data to decide whether the effect is indicative of significant dysfunction.  However, the 
Agency has established guidelines and policies that are used to classify these end points.  ATSDR 
believes that there is sufficient merit in this approach to warrant an attempt at distinguishing between 
"less serious" and "serious" effects.  The distinction between "less serious" effects and "serious" effects is 
considered to be important because it helps the users of the profiles to identify levels of exposure at which 
major health effects start to appear.  LOAELs or NOAELs should also help in determining whether or not 
the effects vary with dose and/or duration, and place into perspective the possible significance of these 
effects to human health. 
The significance of the exposure levels shown in the Levels of Significant Exposure (LSE) tables and 
figures may differ depending on the user's perspective.  Public health officials and others concerned with 
appropriate actions to take at hazardous waste sites may want information on levels of exposure 
associated with more subtle effects in humans or animals (LOAELs) or exposure levels below which no 
adverse effects (NOAELs) have been observed.  Estimates of levels posing minimal risk to humans 
(Minimal Risk Levels or MRLs) may be of interest to health professionals and citizens alike. 
A User's Guide has been provided at the end of this profile (see Appendix B).  This guide should aid in 
the interpretation of the tables and figures for Levels of Significant Exposure and the MRLs. 
3.2.1 Inhalation Exposure 
Studies evaluating the effects of barium following acute, intermediate, and chronic inhalation exposure 
are limited to several case reports of humans exposed occupationally (Doig 1976; Essing et al. 1976; 
Seaton et al. 1986; Shankle and Keane 1988), an experimental exposure to barium in welding fumes 
(Zschiesche et al. 1992), and three experimental studies with animals (Cullen et al. 2000; Hicks et al. 
1986; Tarasenko et al. 1977).  These case reports and animal studies are not adequate for firmly 
establishing the health effects of barium by inhalation because of a number of significant study 
limitations.  The case reports are generally inadequate because data were available for a limited number 
of exposed subjects and because exposure conditions (duration, frequency, dose) were not well 
characterized (Doig 1976; Essing et al. 1976; Seaton et al. 1986; Shankle and Keane 1988).  One of the 
animal studies was limited in that apparently no control animals were used, an inhalation chamber 
providing a controlled dose and environment was not used, and there was a lack of information regarding 
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the vehicle used, purity of the test material, duration and frequency of exposure, and number of animals 
tested (Hicks et al. 1986).  The second animal study consisted of several experiments, but was generally 
limited in that the authors provided few details regarding experimental methods, exposure conditions, and 
test results, and no information as to the number of animals tested, purity of the test material, or statistical 
methods used; furthermore, in some experiments, it was not clear whether or not control animals were 
used (Tarasenko et al. 1977).  The third study examined a limited number of end points (Cullen et al. 
2000). In view of the major limitations associated with the available case reports and studies, results from 
these reports should be regarded as providing only preliminary and/or suggestive evidence that acute, 
intermediate, and chronic inhalation exposure to barium may potentially be associated with adverse health 
effects. Findings from the various case reports and animal studies are briefly described below. 
3.2.1.1 Death 
No studies were located regarding death in humans or animals after inhalation exposure to barium. 
3.2.1.2 Systemic Effects  
No studies were located regarding endocrine, dermal, or ocular effects in humans or animals after 
inhalation exposure to barium. 
Respiratory Effects.    Two reports of workers exposed chronically to dust from barium sulfate 
demonstrated that this exposure had a minor effect on the lungs.  In one study, a benign pneumo­
noconiosis was observed in several factory workers (Doig 1976).  In a second study in which workers 
were exposed by mining barium sulfate, silicosis was observed but was attributed to inhalation of quartz 
(Seaton et al. 1986).  In contrast, a study of workers chronically exposed to barium carbonate dust 
reported no respiratory symptoms attributable to barium exposure (Essing et al. 1976).  X-ray analysis of 
the lungs also showed no abnormalities attributable to barium dust. 
Studies regarding respiratory effects in animals following inhalation exposure to barium are limited to 
three reports (Cullen et al. 2000; Hicks et al. 1986; Tarasenko et al. 1977).  Pulmonary lesions 
(perivascular and peribronchial sclerosis and focal thickening of the interalveolar septa) were observed in 
rats exposed to 3.6 mg barium/m3 as barium carbonate dust 4 hours/day, 6 days/week for 4 months 
(Tarasenko et al. 1977).  Bronchoconstriction was reportedly noted in guinea pigs following inhalation for 
an unspecified period of time to 0.06 mg barium/m3/minute as aerosolized barium chloride solution 
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(Hicks et al. 1986).  In contrast to these finding, no adverse histological alterations were observed in the 
lungs of rats exposed to 44.1 mg barium/m3 as barium sulfate for 119 days (Cullen et al. 2000). 
Cardiovascular Effects. Three of 12 workers chronically exposed to barium carbonate dust had 
elevated blood pressure and 2 workers had ECG abnormalities (Essing et al. 1976).  However, it is 
unknown whether this represented an increased incidence because no comparison with a control 
population was performed.  Increased blood pressure and cardiac irregularities were reportedly observed 
in guinea pigs exposed by inhalation for an unspecified period of time to 0.06 mg barium/m3/minute as 
aerosolized barium chloride solution (Hicks et al. 1986).  Tarasenko et al. (1977) reported a 32% increase 
in arterial pressure and alterations in ECG readings suggestive of disturbances in heart conductivity 
following proserine administration in rats exposed to 3.6 mg barium/m3 as barium carbonate; no ECG 
alterations were observed prior to proserine administration. 
Gastrointestinal Effects.    Abdominal cramps, nausea, and vomiting were experienced by a 22-year­
old factory worker accidentally exposed by acute inhalation to a large but unspecified amount of barium 
carbonate powder (Shankle and Keane 1988).  No animal studies were located regarding gastrointestinal 
effects in animals after inhalation exposure to barium. 
Hematological Effects.    Altered hematological parameters were observed in rats following inhalation 
for an intermediate exposure period to 3.6 mg barium/m3 as barium carbonate dust (Tarasenko et al. 
1977). Reported changes included decreased blood hemoglobin and thrombocyte count.  
Musculoskeletal Effects.    After accidental exposure to a large amount of barium carbonate powder 
by acute inhalation, a 22-year-old factory worker developed progressive muscle weakness and paralysis 
of the extremities and neck (Shankle and Keane 1988); this is likely due to the low serum potassium level 
rather than a direct effect on muscle tissue.  X-ray analysis of the bones and skeletal muscles of the pelvis 
and thighs of workers chronically exposed to barium carbonate dust revealed no apparent build up of 
insoluble barium in these tissues (Essing et al. 1976). No studies were located regarding musculoskeletal 
effects in animals after inhalation exposure to barium. 
Hepatic Effects.    No studies were located regarding hepatic effects in humans after inhalation 
exposure to barium.  Impaired detoxifying function of the liver was noted in rats exposed to 3.6 mg 
barium/m3 as barium carbonate dust (Tarasenko et al. 1977).  No other details were reported. 
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Renal Effects.    Renal failure occurred in a 22-year-old worker accidentally exposed by acute 
inhalation to barium carbonate powder (Shankle and Keane 1988).  No studies were located regarding 
renal effects in animals after inhalation exposure to barium. 
Body Weight Effects.    A 21% decrease in body weight gain was observed in rats exposed to 3.6 mg 
barium/m3 as barium carbonate dust for 4 months (Tarasenko et al. 1977). 
Metabolic Effects.    Decreases in plasma potassium concentrations were observed in two groups of 
welders using barium-containing electrodes; the barium levels in the work environment were 4.4 and 
0.3 mg/m3 (Zschiesche et al. 1992).  However, this was not observed in a third group of welders exposed 
to 2.0 mg barium/m3. A low serum potassium level was also observed in a worker accidentally exposed 
to barium carbonate powder (Shankle and Keane 1988).  Additionally, the plasma potassium 
concentrations were not statistically different from levels measured prior to barium exposure. Tarasenko 
et al. (1977) reported a decrease in urinary calcium levels and increased blood phosphorus levels in rats 
exposed to 3.6 mg barium/m3 as barium carbonate dust for an intermediate duration (Tarasenko et al. 
1977). This study also reported a decrease in blood glucose levels in barium-exposed rats. 
3.2.1.3 Immunological and Lymphoreticular Effects  
No studies were located regarding immunological effects in humans or animals after inhalation exposure 
to barium. 
3.2.1.4 Neurological Effects 
Absence of deep tendon reflexes was observed in a 22-year-old man accidentally exposed by acute 
inhalation to barium carbonate powder (Shankle and Keane 1988); as noted previously, this is probably 
due to the barium-induced low potassium levels.  No studies were located regarding neurological effects 
in animals after inhalation exposure to barium. 
3.2.1.5 Reproductive Effects  
No studies were located regarding reproductive effects in humans after inhalation exposure to barium.  
Only one limited report was available regarding reproductive effects in animals following intermediate 
inhalation exposure to barium carbonate (Tarasenko et al. 1977).  Disturbances in spermatogenesis, 
including decreased number of sperm, decreased percentage of motile sperm, and decreased osmotic 
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resistance of sperm, were reportedly observed in male rats exposed by inhalation for one cycle of 
spermatogenesis to 15.8 mg barium/m3 as barium carbonate dust.  The testicles of these treated rats 
reportedly had an increase in the number of ducts with desquamated epithelium and a reduced number of 
ducts with 12th-stage meiosis. The condition of the testicles of treated rats returned to normal 30 days 
after cessation of barium carbonate treatment (Tarasenko et al. 1977).  Similar observations were noted in 
a second experiment in which male rats were exposed by inhalation for an intermediate period to 3.6 mg 
barium/m3 as barium carbonate dust.  In a third experiment by the same authors, female rats exposed by 
inhalation for an intermediate period to 2.2 or 9.4 mg barium/m3 as barium carbonate dust reportedly 
developed a shortened estrous cycle and alterations in the morphological structure of the ovaries. 
3.2.1.6 Developmental Effects 
No studies were located regarding developmental effects in humans after inhalation exposure to barium.  
Only one limited report was available regarding developmental effects in animals after intermediate 
inhalation exposure to barium (Tarasenko et al. 1977).  Reduced survival, underdevelopment, lowered 
weight gain, and various hematologic alterations (erythropenia, leukocytosis, eosinophilia, neutrophilia) 
were reported in the offspring of female rats exposed by inhalation for an intermediate period to 2.2 or 
9.4 mg barium/m3 as barium carbonate dust (Tarasenko et al. 1977).  No other significant details 
regarding this developmental study were reported. 
3.2.1.7 Cancer 
No studies were located regarding cancer in humans or animals after inhalation exposure to barium. 
3.2.2 Oral Exposure  
The majority of studies evaluating the health effects of barium are oral exposure studies.  The available 
oral studies include numerous case reports of humans exposed orally to barium through accidental or 
intentional ingestion, several epidemiological and statistical investigations of humans exposed to drinking 
water containing barium, and various experimental animal studies involving acute, intermediate, or 
chronic exposure to barium either by gavage or by drinking water.  Findings from the various oral studies 
are summarized below. 
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3.2.2.1 Death 
Death has been reported in a number of case reports of accidental or intentional ingestion of barium salts.  
The cause of death was attributed to cardiac arrest, severe gastrointestinal hemorrhage, or unknown 
causes (Das and Singh 1970; Deng et al. 1991; Diengott et al. 1964; Downs et al. 1995; Jourdan et al. 
2001; McNally 1925; Ogen et al. 1967; Talwar and Sharma 1979).  Doses in these cases were not known. 
In addition to case reports of death in humans, several studies have examined mortality rates in residents 
living in communities with elevated barium levels in the drinking water (Brenniman and Levy 1985; 
Brenniman et al. 1979a, 1979b, 1981; Elwood et al. 1974; Schroeder and Kraemer 1974). Two studies 
found no statistical correlations between barium concentrations in drinking water and total mortality 
and/or cardiovascular mortality rates in exposed populations (Elwood et al. 1974; Schroeder and Kraemer 
1974).  Interpretation of the study results are limited by the lack of information on exposure conditions 
(dose, duration, frequency) and the number of people exposed.  Results of a third study indicated that 
relative to communities with little or no barium in drinking water, communities with elevated 
concentrations of barium in their drinking water had significantly higher mortality rates for all causes, 
heart disease, arteriosclerosis, and all cardiovascular disease (Brenniman and Levy 1985; Brenniman et al. 
1979a, 1979b, 1981).  This epidemiological study had a number of confounding variables, including 
possible use in the study population of home water softeners that would remove barium from the drinking 
water, inclusion of communities that had significant changes in population, lack of a way to control for 
length of time an individual lived in a community, and widely varying concentrations of other 
contaminants (calcium, sodium, magnesium) in the drinking water.   
The LD50 values for barium chloride in rats range from 132 to 277 mg barium/kg (Borzelleca et al. 1988; 
Tardiff et al. 1980).  Significant increases in mortality were observed in rats and mice exposed to 200 or 
450 mg barium/kg/day as barium chloride in drinking water for 90 days (NTP 1994).  Survival was not 
affected at 110 or 205 mg barium/kg/day in the rats or mice, respectively.  No changes in mortality were 
observed in rats chronically exposed to doses as high as 60 mg barium/kg/day as barium chloride in the 
drinking water (NTP 1994).  An increase in mortality, attributable to nephropathy, was observed in mice 
chronically exposed to 160 mg barium/kg/day as barium chloride in drinking water (NTP 1994); the 
number of deaths was similar to controls in mice exposed to 75 mg barium/kg/day.  In male mice exposed 
to 0.95 mg barium/kg/day as barium acetate in drinking water, a significant decrease in longevity (defined 
as average lifespan of the last five surviving animals) was observed; however, no significant differences 
in mean lifespan were observed (Schroeder and Mitchener 1975b).  Similarly, lifespan was not 
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significantly altered in female mice exposed to 0.95 mg barium/kg/day (Schroeder and Mitchener 1975b) 
or male or female rats exposed to 0.7 mg barium/kg/day as barium acetate in drinking water (Schroeder 
and Mitchener 1975a). 
LD50 values and reliable LOAEL values for death in each species and duration category are recorded in 
Table 3-1 and plotted in Figure 3-1. 
3.2.2.2 Systemic Effects  
The highest NOAEL values and all reliable LOAEL values for systemic effects in each species and 
duration category are recorded in Table 3-1 and plotted in Figure 3-1. 
Respiratory Effects.    Limited data are available regarding respiratory effects in animals following 
oral barium exposure.  Fluid in the trachea was observed in rats receiving a single gavage dose of 198 mg 
barium/kg as barium chloride (Borzelleca et al. 1988).  However, this effect was not observed when rats 
were dosed with 198 mg barium/kg/day as barium chloride for 10 days (Borzelleca et al. 1988).  No 
significant alterations in lung weights, gross lesions, or histopathological alterations were observed in the 
respiratory tracts of rats and mice exposed to doses as high as 110 or 70 mg barium/kg/day, 180 or 
450 mg barium/kg/day, or 60 and 160 mg barium/kg/day for intermediate or chronic durations, 
respectively (McCauley et al. 1985; NTP 1994; Tardiff et al. 1980) or lifetime exposure to 0.7 or 0.95 mg 
barium/kg/day, respectively, as barium acetate via drinking water (Schroeder and Mitchener 1975a).   
Cardiovascular Effects.    As demonstrated in numerous case reports, acute exposure to presumably 
high doses of barium carbonate, barium sulfate, or barium chloride can result in serious effects on heart 
rhythm.  Barium adversely affects cardiac automaticity resulting in ventricular tachycardia and other 
disruptions of rhythm (Deng et al. 1991; Diengott et al. 1964; Downs et al. 1995; Gould et al. 1973; Jha et 
al. 1993; Koch et al. 2003; Silva 2003; Talwar and Sharma 1979; Wetherill et al. 1981).  Hypotension has 
also been reported in some cases (Koch et al. 2003; Talwar and Sharma 1979).  The likely cause of these 
effects was barium-induced hypokalemia. 
Several human studies have investigated a possible association between exposure to low levels of barium 
and alterations in blood pressure and cardiac rhythms.  In a small-scale (11 subjects) study of individuals 
exposed to 0.1 or 0.2 mg barium/kg/day as barium chloride in drinking water for 4 weeks, no significant 
alterations in blood pressure or ECG readings were found (Wones et al. 1990).  There was no significant  
55
198
59
269
34
132
220
58
198
198
198
198
198
198
198
198
Table 3-1 Levels of Significant Exposure to Barium - Oral 
Exposure/ 
Duration/ 
a 
Key to 
Figure 
Species 
(Strain) 
Frequency 
(Route) 
ACUTE EXPOSURE 
Death 
1 Rat 
(Sprague-
Dawley) 
once 
(GW) 
System 
NOAEL 
(mg/kg/day) 
Less Serious 
(mg/kg/day) 
LOAEL 
Serious 
(mg/kg/day) 
198 (death in 15/20 rats) 
Reference 
Chemical Form 
Borzelleca et al. 1988 
Barium chloride 
Comments 
2 Rat 
(Sprague-
Dawley) 
once 
(GW) 
269 F (LD50 in females) Borzelleca et al. 1988 
Barium chloride 
3 Rat 
(NS) 
once 
(GW) 
132 (LD50 adult) 
220 (LD50 weanling) 
Tardiff et al. 1980 
Barium chloride 
Systemic 
4 Rat 
(Sprague-
Dawley) 
10 d 
1 x/d 
(GW) 
Resp 198 Borzelleca et al. 1988 
Barium chloride 
Cardio 198 
Gastro 198 
Hemato 198 
Hepatic 
Renal 
198 
198 
Ocular 198 
Bd Wt 198 
B
A
R
IU
M
 A
N
D
 B
A
R
IU
M
 C
O
M
P
O
U
N
D
S
3.  H
E
A
LTH
 E
FFE
C
TS
29
766 198
198
66
198
198
66
198
66
198
66 198
66 198
198
119
198
57
198
Table 3-1 Levels of Significant Exposure to Barium - Oral (continued) 
Exposure/ LOAEL 
Duration/ 
a 
Key to Species Frequency NOAEL Less Serious Serious Reference 
Figure (Strain) (Route) System (mg/kg/day) (mg/kg/day) (mg/kg/day) Chemical Form Comments 
5 Rat 
(Sprague-
Dawley) 
once 
(GW) 
Resp 66 198 (fluid in trachea) Borzelleca et al. 1988 
Barium chloride 
Cardio 198 
Gastro 66 198 (inflammation of small 
and large intestine) 
Hemato 198 
Hepatic 66 198 (decreased liver/brain 
weight ratio; darkened 
liver) 
Renal 66 198 (increased kidney/body 
weight ratio) 
Ocular 66 198 (ocular discharge) 
Bd Wt 66 198 (decreased body weight) 
Immuno/ Lymphoret 
6 Rat 
(Sprague-
Dawley) 
Neurological 
7 Rat 
(Sprague-
Dawley) 
10 d 
1 x/d 
(GW) 
10 d 
1 x/d 
(GW) 
Other 198 
198 
198 
Borzelleca et al. 1988 
Barium chloride 
Borzelleca et al. 1988 
Barium chloride 
Evaluated weight and 
occurrence of gross 
lesions in thymus. 
B
A
R
IU
M
 A
N
D
 B
A
R
IU
M
 C
O
M
P
O
U
N
D
S
3.  H
E
A
LTH
 E
FFE
C
TS
30
53
198
60
138
198
90
200
102
450
39
0.2
15
150
15
150
Table 3-1 Levels of Significant Exposure to Barium - Oral (continued) 
Exposure/ LOAEL 
Duration/ 
a 
Key to Species Frequency NOAEL Less Serious Serious Reference 
Figure (Strain) (Route) System (mg/kg/day) (mg/kg/day) (mg/kg/day) Chemical Form Comments 
Reproductive 
8 Rat 
(Sprague-
Dawley) 
once 
(GW) 
198 Borzelleca et al. 1988 
Barium chloride 
Evaluated testes and 
ovary weights. 
9 Rat 
(Sprague-
Dawley) 
10 d 
1 x/d 
(GW) 
138 F 198 F (decreased ovary weight 
and ovaries/brain ratio) 
Borzelleca et al. 1988 
Barium chloride 
Evaluated testes and 
ovary weights. 
INTERMEDIATE EXPOSURE 
Death 
10 Rat 
(Fischer- 344) 
90 d 
(W) 
200 M (30% mortality) NTP 1994 
Barium chloride 
B
A
R
IU
M
 A
N
D
 B
A
R
IU
M
 C
O
M
P
O
U
N
D
S
11 Mouse 
(B6C3F1) 
Systemic 
12 Human 
(NS) 
90 d 
(W) 
4 wk 
7 d/wk 
(W) 
Cardio 0.2 M 
450 M (60% mortality) NTP 1994 
Barium chloride 
Wones et al. 1990 
Barium chloride 
13 Rat 
(Dahl) 
16 wk 
(W) 
Cardio 150 McCauley et al. 1985 
NR 
Study used salt 
resistant and salt 
sensitive rat strains. 
Renal 15 150 (fused podocytes and 
thickening of the capillary 
basement membrane in 
glomeruli) 
3.  H
E
A
LTH
 E
FFE
C
TS
31
61
150
15
150
65
37.5
37.5
37.5
37.5
37.5
37.5
37.5
37.5
Table 3-1 Levels of Significant Exposure to Barium - Oral (continued) 
Exposure/ LOAEL 
Duration/ 
a 
Key to Species Frequency NOAEL Less Serious Serious Reference 
Figure (Strain) (Route) System (mg/kg/day) (mg/kg/day) (mg/kg/day) Chemical Form Comments 
14 Rat 
(Sprague-
Dawley) 
16 wk 
(W) 
Cardio 150 McCauley et al. 1985 
NR 
Study used 
uninephrecomized rats. 
Renal 15 150 (fused podocytes and 
thickening of the capillary 
basement membrane in 
glomeruli) 
15 Rat 
(Sprague-
Dawley) 
36 wk 
(W) 
Resp 37.5 M McCauley et al. 1985 
NR 
Cardio 37.5 M 
Gastro 37.5 M 
Musc/skel 
Hepatic 
Renal 
37.5 M 
37.5 M 
37.5 M 
Ocular 37.5 M 
Bd Wt 37.5 M 
B
A
R
IU
M
 A
N
D
 B
A
R
IU
M
 C
O
M
P
O
U
N
D
S
3.  H
E
A
LTH
 E
FFE
C
TS
32
72
37.5
37.5
37.5
37.5
37.5
37.5
37.5
37.5
88
110
110
110
110
110
110
110
110
	








	
Table 3-1 Levels of Significant Exposure to Barium - Oral  (continued) 
Exposure/  
Duration/  
a 
 FrequencyKey to Species (Route)Figure (Strain) 	 System 
16 Rat 46 wk Resp
(Sprague- (W) 
Dawley) 
Cardio 
Gastro 
Musc/skel 
Hepatic 
Renal 
Ocular 
Bd Wt 
17 Rat 15 d Resp
(Fischer- 344) (W) 
Cardio 
Gastro 
Hemato 
Hepatic 
Renal 
Bd Wt 
Metab 
LOAEL 
NOAEL 
(mg/kg/day) 
Less Serious 
(mg/kg/day) 
Serious 
(mg/kg/day) 
Reference 
Chemical Form Comments 
37.5 F 	 McCauley et al. 1985 
NR 
37.5 F 
37.5 F 
37.5 F 
37.5 F 
37.5 F 
37.5 F 
37.5 F 
110  NTP 1994 
Barium chloride 
110 
110 
110 
110 
110 
110 
110 
B
A
R
IU
M
 A
N
D
 B
A
R
IU
M
 C
O
M
P
O
U
N
D
S
3.  H
E
A
LTH
 E
FFE
C
TS
33
89
180
180
180
180
180
180
65
180
115
180
110
200
180
77
1
8.6
78
1.2
11
	
	
	
	
 
Table 3-1 Levels of Significant Exposure to Barium - Oral  (continued) 
Exposure/ 
Duration/ 
a FrequencyKey to Species (Route)Figure (Strain) 
18  Rat 90 d 
(Fischer- 344) (W) 
19  Rat 1 mo 
(Long- Evans) 7 d/wk 
(W) 
20  Rat 4 mo 
(Long- Evans) 7 d/wk 
(W) 
System 
Resp 
Cardio 
Gastro 
Hemato 
Musc/skel 
Hepatic 
Renal 
Ocular 
Bd Wt 
Metab 
Cardio 
Cardio 
NOAEL 
(mg/kg/day) 
180 F 
180 F 
180 F 
180 F 
180 F 
180 F 
b
65 F 
180 F 
110 M 
180 F 
1 F 
1.2 F 
LOAEL 
Less Serious 	 Serious 
(mg/kg/day) 	 (mg/kg/day) 
180 F (dilatation of proximal 
renal cortex) 
115 F (increased kidney weight) 
200 M (13% lower final body 
weight) 
8.6 F (increased blood 

pressure) 

11 F (increased blood 

pressure) 

Reference 
Chemical Form 
NTP 1994 
Barium chloride 
Perry et al. 1983, 1985, 1989 
Barium chloride 
Perry et al. 1983, 1985, 1989 
Barium chloride 
Comments 
Animals were fed a low 
mineral diet. 
Animals were fed a low 
mineral diet. 
B
A
R
IU
M
 A
N
D
 B
A
R
IU
M
 C
O
M
P
O
U
N
D
S
3.  H
E
A
LTH
 E
FFE
C
TS
34
87
35
35
35
35
35
35
35
100
450
450
450
450
450
450
205 450
450
205
450
450
21 
22 
Table 3-1 Levels of Significant Exposure to Barium - Oral 	 (continued) 
Exposure/ 
Duration/ 
a FrequencyKey to Species (Route)Figure (Strain) 
Rat 	 13 wk 
7 d/wkCharles-River 
(W) 
Mouse 90 d 
(B6C3F1) (W) 
System 
Resp 
Cardio 
Hemato 
Musc/skel 
Hepatic 
Renal 
Bd Wt 
Resp 
Cardio 
Gastro 
Hemato 
Musc/skel 
Hepatic 
Renal 
Ocular 
Bd Wt 
Metab 
LOAEL 
ReferenceNOAEL Less Serious Serious 
(mg/kg/day) (mg/kg/day) (mg/kg/day) Chemical Form Comments 
35 Tardiff et al. 1980 
Barium chloride 
35 
35 
35 
35 
35 
35 
450 M 
450 M 
NTP 1994 
Barium chloride 
450 M 
450 M 
450 M 
450 M 
205 M 
450 M 
450 M (nephropathy) 
205 M 450 M (30% lower final body 
weight) 
450 M 
B
A
R
IU
M
 A
N
D
 B
A
R
IU
M
 C
O
M
P
O
U
N
D
S
3.  H
E
A
LTH
 E
FFE
C
TS
35
97
70
70
70
70
70
70
70
70
120
37.5
75
37.5
123
180
122
205
450
	
	
	
	
23 
Table 3-1 Levels of Significant Exposure to Barium - Oral  (continued) 
Exposure/ 
Duration/ 
a FrequencyKey to Species (Route)Figure (Strain) 
Mouse 15 d 
(B6C3F1) (W) 
Immuno/ Lymphoret 
24 Rat 36 wk 
(Sprague-
Dawley) 
(W) 
25  Rat 46 wk 
(Sprague- (W) 
Dawley) 
26  Rat 90 d 
(Fischer- 344) (W) 
27  Mouse 90 d 
(B6C3F1) (W) 
System 
Resp 
Cardio 
Gastro 
Hemato 
Hepatic 
Renal 
Bd Wt 
Metab 
LOAEL 
ReferenceNOAEL Less Serious Serious 
(mg/kg/day) (mg/kg/day) (mg/kg/day) Chemical Form 
70 M 
70 M 
70 M 
70 M 
70 M 
70 M 
70 M 
70 M 
NTP 1994 
Barium chloride 
37.5 M McCauley et al. 1985 
NR 
37.5 F McCauley et al. 1985 
NR 
180 F NTP 1994 
Barium chloride 
205 M 450 M (thymic and splenic 
atrophy) 
NTP 1994 
Barium chloride 
Comments 
Histological 
examination of thymus 
and lymph nodes. 
Histological 
examination of thymus 
and lymph nodes. 
Histological 
examination of spleen 
and thymus. 
Histological 
examination of spleen 
and thymus. 
B
A
R
IU
M
 A
N
D
 B
A
R
IU
M
 C
O
M
P
O
U
N
D
S
3.  H
E
A
LTH
 E
FFE
C
TS
36
67
37.5
70
37.5
91
115
180
93
110
85
35
101
200
495
98
70
107
200
180
 
31 
32 
33 
Table 3-1 Levels of Significant Exposure to Barium - Oral (continued) 
Exposure/ LOAEL 
Duration/ 
a 
Key to Species Frequency NOAEL Less Serious Serious Reference 
Figure (Strain) (Route) System (mg/kg/day) (mg/kg/day) (mg/kg/day) Chemical Form Comments 
Neurological 
28 Rat 
(Sprague-
Dawley) 
36 wk 
(W) 
37.5 M McCauley et al. 1985 
NR 
Histological 
examination of brain. 
29 Rat 
(Sprague-
Dawley) 
46 wk 
(W) 
37.5 F McCauley et al. 1985 
NR 
Histological 
examination of brain. 
30 Rat 
(Fischer- 344) 
90 d 
(W) 
115 F 180 F (decreased spontaneous 
motor activity) 
NTP 1994 
Barium chloride 
B
A
R
IU
M
 A
N
D
 B
A
R
IU
M
 C
O
M
P
O
U
N
D
S
Rat 15 d 110 NTP 1994 
(Fischer- 344) (W) Barium chloride 
Rat 13 wk 35 Tardiff et al. 1980 Histological 
Charles-River 7 d/wk examination of brain.Barium chloride(W) 
3.  H
E
A
LTH
 E
FFE
C
TS
Mouse 90 d 200 F 495 F (decreased forelimb grip NTP 1994 
(B6C3F1) (W) strength) Barium chloride 
34 Mouse 
(B6C3F1) 
15 d 
(W) 
70 M NTP 1994 
Barium chloride 
Reproductive 
35 Rat 
(Fischer- 344) 
M: 60 d 
F: 30 d 
(W) 
200 M 
c
180 F 
Dietz et al. 1992 
Barium chloride 
37
66
37.5
71
37.5
92
200
180
94
110
110
205
200
103
450
495
 
 
 
38 
Table 3-1 Levels of Significant Exposure to Barium - Oral (continued) 
Exposure/ LOAEL 
Duration/ 
a 
Key to Species Frequency NOAEL Less Serious Serious Reference 
Figure (Strain) (Route) System (mg/kg/day) (mg/kg/day) (mg/kg/day) Chemical Form 
36 Rat 36 wk 37.5 M McCauley et al. 1985
(Sprague- (W) NRDawley) 
37 Rat 46 wk 37.5 F McCauley et al. 1985
(Sprague- (W) NRDawley) 
Rat 90 d 200 M NTP 1994 
(Fischer- 344) (W) 
c Barium chloride 
180 F 
39 Rat 15 d 110 NTP 1994 
(Fischer- 344) (W) Barium chloride 
40 Mouse M: 60 d 205 M Dietz et al. 1992F: 30 d(B6C3F1) 
c Barium chloride(W) 200 F 
41 Mouse 90 d c450 M NTP 1994 
(B6C3F1) (W) Barium chloride 
495 F 
Comments 
Histological 
examination of 
reproductive tissues. 
Histological 
examination of 
reproductive tissues. 
Histological 
examination of 
reproductive tissues. 
Histological 
examination of 
reproductive tisses. 
B
A
R
IU
M
 A
N
D
 B
A
R
IU
M
 C
O
M
P
O
U
N
D
S
3.  H
E
A
LTH
 E
FFE
C
TS
38
99
70
85
108
115
180
109
200
105
160
73
15
15
15
15
15
15
15
15
 
Table 3-1 Levels of Significant Exposure to Barium - Oral (continued) 
Exposure/ LOAEL 
Duration/ 
a 
Key to Species Frequency NOAEL Less Serious Serious Reference 
Figure (Strain) (Route) System (mg/kg/day) (mg/kg/day) (mg/kg/day) Chemical Form Comments 
B
A
R
IU
M
 A
N
D
 B
A
R
IU
M
 C
O
M
P
O
U
N
D
S
42 Mouse 15 d c70 M NTP 1994 
(B6C3F1) (W) Barium chloride 
85 F 
Developmental 
43 Rat M: 60 d 115 F 180 F (decreased pup body Dietz et al. 1992F: 30 d(Fischer- 344) weight and nonsignificant Barium chloride(W) decrease in litter size) 
44 Mouse 
(B6C3F1) 
M: 60 d 
F: 30 d 
(W) 
200 F Dietz et al. 1992 
Barium chloride 
CHRONIC EXPOSURE 
Death 
45 Mouse 
(B6C3F1) 
2 yr 
(W) 
160 M (increased mortality) NTP 1994 
Barium chloride 
Systemic 
46 Rat 
(Sprague-
Dawley) 
68 wk 
(W) 
Resp 15 M McCauley et al. 1985 
NR 
3.  H
E
A
LTH
 E
FFE
C
TS
Cardio 15 M 
Gastro 15 M 
Musc/skel 15 M 
Hepatic 15 M 
Renal 15 M 
Ocular 15 M 
Bd Wt 15 M 39
95
60
60
60
60
60
60
60
60
60
60
46
0.17
0.8
7.2
Table 3-1 Levels of Significant Exposure to Barium - Oral (continued) 
Exposure/ LOAEL 
Duration/ 
a 
Key to Species Frequency NOAEL Less Serious Serious Reference 
Figure (Strain) (Route) System (mg/kg/day) (mg/kg/day) (mg/kg/day) Chemical Form Comments 
47 Rat 
(Fischer- 344) 
2 yr 
(W) 
Resp 60 M NTP 1994 
Barium chloride 
Cardio 60 M 
Gastro 60 M 
Hemato 60 M 
Musc/skel 60 M 
Hepatic 60 M 
Renal 60 M 
Ocular 60 M 
Bd Wt 60 M 
Metab 60 M 
48 Rat 
(Long- Evans) 
16 mo 
7 d/wk 
(W) 
Cardio 0.17 F 0.8 F (increased blood 
pressure) 
Perry et al. 1983, 1985, 1989 
Barium chloride 
Animals were fed a low 
mineral diet. 
B
A
R
IU
M
 A
N
D
 B
A
R
IU
M
 C
O
M
P
O
U
N
D
S
3.  H
E
A
LTH
 E
FFE
C
TS
7.2 F (depressed rates of 
cardiac contraction and 
electrical conductivity) 
40
104
160
160
160
160
160
160
75 160
160
75 160
63
15
124
60
125
75
160
	
	
	
	
 
Table 3-1 Levels of Significant Exposure to Barium - Oral  (continued) 
Exposure/ 
Duration/ 
a FrequencyKey to Species (Route)Figure (Strain) 
49  Mouse 2 yr 
(B6C3F1) (W) 
Immuno/ Lymphoret 
50 Rat 68 wk 
(Sprague- (W) 
Dawley) 
51  Rat 2 yr 
(Fischer- 344) (W) 
52  Mouse 2 yr 
(B6C3F1) (W) 
System 
Resp 
Cardio 
Gastro 
Hemato 
Musc/skel 
Hepatic 
Renal 
Ocular 
Bd Wt 
NOAEL 
(mg/kg/day) 
160 M 
160 M 
160 M 
160 M 
160 M 
160 M 
d
75 M 
160 M 
75 M 
15 M 
60 M 
75 M 
Less Serious 
(mg/kg/day) 
160 M (lymphoid depletion in 
the spleen and 
decreased relative and 
absolute spleen weight) 
LOAEL 
Serious 
(mg/kg/day) 
160 M (marked nephropathy) 
160 M (weight loss) 
Reference 
Chemical Form 
NTP 1994 
Barium chloride 
McCauley et al. 1985 
NR 
NTP 1994 
Barium chloride 
NTP 1994 
Barium chloride 
Comments 
Histological 
examination of thymus 
and lymph nodes. 
Histological 
examination of spleen 
and thymus. 
Histological 
examination of thymus 
and spleen. 
B
A
R
IU
M
 A
N
D
 B
A
R
IU
M
 C
O
M
P
O
U
N
D
S
3.  H
E
A
LTH
 E
FFE
C
TS
41
74
15
126
60
127
160
62
15
96
60
75
106
160
200
 
 
Table 3-1 Levels of Significant Exposure to Barium - Oral (continued) 
Exposure/ LOAEL 
Duration/ 
a 
Key to Species Frequency NOAEL Less Serious Serious Reference 
Figure (Strain) (Route) System (mg/kg/day) (mg/kg/day) (mg/kg/day) Chemical Form 
Neurological 
53 Rat 
(Sprague-
Dawley) 
68 wk 
(W) 
15 M McCauley et al. 1985 
NR 
54 Rat 
(Fischer- 344) 
2 yr 
(W) 
60 M NTP 1994 
Barium chloride 
55 Mouse 
(B6C3F1) 
Reproductive 
56 Rat 
(Sprague-
Dawley) 
2 yr 
(W) 
68 wk 
(W) 
160 M 
15 M 
NTP 1994 
Barium chloride 
McCauley et al. 1985 
NR 
57 Rat 2 yr c60 M NTP 1994 
(Fischer- 344) (W) Barium chloride 
75 F 
58 Mouse 2 yr c160 M NTP 1994 
(B6C3F1) (W) Barium chloride 
200 F 
Comments 
Histological 
examination of brain. 
Histological 
examination of brain. 
Histological 
examination of brain. 
Histological 
examination of 
reproductive tissues. 
Histological 
examination of 
reproductive tissues. 
Histological 
examination of 
reproductive tissues. 
B
A
R
IU
M
 A
N
D
 B
A
R
IU
M
 C
O
M
P
O
U
N
D
S
3.  H
E
A
LTH
 E
FFE
C
TS
a The number corresponds to entries in Figure 3-1. 
b Used to derive an intermediate duration oral minimal risk level (MRL) of 0.2 mg barium/kg/day; dose divided by an uncertainty factor of 100 (10 for extrapolation from animals to 
humans and 10 for human variability) and modifying factor of 3 to account for database deficiencies. 
c Differences in levels of health effects and cancer effects between male and females are not indicated in Figure 3-1. Where such differences exist, only the levels of effect for the 
most sensitive gender are presented. 
d The chronic-duration oral MRL of 0.2 mg barium/kg/day was calculated using benchmark dose analysis. The BMDL5 of 61 mg barium/kg/day was divided by an uncertainty factor 
of 100 (10 to account for extrapolation from animals to humans and 10 for human variability) and modifying factor of 3 to account for database deficiencies. 
Cardio = cardiovascular; d = day; F = female; Gastro = gastrointestinal; (GW) = gavage in water; Hemato = hematological; LD50 = lethal dose, 50% kill; M = male; mo = month; 
Musc/skel = musculoskeletal; NS = not specified; NR = not reported; Resp = respiratory; (W) = drinking water; wk = week; x = time(s); yr = year 
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Figure 3-1 Levels of Significant Exposure to Barium - Oral 	
Acute (≤14 days) 	
Systemic 
BARIUM AND BARIUM COMPOUNDS
mg/kg/day 
2r 
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 other than
 Cancer 
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Figure 3-1 Levels of Significant Exposure to Barium - Oral (Continued)  
Acute (≤14 days) 	
mg/kg/day 
1000 
8r 9r 
9r 
100 
10 
BARIUM AND BARIUM COMPOUNDS
3.  HEALTH EFFECTS
c-Cat 
d-Dog
r-Rat 
p-Pig
q-Cow
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s-Hamster 
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 Cancer Effect Level-Animals
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NOAEL - Animals
 Cancer Effect Level-Humans
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NOAEL - Humans
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 for effects
 other than
 Cancer 
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Figure 3-1 Levels of Significant Exposure to Barium - Oral (Continued)  
Intermediate (15-364 days) 	
Systemic 
BARIUM AND BARIUM COMPOUNDS
mg/kg/day 
1000 
11m 22m 22m 
10r 18r 
13r 14r 
17r100 
23m 23m 
15r 16r 15r21r 
10 
1 
12 
0.1 
22m 
15r 
22m 22m 
22m18r 18r 
13r 
17r 
23m 23m 
16r 15r 16r21r 21r 
13r 
18r 
14r 
17r 
18r 
15r 16r 
14r 
18r 
17r 
16r 
20r 
19r 
20r 
19r 
3.  HEALTH EFFECTS
c-Cat 
d-Dog
r-Rat 
p-Pig
q-Cow
 -Humans 
k-Monkey
m-Mouse 
h-Rabbit 
a-Sheep 
f-Ferret 
j-Pigeon
e-Gerbil 
s-Hamster 
g-Guinea Pig 
n-Mink 
o-Other
 Cancer Effect Level-Animals
 LOAEL, More Serious-Animals
LOAEL, Less Serious-Animals
NOAEL - Animals
 Cancer Effect Level-Humans
 LOAEL, More Serious-Humans
LOAEL, Less Serious-Humans
NOAEL - Humans
 LD50/LC50
 for effects
 other than
 Cancer 
Minimal Risk Level 
45
22m 22m 
18r 18r 
17r 17r 
23m 23m 
15r 16r21r 21r 
Re
na
l 
Oc
ula
r 
Bo
dy 
We
igh
t 
Me
tab
olic
 
Im
mu
no
/Ly
mp
ho
r 
Ne
uro
log
ica
l 
Re
pro
du
ctiv
e 
De
vel
op
me
nta
l 




Figure 3-1 Levels of Significant Exposure to Barium - Oral (Continued)  
Intermediate (15-364 days) 	
Systemic 

BARIUM AND BARIUM COMPOUNDS
mg/kg/day 
1000 
18r
100 
21r 
10 
1 
0.1 
33m22m 22m 22m 27m 41m 
22m 27m18r 33m 40m 44m18r 18r 26r 30r 35r 38r 43r 
30r 43r17r 18r 17r 31r 39r 
23m 23m 34m 42m 
15r 16r 15r 16r 24r 25r 28r 29r 36r 37r21r 32r 
3.  HEALTH EFFECTS
c-Cat 
d-Dog
r-Rat 
p-Pig
q-Cow
 -Humans 
k-Monkey
m-Mouse 
h-Rabbit 
a-Sheep 
f-Ferret 
j-Pigeon
e-Gerbil 
s-Hamster 
g-Guinea Pig 
n-Mink 
o-Other
 Cancer Effect Level-Animals
 LOAEL, More Serious-Animals
LOAEL, Less Serious-Animals
NOAEL - Animals
 Cancer Effect Level-Humans
 LOAEL, More Serious-Humans
LOAEL, Less Serious-Humans
NOAEL - Humans
 LD50/LC50
Minimal Risk Level
 for effects
 other than
 Cancer 
46
De
ath
 
Re
spi
rat
ory
 
Ca
rdi
ova
scu
lar
 
Ga
str
oin
tes
tina
l 
He
ma
tolo
gic
al 
Mu
scu
los
kel
eta
l 
He
pa
tic 
Re
na
l 
Oc
ula
r 
Bo
dy 
We
igh
t 
Me
tab
olic
 
Im
mu
no
/Ly
mp
ho
r 
Ne
uro
log
ica
l 
Re
pro
du
ctiv
e 
 Figure 3-1 Levels of Significant Exposure to Barium - Oral (Continued)
Chronic (≥365 days) 
Systemic 
mg/kg/day 
1000 
45m 49m 49m 49m 49m 49m 49m 49m 49m 49m 52m 55m 58m 
100 
49m 49m 52m 
47r 47r 47r 47r 47r 47r 47r 47r 47r 47r 51r 54r 57r 
46r 46r 46r 46r 46r 46r 46r 46r 50r 53r 56r 
BARIUM AND BARIUM COMPOUNDS
3.  HEALTH EFFECTS
10 
48r 
1 
48r 
48r 
0.1 
c-Cat 
d-Dog
r-Rat 
p-Pig
q-Cow
 -Humans 
k-Monkey
m-Mouse 
h-Rabbit 
a-Sheep 
f-Ferret 
j-Pigeon
e-Gerbil 
s-Hamster 
g-Guinea Pig 
n-Mink 
o-Other
 Cancer Effect Level-Animals
 LOAEL, More Serious-Animals
LOAEL, Less Serious-Animals
NOAEL - Animals
 Cancer Effect Level-Humans
 LOAEL, More Serious-Humans
LOAEL, Less Serious-Humans
NOAEL - Humans
 LD50/LC50
 for effects
 other than
 Cancer 
Minimal Risk Level 
47
 48 BARIUM AND BARIUM COMPOUNDS 
3. HEALTH EFFECTS 
alteration in blood pressure measurements or alterations in hypertension, heart disease, or stroke among 
residents of two communities with elevated (0.2 mg barium/kg/day) or low (0.003 mg barium/kg/day) 
levels of barium in drinking water (Brenniman and Levy 1985; Brenniman et al. 1979a, 1981). 
Interpretation of this study is limited by the lack of information on tap water consumption, and the fact 
that blood pressure was measured 3 times in a single 20-minute period and not repeatedly over a longer 
period, and the incidence of hypertension, stroke, and heart disease was taken from subject-completed 
questionnaires and not confirmed by testing or examination of medical records.  Brenniman and 
associates (Brenniman and Levy 1985; Brenniman et al. 1979a, 1981) also conducted a mortality study of 
residents living in communities with elevated or low barium levels in drinking water.  Significantly 
higher mortality rates for cardiovascular disease and heart disease (arteriosclerosis) were found in the 
elevated barium communities (0.06–0.3 mg barium/kg/day) than in the low barium communities 
(0.006 mg barium/kg/day).  The largest difference between the groups was in individuals 65 years of age 
and older. These results should be interpreted cautiously because the study did not control for a number 
of potential confounding variables such as the use of water softeners, which would reduce the amount of 
barium and increase sodium levels, duration of exposure, or actual barium intakes. 
Several animal studies have examined potential cardiovascular end points following acute-, intermediate-, 
or chronic-duration exposures.  No histological alterations have been observed in the hearts of rats and 
mice exposed to barium chloride, barium acetate, or an unspecified barium compound for intermediate or 
chronic durations (Borzelleca et al. 1988; McCauley et al. 1985; NTP 1994; Perry et al. 1983, 1985, 1989; 
Schroeder and Mitchener 1975a; Tardiff et al. 1980).  Significant increases in systolic blood pressure 
were observed in rats exposed to 8.6 or 11 mg barium/kg/day for 1 or 4 months, respectively; no effect 
levels were 1.0 and 1.2 mg barium/kg/day (Perry et al. 1983, 1985, 1989).  When the duration of exposure 
was longer (8–16 months), the LOAEL for increased blood pressure was 0.80 mg barium/kg/day and the 
NOAEL was 0.17 mg barium/kg/day (Perry et al. 1983, 1985, 1989).  Depressed rates of cardiac 
contraction and cardiac conductivity and decreased cardiac ATP levels were observed in another group of 
rats exposed to 7.2 mg barium/kg/day.  In contrast to the findings in the Perry study (1983, 1985, 1989), 
no significant alterations in blood pressure were observed in rats exposed to up to 150 mg barium/kg/day 
in drinking water for 16 weeks (McCauley et al. 1985); it should be noted that the McCauley et al. (1985) 
studies were conducted in uninephrectomized rats or Dahl salt-sensitive and salt-resistant rats.  NTP 
(1994) also found no significant alterations in blood pressure, heart rate, or ECG readings in rats exposed 
to 180 mg barium/kg/day for 45 or 90 days.  The low metal diet used in the Perry et al. (1983, 1985, 
1989) study may have influenced the study outcome. 
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Gastrointestinal Effects.    All cases of acute oral barium poisoning in adults exhibit gastrointestinal 
disturbances as the initial symptoms.  These include gastric pain, vomiting, and diarrhea (Das and Singh 
1970; Diengott et al. 1964; Downs et al. 1995; Gould et al. 1973; Jha et al. 1993; Lewi and Bar-Khayim 
1964; McNally 1925; Morton 1945; Ogen et al. 1967; Phelan et al. 1984; Silva 2003; Talwar and Sharma 
1979; Wetherill et al. 1981).  In one case, severe gastrointestinal hemorrhage occurred in an adult male 
victim (Diengott et al. 1964). 
Although gastrointestinal effects have been observed in some animal studies, most studies have not found 
effects. Inflammation of the intestines was noted in rats receiving a single gavage dose of 198 mg 
barium/kg as barium chloride (Borzelleca et al. 1988); but not in rats administered 10 doses of 198 mg 
barium/kg/day (Borzelleca et al. 1988).  Stomach rupture, bowel obstruction, and gastrointestinal 
hemorrhage have been observed in rats dosed with barium sulfate; however, those adverse effects were 
most likely due to the massive doses of barium sulfate used in the study (25–40% of body weight) and not 
necessarily to barium toxicity (Boyd and Abel 1966). A 15-day exposure of male and female rats and 
mice to 110 or 70 mg barium/kg/day as barium chloride in drinking water, respectively, did not result in 
histological alterations in the gastrointestinal tract (NTP 1994).  No gross or microscopic lesions of the 
esophagus, stomach, pancreas, small intestines, or colon were noted in several intermediate and chronic 
experiments in which male and female rats were exposed to doses as high as 180 mg barium/kg/day as an 
unspecified barium compound or barium chloride in drinking water (McCauley et al. 1985; NTP 1994) or 
male and female mice exposed to doses as high as 450 mg barium/kg/day as barium chloride (NTP 1994). 
Hematological Effects.    Results of animal studies indicate that acute, intermediate, and chronic oral 
exposure to barium is not associated with any adverse hematological effects.  No alterations were found 
in rats administered 198 mg barium/kg/day as barium chloride for 10 days (Borzelleca et al. 1988) or in 
rats or mice exposed to 110 or 70 mg/kg/day, respectively, as barium chloride in drinking water for 
15 days (NTP 1994).  Intermediate and chronic oral exposure of rats to barium acetate and barium 
chloride in drinking water has not been associated with any significant or treatment-related changes in a 
variety of hematological parameters (NTP 1994; Tardiff et al. 1980).  Elemental barium doses in these 
intermediate and chronic drinking water studies ranged from 15 to 450 mg/kg/day. 
Musculoskeletal Effects.    The predominant musculoskeletal effect observed in cases of barium 
toxicity in humans is progressive muscle weakness, often leading to partial or total paralysis (Das and 
Singh 1970; Diengott et al. 1964; Gould et al. 1973; Lewi and Bar-Khayim 1964; McNally 1925; Morton 
1945; Ogen et al. 1967; Phelan et al. 1984; Wetherill et al. 1981). In severe cases, the paralysis affects 
50 BARIUM AND BARIUM COMPOUNDS 
3. HEALTH EFFECTS 
the respiratory system (Das and Singh 1970; Gould et al. 1973; Lewi and Bar-Khayim 1964; Morton 
1945; Ogen et al. 1967; Phelan et al. 1984; Wetherill et al. 1981). The likely cause of the muscle 
weakness was the barium-induced hypokalemia rather than a direct effect on muscles. 
Very limited animal data are available regarding the musculoskeletal effects of barium following oral 
exposure. No gross and microscopic lesions were observed in skeletal system of several intermediate and 
chronic experiments in which rats were exposed to an unspecified barium compound or barium chloride 
in drinking water at doses as high as 180 mg barium/kg/day for intermediate duration and as high as 
60 mg barium/kg/day for chronic duration (McCauley et al. 1985; NTP 1994; Tardiff et al. 1980); 
similarly, no effects were observed in mice exposed to 450 or 160 mg barium/kg/day as barium chloride 
in drinking water for intermediate or chronic durations, respectively (NTP 1994).   
Hepatic Effects.    In one case study involving accidental acute ingestion of barium carbonate in an 
adult female, some degeneration of the liver was noted post-mortem (McNally 1925).  Adverse hepatic 
effects in animals following oral barium exposure have been minor or have not been observed.  Decreased 
liver/brain weight ratio and darkened liver were observed in rats administered a single gavage dose of 
198 mg barium/kg as barium chloride; however, these changes were not associated with any microscopic 
hepatic lesions or alterations in serum enzymes (e.g., serum glutamic-oxaloacetic transaminase [SGOT], 
serum glutamic pyruvic transaminase [SGPT], alkaline phosphatase).  No histological or liver weight 
alterations were observed in rats dosed with 198 mg barium/kg/day as barium chloride for 1 or 10 days 
(Borzelleca et al. 1988) or in rats and mice exposed to 110 or 70 mg barium/kg/day, respectively, as 
barium chloride in drinking water for 15 days (NTP 1994).  Intermediate and chronic studies involving 
oral exposure of rats or mice to barium in drinking water did not find significant alterations in liver 
weight or liver histopathology following exposure to doses as high as 180 mg barium/kg/day for rats and 
450 mg barium/kg/day for mice (McCauley et al. 1985; NTP 1994; Schroeder and Mitchener 1975a, 
1975b; Tardiff et al. 1980). 
Renal Effects.    Toxic effects on the kidneys have been observed in several adult cases of acute barium 
poisoning.  Effects include hemoglobin in the urine (Gould et al. 1973) (which may be indicative of 
kidney damage), renal insufficiency (Lewi and Bar-Khayim 1964; Phelan et al. 1984), degeneration of the 
kidneys (McNally 1925), and acute renal failure (Wetherill et al. 1981). 
Studies in animals suggest that the kidney is a critical target of barium toxicity.  An increase in relative 
kidney weight (kidney/brain weight ratio) was observed in male and female rats receiving a single gavage 
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dose of 198 mg barium/kg/day as barium chloride in water (Borzelleca et al. 1988).  Increases in relative 
kidney weight (kidney to brain weight ratio) were also observed in female rats receiving gavage doses of 
66, 96, or 138 mg barium/kg/day as barium chloride in water for 10 days, but not at 198 mg 
barium/kg/day (Borzelleca et al. 1988).  Significant reductions in blood urea nitrogen (BUN) were also 
observed in females exposed to 66–198 mg barium/kg/day and in males exposed to 198 mg 
barium/kg/day.  The changes in BUN levels were not considered to be biologically significant because 
BUN levels are typically increased in response to kidney damage, the magnitude of change was slight 
(less than 15%), and there were no differences between the barium-exposed groups.  The changes in 
relative kidney weights or BUN levels were not associated with gross or microscopic renal lesions.  
Studies of rats and mice did not find significant alterations in kidney weights or the incidence of renal 
lesions following a 15-day exposure to 110 or 70 mg barium/kg/day, respectively, as barium chloride in 
drinking water (NTP 1994).   
Exposure of rats to doses as high as 65 mg barium/kg/day for an intermediate duration did not result in 
any alterations in kidney weight or the occurrence of histopathological lesions (McCauley et al. 1985; 
NTP 1994; Tardiff et al. 1980).  At 115 mg barium/kg/day, significant increases in absolute and relative 
kidney weights were observed in female rats (NTP 1994).  Electron microscopy detected glomerular 
lesions consisting of fused podocyte processes and thickening of the capillary basement membrane in rats 
exposed to 150 mg barium/kg/day (McCauley et al. 1985).  At slightly higher doses (180 mg 
barium/kg/day), minimal to mild dilatation of the proximal convoluted tubules of the outer medulla and 
renal cortex was observed in male and female rats (NTP 1994).  In mice, nephropathy characterized by 
mild to moderate tubule dilatation, regeneration, and atrophy was observed in males and females exposed 
to 450 mg barium/kg/day as barium chloride, but not to 205 mg barium/kg/day (NTP 1994). 
Three chronic-duration studies assessed the renal toxicity of barium.  No adverse effects were observed in 
rats exposed via drinking water to 15 mg barium/kg/day of an unspecified barium compound for 68 weeks 
(McCauley et al. 1985), 60 mg barium/kg/day as barium chloride for 2 years (NTP 1994), or lifetime 
exposure to 0.7 mg barium/kg/day as barium acetate (Schroeder and Mitchener 1975a).  In mice, exposure 
to 160–200 mg barium/kg/day resulted in moderate to marked nephropathy, characterized by extensive 
regeneration of cortical and medullary tubule epithelium, tubule dilatation, hyaline cast formation, 
interstitial fibrosis, and glomerulosclerosis (NTP 1994); at the next lowest dose tested (75 mg 
barium/kg/day), the incidence of nephropathy did not differ from controls.  No kidney lesions were 
observed in mice following lifetime exposure to 0.95 mg barium/kg/day as barium acetate (Schroeder and 
Mitchener 1975b). 
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Dermal Effects.    No studies were located regarding dermal effects in humans or animals after oral 
exposure to barium.   
Ocular Effects.    No studies were located regarding ocular effects in humans after oral exposure to 
barium.  In studies with Sprague-Dawley rats, ocular discharge following administration of a single 
gavage dose of 198 mg barium/kg/day as barium chloride (Borzelleca et al. 1988); this was not reported 
in rats dosed for 10 days (Borzelleca et al. 1988).  A nonsignificant increase in retinal dystrophy was 
observed in rats following intermediate and chronic oral exposure to 12–37.5 mg barium/kg/day as an 
unspecified barium compound (McCauley et al. 1985).  Although the retinal dystrophy was statistically 
insignificant, a dose-related trend was observed if different duration exposure groups were combined 
(McCauley et al. 1985).  Both ocular discharge and retinal dystrophy are commonly observed in Sprague-
Dawley rats; consequently, the ocular lesions noted in these animal studies cannot necessarily be 
attributed to oral barium exposure.  Ocular lesions were not observed in F344 rats or B6C3F1 mice 
exposed to barium chloride in drinking water for 90 days or 2 years to doses as high as 180 mg 
barium/kg/day in rats and 450 mg barium/kg/day in mice (NTP 1994). 
Body Weight Effects.    Body weight has been monitored in a number of acute, intermediate, and 
chronic studies in which rats and mice were exposed orally to barium compounds (Borzelleca et al. 1988; 
McCauley et al. 1985; NTP 1994; Perry et al. 1983, 1985, 1989; Schroeder and Mitchener 1975a, 1975b; 
Tardiff et al. 1980). In general, body weight effects have only been observed at lethal doses.  A decrease 
in body weight was observed in rats receiving a single gavage dose of 198 mg barium/kg/day as barium 
chloride (Borzelleca et al. 1988), in rats exposed to 200 mg barium/kg/day as barium chloride in drinking 
water for an intermediate duration (NTP 1994), and in mice exposed to 450 or 160 mg barium/kg/day as 
barium chloride in drinking water for intermediate and chronic durations, respectively (NTP 1994).   
Metabolic Effects. Hypokalemia is a common finding in cases of severe barium poisoning (Deng et 
al. 1991; Diengott et al. 1964; Downs et al. 1995; Gould et al. 1973; Jha et al. 1993; Koch et al. 2003; 
Lewi and Bar-Khayim 1964; Phelan et al. 1984; Talwar and Sharma 1979; Wetherill et al. 1981).  In a 
group of cases examined by Deng et al. (1991), serum potassium levels ranged from 0.8 to 2.7 mEq/L; 
normal values range from 3.5 to 5 mEq/L.  Alterations in serum potassium levels have not been reported 
in rats exposed to 110 or 180 mg barium/kg/day as barium chloride in drinking water for 15 or 90 days,, 
respectively (NTP 1994). 
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3.2.2.3 Immunological and Lymphoreticular Effects  
No studies were located regarding immunological effects in humans after oral exposure to barium.  
Several animal studies have examined potential lymphoreticular effects, particularly damage to the 
thymus, spleen, and lymph nodes.  Acute gavage exposure of rats to doses as high as 198 mg 
barium/kg/day as barium chloride for 1 or 10 days was not associated with any changes in thymus weight 
or any gross lesions of the thymus (Borzelleca et al. 1988).  Intermediate and chronic oral exposure of rats 
to nominal concentrations of barium in drinking water of 37.5 and 15 mg/kg/day, respectively, of an 
unspecified barium compound was not associated with lesions of the lymph nodes or thymus upon gross 
and histopathologic examination (McCauley et al. 1985).  No histopathological alterations were observed 
in the spleen or thymus of rats exposed to 180 or 60 mg barium/kg/day for an intermediate or chronic 
duration, respectively (NTP 1994).  In mice, thymic and splenic atrophy were observed at 450 mg 
barium/kg/day after intermediate exposure and lymphoid depletion in the spleen and decreased spleen 
weight were observed at 160 mg barium/kg/day after chronic exposure (NTP 1994).  These effects were 
probably secondary to the severe nephropathy and weight loss observed at these doses.   
No studies have assessed the potential of barium to impair immune function. 
The highest NOAEL values for lymphoreticular effects in each species and duration category are recorded 
in Table 3-1 and plotted in Figure 3-1. 
3.2.2.4 Neurological Effects 
Numbness and tingling around the mouth and neck were sometimes among the first symptoms of barium 
toxicity in humans (Lewi and Bar-Khayim 1964; Morton 1945).  Occasionally, these neurological 
symptoms extended to the extremities (Das and Singh 1970; Lewi and Bar-Khayim 1964).  Partial and 
complete paralysis occurred in severe cases, often accompanied by an absence of deep tendon reflexes 
(Das and Singh 1970; Diengott et al. 1964; Gould et al. 1973; Lewi and Bar-Khayim 1964; Morton 1945; 
Ogen et al. 1967; Phelan et al. 1984; Wetherill et al. 1981). Post-mortem examination in one case of 
poisoning by ingestion of barium sulfide revealed brain congestion and edema (McNally 1925). 
Animal studies have not found significant alterations in brain weight or histopathology following acute 
gavage exposure of rats for 1 or 10 days to doses as high as 198 mg barium/kg/day as barium chloride 
(Borzelleca et al. 1988), intermediate oral exposure of rats to doses as high as 115 mg barium/kg/day in 
drinking water (McCauley et al. 1985; NTP 1994; Tardiff et al. 1980), intermediate-duration exposure of 
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mice to doses less than 450 mg barium/kg/day as barium chloride in drinking water (NTP 1994), or 
chronic exposure of rats and mice to doses greater than 60 or 160 mg barium/kg/day as barium chloride in 
drinking water, respectively (NTP 1994).  Neurobehavioral performance (spontaneous motor activity, grip 
strength, tail flick latency, startle response, hindlimb foot splay) was evaluated in rats and mice exposed 
to barium chloride for 15 or 90 days (NTP 1994).  No alterations were observed in rats or mice following 
a 15-day exposure to 110 or 70 mg barium/kg/day. Slight decreases in motor activity were observed in 
rats exposed to 10–115 mg barium/kg/day for 90 days; these changes were not considered to be 
biologically significant.  However, in female rats exposed to 180 mg barium/kg/day, spontaneous motor 
activity was 30% lower than controls; this difference was considered to be biologically significant.  In 
mice, the only alteration noted was a decrease in forelimb grip strength in females exposed to 495 mg 
barium/kg/day for 90 days; the investigators noted that this may have been due to debilitation.  The 
highest NOAEL values and reliable LOAEL values for neurological effects in each species and duration 
category are recorded in Table 3-1 and plotted in Figure 3-1. 
3.2.2.5 Reproductive Effects  
No studies were located regarding reproductive effects in humans after oral exposure to barium.  
However, limited data are available from acute, intermediate, and chronic animal studies in which certain 
reproductive organs were weighed and examined grossly and microscopically following oral barium 
exposure. Gavage exposure of rats to doses of 198 mg barium/kg/day as barium chloride for 10 days 
resulted in decreased ovary weight and decreased ovary/brain weight ratio (Borzelleca et al. 1988); no 
alterations were observed after a single gavage dose with 198 mg barium/kg/day (Borzelleca et al. 1988).  
Neither study found changes in testicular weight, and no gross lesions of the ovaries or testes were 
observed at this dose. No histological alterations were observed in the reproductive tissues of male and 
female rats and mice exposed to 110 mg barium/kg/day (rats) or 70/85 mg barium/kg/day (mice) as 
barium chloride in drinking water (NTP 1994).  Intermediate and chronic oral exposure of rats to barium 
in drinking water at doses of 200 mg barium/kg/day and lower was not associated with any gross or 
histopathologic lesions of the uterus, ovaries, or testes (Dietz et al. 1992; McCauley et al. 1985; NTP 
1994).  Similarly, no histopathological alterations were observed in reproductive tissues of mice exposed 
to 495 mg barium/kg/day and lower for an intermediate duration (NTP 1994) or 160 mg barium/kg/day or 
lower for a chronic duration (NTP 1994).  Additionally, no alterations in epididymal sperm counts, sperm 
motility, or sperm morphology were observed in rats or mice exposed to 200 or 205 mg barium/kg/day, 
respectively, as barium chloride in drinking water for 60 days (Dietz et al. 1992). 
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There are limited data on the potential of barium to impair reproductive function.  No significant 
alterations in pregnancy rate or gestation length were observed in rats or mice exposed to approximately 
200 mg barium/kg/day as barium chloride in drinking water (Dietz et al. 1992); the males were exposed 
for 60 days prior to mating and the females were exposed for 30 days. 
The highest NOAEL values and all reliable LOAEL values for reproductive effects in each species and 
duration category are recorded in Table 3-1 and plotted in Figure 3-1. 
3.2.2.6 Developmental Effects 
Studies regarding developmental effects of barium following oral exposure are limited to one human 
study (Morton et al. 1976) and three animal studies (Dietz et al. 1992; Tarasenko et al. 1977).  A 
statistically significant negative correlation was found between barium concentrations in drinking water 
and human congenital malformation rates of the central nervous system in South Wales (Morton et al. 
1976). A negative correlation implies that as the barium concentration in drinking water increased, the 
rate of central nervous system malformations decreased.  This statistical study is of limited value in 
identifying a NOAEL for developmental effects because exposure conditions (duration and frequency of 
exposure, dose, number of subjects exposed) were not characterized. 
Developmental effects were reported in a study in which an unspecified animal species was orally 
administered a dose of barium carbonate that was equal to 1/16 of the LD50 for 24 days prior to 
conception and pregnancy (Tarasenko et al. 1977).  Reported effects in offspring included increased 
mortality during the first 2 months, increased leukocyte count, disturbances in liver function, and 
increased urinary excretion of hippuric acid.  This study is inadequate for evaluating developmental 
effects of oral barium exposure because of major study limitations.  These limitations include a general 
lack of information provided by the authors regarding experimental methods, exposure conditions, and 
test results, and no information as to the species and number of animals tested, the purity of the test 
material, the statistical methods used, and whether or not controls were used.   
In studies by Dietz et al. (1992), male rats and mice were exposed to barium chloride in drinking water 
for 60 days and mated to females exposed to barium chloride for 30 days.  In the rats, exposure to 
180/200 mg barium/kg/day resulted in significant decreases in pup birth weights.  Decreases in the live 
litter size at postnatal days 0 and 5 were also observed in the 180/200 mg barium/kg/day group, but the 
difference was not statistically significant; litter sizes were 9.0 and 9.3 pups in controls on days 0 and 5, 
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and 7.2 and 7.1 pups on days 0 and 5 in the 200 mg barium/kg/day group.  No adverse developmental 
effects were observed in the mice (highest dose tested was 200 mg barium/kg/day). 
The highest NOAEL values and all reliable LOAEL values for developmental effects in each species and 
duration category are recorded in Table 3-1 and plotted in Figure 3-1. 
3.2.2.7 Cancer 
No studies were located regarding cancer in humans after oral exposure to barium.  Several animal studies 
evaluated the induction of tumors following chronic oral exposure to barium (NTP 1994; Schroeder and 
Mitchener 1975a, 1975b). In studies by Schroeder and Mitchener (1975a, 1975b), rats and mice were 
exposed to 0.7 and 0.95 mg barium/kg/day, respectively, as barium acetate in drinking water for lifetime.  
No differences in the incidence of tumors were noted between treated animals and vehicle controls in 
either study. These studies are inadequate for evaluating the carcinogenic potential of barium because 
insufficient numbers of animals were used for a carcinogenicity study, it was not determined whether or 
not a maximum tolerated dose was achieved, a complete histological examination was not performed, the 
purity of the test material was not specified, and only one exposure dose was used in each study.  Studies 
conducted by the NTP (1994) are considered adequate for carcinogenicity assessment.  In rats exposed to 
doses as high as 60–75 mg barium/kg/day as barium chloride in drinking water, significant negative 
trends for mononuclear cell leukemia, adrenal medulla pheochromocytoma, and mammary gland 
neoplasms were found.  No significant increases in malignant tumors were observed.  Similarly, no 
increases in malignant tumor incidences were observed in mice chronically exposed to doses up to 160– 
200 mg barium/kg/day as barium chloride in drinking water. 
3.2.3 Dermal Exposure  
Limited information is available regarding the health effects of barium following dermal exposure.  
Barium salts would be expected to have a local effect on skin surfaces and would not likely be absorbed 
systematically to any great extent.  Available studies include a case report of an individual exposed 
dermally to molten barium chloride (Stewart and Hummel 1984), a skin irritation study evaluating barium 
carbonate in experimental animals (Tarasenko et al. 1977), and a skin-painting study in which mice were 
exposed dermally to a barium hydroxide extract of tobacco leaf (Van Duuren et al. 1968).  No reliable 
information was available from any of these dermal studies to identify study NOAELs or LOAELs for 
barium.  In the case report (Stewart and Hummel 1984), the dermal burns that developed in the individual 
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exposed to molten barium chloride may potentially have contributed to some of the reported health 
effects, which are described briefly in Section 3.2.3.2 (Systemic Effects). 
3.2.3.1 Death 
No studies were located regarding death in humans or animals after dermal exposure to barium. 
3.2.3.2 Systemic Effects  
No studies were located regarding respiratory, hematological, musculoskeletal, hepatic, renal, endocrine, 
or body weight effects in humans or animals after dermal exposure to barium. 
Cardiovascular Effects.    An abnormal electrocardiogram was observed in a 62-year-old man burned 
by molten barium chloride (Stewart and Hummel 1984).  No studies were located regarding 
cardiovascular effects in animals after dermal exposure to barium. 
Gastrointestinal Effects.    A 62-year-old man experienced vomiting after he was accidentally burned 
by molten barium chloride (Stewart and Hummel 1984).  No studies were located regarding 
gastrointestinal effects in animals after dermal exposure to barium. 
Dermal Effects.    Molten barium chloride induced burns on the skin of a 62-year-old man who was 
accidentally exposed through an explosion.  The dermal burns, however, were very probably due to the 
molten nature of the material and not necessarily to barium chloride (Stewart and Hummel 1984). 
The dermal effects of barium carbonate were examined in a study with rats and rabbits (Tarasenko et al. 
1977). When barium carbonate in lanolin was applied to the skin, ulcers developed.  These dermal 
lesions reportedly disappeared within a month when dermal treatment was discontinued. Although these 
findings suggest that barium carbonate may be a dermal irritant, these particular investigations are 
inadequate for establishing the dermal effects of barium because of a number of significant study 
limitations.  The authors provided few details regarding experimental methods and results, and no 
information as to the concentration of barium carbonate used, the number of animals used, and whether or 
not controls were used.   
Ocular Effects.    Information on the ocular toxicity of barium is limited to a study conducted by 
Tarasenko et al. (1977) in rats and rabbits.  When barium carbonate powder was introduced into the 
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conjunctival sac, purulent discharge, conjunctivitis, and slight opacity of the cornea developed.  As noted 
in the Dermal Effects section, interpretation of these results is limited by the poor reporting of study 
methods and results, lack of information on barium carbonate concentration, and whether controls were 
used. 
Metabolic Effects. A 62-year-old victim accidentally exposed to molten barium chloride had a 
depressed plasma potassium level when admitted to the hospital (Stewart and Hummel 1984).   
No studies were located regarding the following health effects in humans or animals after dermal 
exposure to barium: 
3.2.3.3 Immunological and Lymphoreticular Effects  
3.2.3.4 Neurological Effects 
3.2.3.5 Reproductive Effects  
3.2.3.6 Developmental Effects 
3.2.3.7 Cancer 
No studies were located regarding cancer in humans after dermal exposure to barium.  Dysplasia of the 
cervical epithelium was reportedly induced in a woman who had a barium chloride solution applied to her 
cervix (Ayre 1966).  The use of dimethyl sulfoxide in combination with the barium chloride solution 
reportedly enhanced the ability of barium chloride to induce dysplasia.  Dysplasia can be regarded as a 
potential precancerous lesion.  The significance of the observations reported in this study are difficult to 
assess, since only one subject was exposed and because there have been no reports of similar findings in 
other human or animal studies.  Also, the vehicle used was not specified in this study. 
No studies were located regarding cancer in animals after dermal exposure to barium.  However, results 
of one skin-painting study with mice suggest that barium hydroxide extract derived from tobacco leaf 
may act as a tumor-promoting agent (Van Duuren et al. 1968); the purity of the barium hydroxide extract 
was not reported. In this study, mice were treated dermally for an unspecified period of time with either 
barium hydroxide extract alone, 7,12-dimethylbenz(a)anthracene (DMBA) alone (an initiating agent), or a 
combination of DMBA and barium hydroxide extract.  After 1 year, none of the mice treated with barium 
hydroxide extract developed skin tumors.  However, 3 out of 20 mice treated with DMBA alone and 7 out 
of 20 mice treated with a combination of both barium hydroxide extract and DMBA developed skin 
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papillomas and carcinomas.  These results provide limited, but suggestive evidence that barium hydroxide 
extract of tobacco leaf acted as a tumor-promoting agent.  However, it can not be determined whether or 
not this apparent positive tumorigenic response was due to barium hydroxide or some other component of 
the barium hydroxide tobacco leaf extract. 
3.3 GENOTOXICITY  
In vivo studies of barium genotoxicity are limited to a study in Drosophila melanogaster. In this study, 
positive results were found in the somatic mutation and recombination test when high levels of barium 
nitrate were used; the results were inconclusive at low barium nitrate levels (Yesilada 2001). In vitro 
studies were limited and summarized in Table 3-2.  No significant alterations in gene mutation frequency 
were observed in Salmonella typhimurium (Monaco et al. 1990, 1991; NTP 1994) or Escherichia coli 
(Rossman et al. 1991).  Similarly, barium chloride or barium nitrate did not result in deoxyribonucleic 
acid (DNA) damage in Bacillus subtilis (Kanematsu et al. 1980; Nishioka 1975). Tests of the fidelity of 
DNA synthesis using an avian myeloblastosis virus (AMV) DNA polymerase system showed that neither 
barium acetate nor barium chloride affect the accuracy of DNA replication (Sirover and Loeb 1976a, 
1976b). However, studies with a DNA polymerase I system from Micrococcus luteus, demonstrated that 
concentrations of barium ion ≤0.1 mM stimulated DNA polymerase activity while concentrations greater 
than this inhibited polymerase activity (Korman et al. 1978).  The significance of the inhibitory and 
stimulatory effects has not been determined.  Results from an experiment designed to test the effect of 
barium chloride on sporulation frequency, recombination frequency, and meiotic failures in 
Saccharomyces cerevisiae demonstrated a definite inhibition of sporulation.  Effects on recombination 
frequency and meiotic failures were ambiguous.  Barium chloride may have caused a marginal increase in 
recombination frequency and information of diploid clones (Sora et al. 1986), but the data are 
inconclusive.  In mammalian test systems, barium chloride did not increase the frequency of sister 
chromatid exchange or chromosome aberrations in Chinese hamster cells (NTP 1994).  However, an 
increase in gene mutations was observed at the TK locus of L5178Y mouse lymphoma cells in the 
presence of metabolic activation, but not without metabolic activation (NTP 1994).   
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Table 3-2. Genotoxicity of Barium and Barium Compounds In Vitro 
Species (test system) End point Results Reference Compound 
Prokaryotic organisms: 
Salmonella typhimurium  Gene mutation – Monaco et al. 1990, Barium chloride 
frequency 1991; NTP 1994 
(with or without S9 
activation) 
Escherichia coli Gene mutation – Rossman et al. 1991 Barium chloride 
WP2s(λ) frequency 
Bacillus subtilis DNA damage – Kanematsu et al. 1980; Barium chloride, 
(rec assay) Nishioka 1975 barium nitrate 
Eukaryotic organisms: 
Fungi 
Saccharomyces Meiosis  – Sora et al. 1986 Barium chloride 
cerevesiae 
Avian myeloblastosis DNA synthesis – Sirover and Loeb 1976a, Barium chloride, 
virus DNA polymerase  1976b barium acetate 
 Mammalian cells: 
CHO cells Sister chromatid – NTP 1994 Barium chloride 
exchange 
(with or without S9 
activation) 
CHO cells Chromosome – NTP 1994 Barium chloride 
aberration 
(with or without S9 
activation) 
Mouse lymphoma cells Gene mutation at TK NTP 1994 Barium chloride 
locus  
With S9 activation + 
Without S9 activation – 
– = negative result; + = positive result; CHO = Chinese hamster ovary 
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3.4 TOXICOKINETICS 
3.4.1 Absorption 
3.4.1.1 Inhalation Exposure 
No studies were located regarding absorption of barium in humans following inhalation exposure.  
Several animal studies have investigated the absorption of barium chloride or barium sulfate following 
inhalation, intratracheal injection, or nasal deposition.  The results of these studies suggest that the rate 
and extent of absorption of barium from the respiratory tract depend on the exposure level, how much 
barium reaches the alveolar spaces, the clearance rate from the upper respiratory tract, and the solubility 
of the particular form of barium that was administered.  Approximately 50–75% of inhaled barium 
chloride or barium sulfate is absorbed from the respiratory tract (Cuddihy and Griffith 1972; Morrow et 
al. 1968); approximately 65% of the barium chloride deposited in the nose is absorbed (Cuddihy and 
Ozog 1973b).  Most of the barium absorption occurs within the first 24 hours (Cuddihy and Griffith 1972; 
Cuddihy et al. 1974).  Barium chloride appears to be more rapidly absorbed than barium sulfate (Cuddihy 
et al. 1974), although the differences in particle size (AMADs of 2.3 and 1.0 µm for barium chloride and 
barium sulfate, respectively) may have influenced the absorption rate.  In contrast to the rapid absorption 
of barium following inhalation or nasal deposition, most of the barium sulfate that is injected directly into 
the trachea of rats can be taken up into the epithelium membranes and remains in these membranes for at 
least a few weeks (Gore and Patrick 1982; Takahashi and Patrick 1987), suggesting that clearance in the 
upper respiratory tract is more efficient than in the trachea.  Following intratracheal injection, the 
clearance of barium sulfate from the lungs was independent of lung burden over the range of 23.3– 
2,330 µg (Cember et al. 1961); this is consistent with the lack of evidence of lung overload following 
intermediate-duration inhalation exposure to 37.5 or 75 mg/m3 barium sulfate (MMAD 4.3 µm, σg 1.7) 
(Cullen et al. 2000).  Species differences in the retention of intratracheally administered radiolabelled 
(133Ba) barium sulfate have been found.  The percentages of 133Ba retained in the trachea 1 week after 
administration were 0.41, 0.145, 0.044, and 0.043% in rats, rabbits, dogs, and monkeys, respectively 
(Takahashi and Patrick 1987; Takahashi et al. 1993). 
3.4.1.2 Oral Exposure  
The absorption of barium from the gastrointestinal tract is compound dependent.  Barium sulfate is 
extremely insoluble and very little, if any, ingested barium sulfate is absorbed.  Acid-soluble barium 
compounds, such as barium chloride and barium carbonate, are absorbed through the gastrointestinal 
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tract, although the amount of barium absorbed is highly variable.  Older human studies estimated that 
barium was poorly absorbed; approximately 1–15% of the ingested dose was estimated to be absorbed 
(Harrision et al. 1956; LeRoy et al. 1966; Schroeder et al. 1972; Tipton et al. 1969).  A re-examination of 
the methods used in these studies found a number of flaws; Leggett (1992) estimated that barium 
absorption in these studies was approximately 3–60%.  Studies in adult rats and dogs estimated fractional 
absorption at 7% (Cuddihy and Griffith 1972; Taylor et al. 1962). Several unpublished animal studies 
discussed by Leggett (1992) found absorption rates of 1–50%.  Experiments in rats have shown that 
younger animals (22 days old or less) absorb about 10 times more barium chloride from the 
gastrointestinal tract (63–84%) than do older animals (about 7%) (Taylor et al. 1962).  Absorption was 
higher in fasted adult rats (20%) as compared to fed rats (7%).  The International Commission for 
Radiation Protection (ICRP) estimates that the gastrointestinal absorption of barium is 20% in adults, 
30% for children aged 1–15 years, and 60% in infants (ICRP 1993). 
3.4.1.3 Dermal Exposure  
No studies were located regarding absorption of barium in humans after dermal exposure.  One animal 
study showed that barium applied to the skin of piglets was found in the various layers of the skin 
(Shvydko et al. 1971).  Barium is not expected to cross the intact skin because of the high polarity of the 
forms in which it is most commonly encountered. 
3.4.2 Distribution  
3.4.2.1 Inhalation Exposure 
Shortly after dogs were exposed to radiolabelled (140Ba) barium chloride, elevated activity was found in 
the upper respiratory tract, stomach, and small intestine (30% of initial burden), lungs and 
tracheobronchial tissue (6%), and various internal organs (64%) (Cuddihy and Griffith 1972).  One day 
post-exposure, 44% of the label was detected in the skeleton, 1% in blood, and 4% in muscle; 26% of the 
dose was excreted.   
3.4.2.2 Oral Exposure  
In humans, barium is predominantly found in bone; approximately 90% of the barium in the body was 
detected in the bone (Schroeder et al. 1972). Approximately 1–2% of the total body burden was found in 
muscle, adipose, skin, and connective tissue.  This information is supported by a number of studies 
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(Bauer et al. 1957; Losee et al. 1974; Miller et al. 1985; Sowden 1958; Sowden and Stitch 1957; Sowden 
and Pirie 1958). Significant increases in the levels of barium in bone were found in rats administered 
barium chloride in the diet or barium as a component of Brazil nuts for 29 days (Stoewsand et al. 1988); 
this study did not examine other tissues.  A study by McCauley and Washington (1983) in which rats 
were exposed to barium chloride and barium carbonate in drinking water found the following non-skeletal 
distribution (skeletal tissue was not examined in the study) 24 hours after ingestion:  heart > eye > 
skeletal muscle > kidney > blood > liver. 
3.4.2.3 Dermal Exposure  
No studies were located regarding distribution of barium in humans or animals after dermal exposure. 
3.4.2.4 Other Routes of Exposure 
Human injection studies support the findings of the inhalation and oral exposure studies.  Barium is 
rapidly cleared from the blood and distributed to bone (Bauer et al. 1957; Harrison et al. 1966, 1967; 
Newton et al. 1991).  A long-term study of barium retention in humans injected with 133Ba found that 
after the first couple of years, bone turnover was the most significant contributor to barium losses from 
the skeleton (Newton et al. 2001). 
3.4.3 Metabolism 
Barium is not metabolized in the body, but it may be transported or incorporated into complexes or 
tissues. 
3.4.4 Elimination and Excretion 
3.4.4.1 Inhalation Exposure 
No studies have been located regarding excretion of barium following inhalation exposure in humans.  
Studies in animals demonstrate that the fecal excretion of barium exceeds urinary excretion (Cember et al. 
1961; Cuddihy and Griffith 1972; Cuddihy et al. 1974).  In dogs, 30% of the total barium excretion was 
accounted for by urine (Morrow et al. 1964).   
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3.4.4.2 Oral Exposure  
A study of two humans ingesting a normal diet found that fecal excretion of barium was 2–3 times higher 
than urinary excretion over a 30-day period (Tipton et al. 1966).  A 29-day rat study also demonstrated 
that the feces was the primary route of excretion following exposure to barium chloride in the diet or 
barium from brazil nuts (Stoewsand et al. 1988).  
3.4.4.3 Dermal Exposure  
No studies were located regarding excretion of barium in humans or animals after dermal exposure. 
3.4.4.4 Other Routes of Exposure 
Several human studies have examined the excretion of barium following parenteral administration.  These 
studies confirm the findings of the inhalation or oral exposure studies that barium is primarily excreted in 
the feces. In a study, one subject receiving an intravenous injection of 133Ba, 84% of the radiolabelled 
barium was excreted within the first 6 days, primarily in the feces (75% of total dose) (Harrison et al. 
1967; Newton et al. 1977).  The ratio of fecal to urinary barium excretion in six subjects injected with 
133Ba ranged from 6 to 15 for the first 2 weeks (Newton et al. 1991). 
A study in rats (Edel et al. 1991) found that biliary excretion did not significantly contribute to the total 
amount of barium excreted in the feces, suggesting that other physiological routes were responsible for 
fecal barium.  A study of rabbits administered an intravenous injection of radiolabelled barium also found 
that barium was primarily excreted in the feces.  After the first day, fecal excretion was approximately 
twice as high as urinary excretion.  The barium was primarily excreted in the first 5 days after exposure; 
after 9 days, approximately 50% of the dose was excreted (Liniecki 1971).   
3.4.5 Physiologically Based Pharmacokinetic (PBPK)/Pharmacodynamic (PD) Models  
Physiologically based pharmacokinetic (PBPK) models use mathematical descriptions of the uptake and 
disposition of chemical substances to quantitatively describe the relationships among critical biological 
processes (Krishnan et al. 1994).  PBPK models are also called biologically based tissue dosimetry 
models.  PBPK models are increasingly used in risk assessments, primarily to predict the concentration of 
potentially toxic moieties of a chemical that will be delivered to any given target tissue following various 
combinations of route, dose level, and test species (Clewell and Andersen 1985).  Physiologically based 
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pharmacodynamic (PBPD) models use mathematical descriptions of the dose-response function to 
quantitatively describe the relationship between target tissue dose and toxic end points.   
PBPK/PD models refine our understanding of complex quantitative dose behaviors by helping to 
delineate and characterize the relationships between: (1) the external/exposure concentration and target 
tissue dose of the toxic moiety, and (2) the target tissue dose and observed responses (Andersen and 
Krishnan 1994; Andersen et al. 1987). These models are biologically and mechanistically based and can 
be used to extrapolate the pharmacokinetic behavior of chemical substances from high to low dose, from 
route to route, between species, and between subpopulations within a species.  The biological basis of 
PBPK models results in more meaningful extrapolations than those generated with the more conventional 
use of uncertainty factors. 
The PBPK model for a chemical substance is developed in four interconnected steps:  (1) model 
representation, (2) model parameterization, (3) model simulation, and (4) model validation (Krishnan and 
Andersen 1994).  In the early 1990s, validated PBPK models were developed for a number of 
toxicologically important chemical substances, both volatile and nonvolatile (Krishnan and Andersen 
1994; Leung 1993).  PBPK models for a particular substance require estimates of the chemical substance-
specific physicochemical parameters, and species-specific physiological and biological parameters.  The 
numerical estimates of these model parameters are incorporated within a set of differential and algebraic 
equations that describe the pharmacokinetic processes.  Solving these differential and algebraic equations 
provides the predictions of tissue dose.  Computers then provide process simulations based on these 
solutions. 
The structure and mathematical expressions used in PBPK models significantly simplify the true 
complexities of biological systems.  If the uptake and disposition of the chemical substance(s) are 
adequately described, however, this simplification is desirable because data are often unavailable for 
many biological processes.  A simplified scheme reduces the magnitude of cumulative uncertainty.  The 
adequacy of the model is, therefore, of great importance, and model validation is essential to the use of 
PBPK models in risk assessment. 
PBPK models improve the pharmacokinetic extrapolations used in risk assessments that identify the 
maximal (i.e., the safe) levels for human exposure to chemical substances (Andersen and Krishnan 1994).  
PBPK models provide a scientifically sound means to predict the target tissue dose of chemicals in 
humans who are exposed to environmental levels (for example, levels that might occur at hazardous waste 
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sites) based on the results of studies where doses were higher or were administered in different species.  
Figure 3-2 shows a conceptualized representation of a PBPK model. 
If PBPK models for barium exist, the overall results and individual models are discussed in this section in 
terms of their use in risk assessment, tissue dosimetry, and dose, route, and species extrapolations. 
No information on available PBPK models for barium has been identified. 
3.5 MECHANISMS OF ACTION  
3.5.1 Pharmacokinetic Mechanisms 
No studies were located for animals or humans that describe observed mechanisms for barium absorption 
across the skin, lung, or gut or barium distribution, metabolism, or excretion. 
3.5.2 Mechanisms of Toxicity 
The mechanism of barium toxicity has not been fully elucidated.  Presumably, high-dose exposure to 
barium consistently results in a number of effects including ventricular tachycardia, hypertension and/or 
hypotension, and muscle weakness and paralysis (Deng et al. 1991; Diengott et al. 1964; Downs et al. 
1995; Gould et al. 1973; Jha et al. 1993; Koch et al. 2003; Talwar and Sharma 1979; Wetherill et al. 
1981). There is strong evidence that many of these effects result from increases in intracellular potassium 
levels. Barium is a competitive potassium channel antagonist that blocks the passive efflux of 
intracellular potassium, resulting in a shift of potassium from extracellular to intracellular compartments 
(Roza and Berman 1971).  The intracellular translocation of potassium results in a decreased resting 
membrane potential, making the muscle fibers electrically unexcitable and causing paralysis (Koch et al. 
2003).  Hypokalemia (serum potassium levels below 3.5 mEq/L) has been reported in a number of 
individuals exposed to high doses of barium (Deng et al. 1991; Diengott et al. 1964; Downs et al. 1995; 
Gould et al. 1973; Jha et al. 1993; Koch et al. 2003; Lewi and Bar-Khayim 1964; Phelan et al. 1984; 
Talwar and Sharma 1979; Wetherill et al. 1981).  Intravenous infusion of potassium often relieves many 
of the symptoms of barium toxicity (Dreisbach and Robertson 1987; Haddad and Winchester 1990; 
Proctor et al. 1988). However, there is also evidence that some of these effects may be due to barium-
induced neuromuscular blockade and membrane depolarization (Phelan et al. 1984; Thomas et al. 1998). 
Two investigators (Phelan et al. 1984; Thomas et al. 1998) have shown an apparent direct relationship  
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Figure 3-2. Conceptual Representation of a Physiologically Based 
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Note: This is a conceptual representation of a physiologically based pharmacokinetic (PBPK) model for a 
hypothetical chemical substance.  The chemical substance is shown to be absorbed via the skin, by inhalation, or by 
ingestion, metabolized in the liver, and excreted in the urine or by exhalation. 
Source: adapted from Krishnan and Andersen 1994 
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between serum barium levels and the degree of paralysis or muscle weakness in two individuals orally 
exposed to barium. 
3.5.3 Animal-to-Human Extrapolations 
Most of the available data in humans comes from case reports involving acute oral exposure to 
presumably high doses of barium; the primary effects noted were gastrointestinal distress and effects 
associated with hypokalemia (e.g., ventricular tachycardia, hypo or hypertension, paralysis).  Only one 
human exposure study (Wones et al. 1990) provided reliable information on exposure level; this study did 
not find any significant alterations in blood pressure in subjects exposed to relatively low doses of 
barium.  The available data in laboratory animals suggest that toxicity of ingested barium is similar across 
species. Studies conducted by the NTP (1994) in rats and mice found similar targets of toxicity; although 
some differences in sensitivity were found between the species.  Following intermediate-duration 
exposure, renal effects were observed at lower doses in rats (115 mg barium/kg/day) than in mice 
(450 mg barium/kg/day).  However, NTP (1994) concluded that rats and mice were equally sensitive to 
the barium-induced renal effects because adverse effect levels when estimated on a per unit surface area 
basis were similar for the two species.  In the absence of contrary data, it is assumed that humans and 
animals would have similar targets of toxicity and equal sensitivity.   
3.6 TOXICITIES MEDIATED THROUGH THE NEUROENDOCRINE AXIS  
Recently, attention has focused on the potential hazardous effects of certain chemicals on the endocrine 
system because of the ability of these chemicals to mimic or block endogenous hormones.  Chemicals 
with this type of activity are most commonly referred to as endocrine disruptors. However, appropriate 
terminology to describe such effects remains controversial.  The terminology endocrine disruptors, 
initially used by Thomas and Colborn (1992), was also used in 1996 when Congress mandated the EPA to 
develop a screening program for “...certain substances [which] may have an effect produced by a 
naturally occurring estrogen, or other such endocrine effect[s]...”.  To meet this mandate, EPA convened a 
panel called the Endocrine Disruptors Screening and Testing Advisory Committee (EDSTAC), and in 
1998, the EDSTAC completed its deliberations and made recommendations to EPA concerning endocrine 
disruptors. In 1999, the National Academy of Sciences released a report that referred to these same types 
of chemicals as hormonally active agents. The terminology endocrine modulators has also been used to 
convey the fact that effects caused by such chemicals may not necessarily be adverse.  Many scientists 
agree that chemicals with the ability to disrupt or modulate the endocrine system are a potential threat to 
the health of humans, aquatic animals, and wildlife.  However, others think that endocrine-active 
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chemicals do not pose a significant health risk, particularly in view of the fact that hormone mimics exist 
in the natural environment.  Examples of natural hormone mimics are the isoflavinoid phytoestrogens 
(Adlercreutz 1995; Livingston 1978; Mayr et al. 1992).  These chemicals are derived from plants and are 
similar in structure and action to endogenous estrogen.  Although the public health significance and 
descriptive terminology of substances capable of affecting the endocrine system remains controversial, 
scientists agree that these chemicals may affect the synthesis, secretion, transport, binding, action, or 
elimination of natural hormones in the body responsible for maintaining homeostasis, reproduction, 
development, and/or behavior (EPA 1997).  Stated differently, such compounds may cause toxicities that 
are mediated through the neuroendocrine axis.  As a result, these chemicals may play a role in altering, 
for example, metabolic, sexual, immune, and neurobehavioral function.  Such chemicals are also thought 
to be involved in inducing breast, testicular, and prostate cancers, as well as endometriosis (Berger 1994; 
Giwercman et al. 1993; Hoel et al. 1992). 
No studies were located regarding endocrine disruption in human and/or animals after exposure to 
barium; additionally, in vitro studies were not located. 
3.7 CHILDREN’S SUSCEPTIBILITY  
This section discusses potential health effects from exposures during the period from conception to 
maturity at 18 years of age in humans, when all biological systems will have fully developed.  Potential 
effects on offspring resulting from exposures of parental germ cells are considered, as well as any indirect 
effects on the fetus and neonate resulting from maternal exposure during gestation and lactation.  
Relevant animal and in vitro models are also discussed. 
Children are not small adults.  They differ from adults in their exposures and may differ in their 
susceptibility to hazardous chemicals.  Children’s unique physiology and behavior can influence the 
extent of their exposure.  Exposures of children are discussed in Section 6.6, Exposures of Children. 
Children sometimes differ from adults in their susceptibility to hazardous chemicals, but whether there is 
a difference depends on the chemical (Guzelian et al. 1992; NRC 1993).  Children may be more or less 
susceptible than adults to health effects, and the relationship may change with developmental age 
(Guzelian et al. 1992; NRC 1993).  Vulnerability often depends on developmental stage.  There are 
critical periods of structural and functional development during both prenatal and postnatal life, and a 
particular structure or function will be most sensitive to disruption during its critical period(s).  Damage 
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may not be evident until a later stage of development.  There are often differences in pharmacokinetics 
and metabolism between children and adults.  For example, absorption may be different in neonates 
because of the immaturity of their gastrointestinal tract and their larger skin surface area in proportion to 
body weight (Morselli et al. 1980; NRC 1993); the gastrointestinal absorption of lead is greatest in infants 
and young children (Ziegler et al. 1978).  Distribution of xenobiotics may be different; for example, 
infants have a larger proportion of their bodies as extracellular water, and their brains and livers are 
proportionately larger (Altman and Dittmer 1974; Fomon 1966; Fomon et al. 1982; Owen and Brozek 
1966; Widdowson and Dickerson 1964).  The infant also has an immature blood-brain barrier (Adinolfi 
1985; Johanson 1980) and probably an immature blood-testis barrier (Setchell and Waites 1975).  Many 
xenobiotic metabolizing enzymes have distinctive developmental patterns.  At various stages of growth 
and development, levels of particular enzymes may be higher or lower than those of adults, and 
sometimes unique enzymes may exist at particular developmental stages (Komori et al. 1990; Leeder and 
Kearns 1997; NRC 1993; Vieira et al. 1996).  Whether differences in xenobiotic metabolism make the 
child more or less susceptible also depends on whether the relevant enzymes are involved in activation of 
the parent compound to its toxic form or in detoxification.  There may also be differences in excretion, 
particularly in newborns who all have a low glomerular filtration rate and have not developed efficient 
tubular secretion and resorption capacities (Altman and Dittmer 1974; NRC 1993; West et al. 1948).  
Children and adults may differ in their capacity to repair damage from chemical insults.  Children also 
have a longer remaining lifetime in which to express damage from chemicals; this potential is particularly 
relevant to cancer. 
Certain characteristics of the developing human may increase exposure or susceptibility, whereas others 
may decrease susceptibility to the same chemical.  For example, although infants breathe more air per 
kilogram of body weight than adults breathe, this difference might be somewhat counterbalanced by their 
alveoli being less developed, which results in a disproportionately smaller surface area for alveolar 
absorption (NRC 1993). 
There is limited information on age-related differences in the toxicity of barium in humans or animals.  
Deng et al. (1991) and Lewi and Bar-Khayim (1964) reported cases from two food poisoning incidents 
that involved exposure of adults and children.  Both reports noted that children did not seem to be 
affected by the barium carbonate exposure; however, these data should be interpreted cautiously because 
neither involved examination of exposed children and no information is available on barium carbonate 
intake. There are limited data on the developmental toxicity of barium in laboratory animals.  The body 
weights of the offspring of rats exposed to barium chloride prior to mating were significantly lower than 
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control pup body weights.  A decrease in litter size was also observed, although the difference was not 
statistically significant (Dietz et al. 1992).  No developmental effects were observed in the offspring of 
mice exposed to barium chloride prior to mating (Dietz et al. 1992).  Reduced survival and decreased 
body weight were observed in the offspring of rats exposed to barium carbonate dust (Tarasenko et al. 
1977); however, poor reporting of the study methods and results limits the interpretation of the Tarasenko 
et al. (1977) study. 
There are some data suggesting possible age-related differences in toxicokinetic properties of barium.  A 
higher rate (about 10 times higher) of absorption was found in younger rats compared to older rats 
(Taylor et al. 1962).  A study of cadmium and mercury also found higher permeability in the jejunum of 
immature rats as compared to mature animals (Foulkes and Bergman 1993).  An unpublished study by 
Della Rosa summarized by ICRP (1993) found higher barium retention in dogs aged 43 (2.3% retained) 
or 150 (2.0%) days, compared to dogs aged 250 days (0.8%) or adult dogs (0.4–0.6%).  Information on 
biomarkers, interactions, and methods for reducing toxic effects of barium (discussed in Sections 3.8, 
3.10, and 3.11) comes from studies in adults and mature animals; no child-specific information was 
identified. In the absence of data to the contrary, it is assumed that this information will also be 
applicable to children. 
3.8 BIOMARKERS OF EXPOSURE AND EFFECT 
Biomarkers are broadly defined as indicators signaling events in biologic systems or samples. They have 
been classified as markers of exposure, markers of effect, and markers of susceptibility (NAS/NRC 
1989). 
Due to a nascent understanding of the use and interpretation of biomarkers, implementation of biomarkers 
as tools of exposure in the general population is very limited.  A biomarker of exposure is a xenobiotic 
substance or its metabolite(s) or the product of an interaction between a xenobiotic agent and some target 
molecule(s) or cell(s) that is measured within a compartment of an organism (NAS/NRC 1989).  The 
preferred biomarkers of exposure are generally the substance itself, substance-specific metabolites in 
readily obtainable body fluid(s), or excreta.  However, several factors can confound the use and 
interpretation of biomarkers of exposure.  The body burden of a substance may be the result of exposures 
from more than one source.  The substance being measured may be a metabolite of another xenobiotic 
substance (e.g., high urinary levels of phenol can result from exposure to several different aromatic 
compounds).  Depending on the properties of the substance (e.g., biologic half-life) and environmental 
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conditions (e.g., duration and route of exposure), the substance and all of its metabolites may have left the 
body by the time samples can be taken.  It may be difficult to identify individuals exposed to hazardous 
substances that are commonly found in body tissues and fluids (e.g., essential mineral nutrients such as 
copper, zinc, and selenium).  Biomarkers of exposure to barium are discussed in Section 3.8.1. 
Biomarkers of effect are defined as any measurable biochemical, physiologic, or other alteration within an 
organism that, depending on magnitude, can be recognized as an established or potential health 
impairment or disease (NAS/NRC 1989).  This definition encompasses biochemical or cellular signals of 
tissue dysfunction (e.g., increased liver enzyme activity or pathologic changes in female genital epithelial 
cells), as well as physiologic signs of dysfunction such as increased blood pressure or decreased lung 
capacity.  Note that these markers are not often substance specific.  They also may not be directly 
adverse, but can indicate potential health impairment (e.g., DNA adducts).  Biomarkers of effects caused 
by barium are discussed in Section 3.8.2. 
A biomarker of susceptibility is an indicator of an inherent or acquired limitation of an organism's ability 
to respond to the challenge of exposure to a specific xenobiotic substance.  It can be an intrinsic genetic or 
other characteristic or a preexisting disease that results in an increase in absorbed dose, a decrease in the 
biologically effective dose, or a target tissue response.  If biomarkers of susceptibility exist, they are 
discussed in Section 3.10, Populations That Are Unusually Susceptible. 
At present, there are no well-established biomarkers of exposure and effect for barium.  Data suggesting 
possible biomarkers are presented below. 
3.8.1 Biomarkers Used to Identify or Quantify Exposure to Barium  
Barium can be measured in bone, blood, urine, and feces.  It has been shown to be sequestered in bone 
and teeth and excreted in feces and urine.  Background levels of barium in bone are approximately 2 μg/g 
wet weight (ICRP 1974; Schroeder et al. 1972). Background levels of barium in blood, urine, and feces 
will vary with daily intake of barium.  However, the following levels have been reported:  bone, 2 ppm 
(ICRP 1974; Schroeder et al. 1972); feces, 690–1,215 μg/day (ICRP 1974; Schroeder et al. 1972; Tipton 
et al. 1969); and urine, 17–50 μg/day (ICRP 1974; Schroeder et al. 1972; Tipton et al. 1969).  In the 
United States, the geometric mean concentration of barium in the urine is approximately 1.5 µg/L (CDC 
2005). There are no data correlating bone, blood, urine, or feces levels of barium with specific exposure 
levels. For more detailed information on the toxicokinetics of barium, see Section 3.4. 
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3.8.2 Biomarkers Used to Characterize Effects Caused by Barium  
Reports of individuals exposed to high levels of barium suggest that cardiovascular, nervous, and 
gastrointestinal systems are targets of barium toxicity (Das and Singh 1970; Deng et al. 1991; Diengott et 
al. 1964; Downs et al. 1995; Gould et al. 1973; Jha et al. 1993; Koch et al. 2003; Lewi and Bar-Khayim 
1964; McNally 1925; Ogen et al. 1967; Phelan et al. 1984; Talwar and Sharma 1979; Wetherill et al. 
1981). The likely cause of most of these effects is barium induced hypokalemia.  Gastrointestinal 
disturbances are usually the first symptoms of acute barium exposure.  Hypokalemia, hypertension, and 
abnormalities in heart rhythm frequently occur shortly afterwards.  General muscle weakness is a frequent 
symptom, sometimes followed by paralysis.  Nerve conduction is often affected, resulting in numbness 
and tingling of the mouth, neck and extremities.  Loss of deep tendon reflexes may also occur.  Not all 
symptoms appear in every case of acute barium poisoning.  Although the observation of hypokalemia and 
gastrointestinal upset may be indicative of exposure to high doses of barium, other toxicants and disease 
states can produce these effects.   
Animal studies also suggest that the kidney is a target of barium toxicity; the observed nephropathy is not 
specific to barium and would not be a sensitive biomarker of effect. 
3.9 INTERACTIONS WITH OTHER CHEMICALS  
There are no data regarding the interaction between barium and various chemicals potentially found at 
hazardous waste sites. However, there are data that suggest that barium may interact with other cations 
and certain prescription drugs. Drug interactions are of relevance because individuals exposed to barium 
by living or working near hazardous waste sites contaminated with this substance may also be taking 
prescription drugs. 
The cations potassium, calcium, and magnesium also interact with barium.  Barium exposure, for 
example, may cause a buildup of potassium inside the cell resulting in extracellular hypokalemia, which 
is believed to mediate barium-induced paralysis.  In fact, potassium is a powerful antagonist of the 
cardiotoxic and paralyzing effects of barium in animals (Foster et al. 1977; Jaklinski et al. 1967; Roza and 
Berman 1971; Schott and McArdle 1974) and is used as an antidote in cases of acute barium poisoning.  
Calcium and magnesium suppress uptake of barium by pancreatic islets in vitro. Conversely, barium, in 
low concentrations, stimulates calcium uptake in these cells.  Although the data are insufficient to 
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determine the significance of these findings to human health effects, displacement of calcium may be the 
mechanism by which barium stimulates insulin release (Berggren et al. 1983). 
Among the drugs that are known to interact with barium, the barbiturates sodium pentobarbital and 
phenobarbital, were found to have an increased depressive effect on the hearts of rats exposed to barium 
(Kopp et al. 1985; Perry et al. 1983, 1989).  This hypersensitivity of the cardiovascular system to 
anesthesia was not observed in similarly treated animals that were anesthetized with xylazine plus 
ketamine.  Results of the study indicated that the hypersensitivity was specific to the barbiturates and not 
a generalized effect of anesthesia (Kopp et al. 1985). 
Other medically prescribed drugs interact with barium.  Experiments with mice indicated that atropine 
significantly antagonized antinociception and death induced by intracerebroventricular injection of 
barium chloride (Segreti et al. 1979; Welch et al. 1983).  These same studies also found that naloxone, a 
narcotic antagonist, inhibited the lethal toxicity of barium (Segreti et al. 1979; Welch et al. 1983).  
Propranolol had no effect on barium-induced paralysis in rats (Schott and McArdle 1974).  Verapamil 
rapidly abolished cardiac dysrhythmias in rabbits injected with barium chloride (Mattila et al. 1986).  In 
the same study, pretreatment with the tricyclic antidepressant, doxepin, was found to offer some 
protection against barium-induced dysrhythmias (Mattila et al. 1986).  Ouabain, which is an inhibitor of 
Na+-K+ ATPase, while not widely prescribed, has been shown to rapidly reverse the paralyzing effects of 
barium.  It has been hypothesized that ouabain works by reducing barium-induced hypokalemia by 
allowing some intracellular potassium to escape.  However, this hypothesis has not yet been proved or 
disproved because of the complexity of the mechanism involved (Schott and McArdle 1974). 
Other substances can affect barium pharmacokinetics.  One study showed that sodium alginate could 
reduce retention of orally administered barium, possibly by inhibiting absorption in the gut (Sutton et al. 
1972). This could be useful in treating cases of acute barium ingestion.  Lysine and lactose increase 
absorption of barium and could increase the toxic effects of oral exposure (Lengemann 1959). 
A human study involving one adult female was performed by applying barium chloride, alone and in 
combination, with dimethyl sulfoxide to the cervical epithelium.  Dimethyl sulfoxide significantly 
enhanced the ability of barium chloride to induce dysplasia with unusual cell formation in the cervical 
epithelium (Ayre 1966).  The significance of this is difficult to determine since there was only one 
subject, there were no controls, and few details of the experiment were provided. 
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3.10 POPULATIONS THAT ARE UNUSUALLY SUSCEPTIBLE 
A susceptible population will exhibit a different or enhanced response to barium than will most persons 
exposed to the same level of barium in the environment.  Reasons may include genetic makeup, age, 
health and nutritional status, and exposure to other toxic substances (e.g., cigarette smoke).  These 
parameters result in reduced detoxification or excretion of barium, or compromised function of organs 
affected by barium.  Populations who are at greater risk due to their unusually high exposure to barium 
are discussed in Section 6.7, Populations with Potentially High Exposures. 
The limited data available suggest that certain subgroups of the population may be more susceptible to 
barium exposure than the general population.  These include people with cardiovascular problems or lung 
disease, those taking certain prescription drugs, children, pregnant women, and smokers. 
Animal studies suggest that the kidney may be a sensitive target of barium toxicity; thus, individuals with 
impaired renal function may have a higher risk of developing barium-induced kidney damage.  There is 
suggestive evidence that barium may affect blood pressure.  Therefore, humans with hypertension could 
be at increased risk from either chronic, intermediate, or acute barium exposure.  Barbiturates have been 
shown to have an enhanced depressant effect on the heart in barium-exposed animals (Kopp et al. 1985; 
Perry et al. 1983, 1989).  Individuals on this type of medication may experience an increased risk of heart 
problems on exposure to barium. 
Since exposure to high doses of barium has been repeatedly demonstrated to significantly decrease serum 
potassium in both humans and animals (Foster et al. 1977; Gould et al. 1973; Phelan et al. 1984; Roza and 
Berman 1971), individuals taking diuretics may have a more severe hypokalemic reaction to barium 
toxicity. 
3.11 METHODS FOR REDUCING TOXIC EFFECTS  
This section will describe clinical practice and research concerning methods for reducing toxic effects of 
exposure to barium.  However, because some of the treatments discussed may be experimental and 
unproven, this section should not be used as a guide for treatment of exposures to barium.  When specific 
exposures have occurred, poison control centers and medical toxicologists should be consulted for  
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medical advice. The following texts provide specific information about treatment following exposures to 
barium:   
Dreisbach RH, Robertson WO, eds. 1987.  Handbook of poisoning:  Prevention, diagnosis and treatment. 
12th ed.  Norwalk, CT:  Appleton & Lange, 119-120.
Haddad LM, Winchester JF, eds. 1990.  Clinical management of poisoning and drug overdose.  2nd ed.
Philadelphia, PA:  WB Saunders Company, 1129. 
3.11.1 Reducing Peak Absorption Following Exposure  
The general population is typically exposed to barium through consumption of food and drinking water; 
workers may also be exposed to barium via inhalation or dermal contact.  General recommendations for 
reducing absorption of barium following exposure have included removing the exposed individual from
the contaminated area and removing contaminated clothing, followed by washing with mild soap and 
water. If the eyes and skin were exposed, they are flushed with water.  Lavage or emesis has also been 
suggested; however, high concentrations of barium cause nausea and emesis should not be induced in 
cases where substantial vomiting has already occurred (Haddad and Winchester 1990).  Furthermore, 
there is a risk of aspiration of vomitus during emesis. Administration of soluble sulfates orally will also 
limit absorption of barium by causing precipitation of an insoluble form of barium (barium sulfate) 
(Dreisbach and Robertson 1987; Haddad and Winchester 1990).  However, intravenous administration of 
sulfate salts should be avoided because barium precipitate in the kidneys will cause renal failure 
(Dreisbach and Robertson 1987; Koch et al. 2003).  
3.11.2 Reducing Body Burden  
Barium is primarily distributed to the bone and teeth; it is not known if the barium distributed to these 
tissues would result in toxicity.  A method for reducing the levels of barium in bone and teeth has not 
been identified. Removal of barium from the bloodstream may be facilitated by infusing with saline and 
inducing saline diuresis (Dreisbach and Robertson 1987).  As described in several case reports of barium
poisoning (Bahlmann et al. 2005; Koch et al. 2003; Thomas et al. 1998; Wells and Wood 2001), 
hemodialysis resulted in significant decreases in the levels of barium in the blood and improved clinical 
signs. 
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3.11.3 Interfering with the Mechanism of Action for Toxic Effects  
Hypokalemia is commonly seen in cases of acute barium toxicity and may be responsible for some of the 
symptoms of barium poisoning (Proctor et al. 1988).  Plasma potassium should be monitored and 
hypokalemia may be relieved by intravenous infusion of potassium (Dreisbach and Robertson 1987; 
Haddad and Winchester 1990; Proctor et al. 1988). 
3.12 ADEQUACY OF THE DATABASE 
Section 104(I)(5) of CERCLA, as amended, directs the Administrator of ATSDR (in consultation with the 
Administrator of EPA and agencies and programs of the Public Health Service) to assess whether 
adequate information on the health effects of barium and compounds is available.  Where adequate 
information is not available, ATSDR, in conjunction with the National Toxicology Program (NTP), is 
required to assure the initiation of a program of research designed to determine the health effects (and 
techniques for developing methods to determine such health effects) of barium and compounds. 
The following categories of possible data needs have been identified by a joint team of scientists from 
ATSDR, NTP, and EPA. They are defined as substance-specific informational needs that if met would 
reduce the uncertainties of human health assessment.  This definition should not be interpreted to mean 
that all data needs discussed in this section must be filled.  In the future, the identified data needs will be 
evaluated and prioritized, and a substance-specific research agenda will be proposed. 
3.12.1 Existing Information on Health Effects of Barium and Barium Compounds 
The existing data on health effects of inhalation, oral, and dermal exposure of humans and animals to 
barium and barium compounds are summarized in Figure 3-3.  The purpose of this figure is to illustrate 
the existing information concerning the health effects of barium.  Each dot in the figure indicates that one 
or more studies provide information associated with that particular effect.  The dot does not necessarily 
imply anything about the quality of the study or studies, nor should missing information in this figure be 
interpreted as a “data need”.  A data need, as defined in ATSDR’s Decision Guide for Identifying 
Substance-Specific Data Needs Related to Toxicological Profiles (Agency for Toxic Substances and 
Disease Registry 1989), is substance-specific information necessary to conduct comprehensive public 
health assessments.  Generally, ATSDR defines a data gap more broadly as any substance-specific 
information missing from the scientific literature. 
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There is little information regarding health effects in humans following inhalation, oral, or dermal 
exposure to barium and barium compounds (Figure 3-3).  Inhalation studies are limited to several case 
reports of individuals exposed acutely or chronically through occupational exposure (Doig 1976; Essing 
et al. 1976; Seaton et al. 1986; Shankle and Keane 1988).  A number of case reports of acute oral 
exposure to high doses of barium have been identified (Das and Singh 1970; Deng et al. 1991; Diengott et 
al. 1964; Downs et al. 1995; Gould et al. 1973; Jha et al. 1993; Koch et al. 2003; Lewi and Bar-Khayim 
1964; McNally 1925; Ogen et al. 1967; Phelan et al. 1984; Talwar and Sharma 1979; Wetherill et al. 
1981).  Additionally, there is information from a single intermediate-duration experimental study (Wones 
et al. 1990) and several human epidemiological studies or statistical studies examining mortality and 
morbidity rates in communities having exposure to barium through drinking water supplies (Brenniman 
and Levy 1985; Brenniman et al. 1979a, 1979b, 1981; Elwood et al. 1974; Schroeder and Kraemer 1974).  
Dermal studies are limited to one case report of an exposed individual (Stewart and Hummel 1984). 
The majority of studies conducted on animals have been oral exposure studies (Figure 3-3). Available 
inhalation studies with experimental animals (Hicks et al. 1986; Tarasenko et al. 1977) can only suggest 
information on the health effects of barium because these studies have a number of limitations and 
deficiencies; a third inhalation study (Cullen et al. 2000) is limited to the examination of the respiratory 
tract. The available oral studies have examined a number of end points, although most studies focused on 
various systemic effects for acute (Borzelleca et al. 1988; Boyd and Abel 1966; Tardiff et al. 1980), 
intermediate (Dietz et al. 1992; McCauley et al. 1985; NTP 1994; Perry et al. 1983, 1985, 1989; 
Tarasenko et al. 1977; Tardiff et al. 1980), and chronic exposure (Kopp et al. 1985; McCauley et al. 1985; 
NTP 1994; Perry et al. 1983, 1985, 1989; Schroeder and Mitchener 1975a, 1975b).  Dermal studies with 
experimental animals are limited to one skin irritation study (Tarasenko et al. 1977) and one study 
evaluating the tumor-promoting activity of barium (Van Duuren et al. 1968). 
3.12.2 Identification of Data Needs 
Acute-Duration Exposure.    There are limited data on the acute toxicity of barium following 
inhalation, oral, or dermal exposure.  Data on the toxicity of inhaled barium are limited to a human 
experimental study in which welders were exposed to fumes from barium-containing electrodes 
(Zschiesche et al. 1992), a case of a worker exposed to a large amount barium carbonate dust (Shankle 
and Keane 1988), and a study in which guinea pigs were exposed to a single concentration of barium 
chloride for unspecific amount of time (Hicks et al. 1986).  Although none of these studies are suitable for 
derivation of an MRL, the Hicks et al. (1986) study does identify two potential end points (increased 
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blood pressure and bronchoconstriction).  Additional inhalation studies are needed to fully evaluate the 
toxicity of barium and establish concentration-response relationships. 
Most of the available information on the acute toxicity of barium comes from human case reports 
involving oral exposure to soluble barium compounds and oral toxicity studies in animals.  There are a 
number of case reports of individuals accidentally or intentionally ingesting large doses of barium (Das 
and Singh 1970; Deng et al. 1991; Diengott et al. 1964; Downs et al. 1995; Gould et al. 1973; Jha et al. 
1993; Koch et al. 2003; Lewi and Bar-Khayim 1964; McNally 1925; Ogen et al. 1967; Phelan et al. 1984; 
Talwar and Sharma 1979; Wetherill et al. 1981).  In general, dose levels were not reported; based on the 
severity of the observed effects, it is likely that the doses were very high.  The observed effects included 
effects associated with hypokalemia (cardiac arrest, ventricular tachycardia, muscle weakness, and 
paralysis), gastrointestinal distress (vomiting, gastric pain, and diarrhea), and kidney damage (hemoglobin 
in the urine, renal insufficiency, degeneration, and acute renal failure).  Several studies in experimental 
animals have examined the acute oral toxicity of barium chloride (Borzelleca et al. 1988; Tardiff et al. 
1980). These studies have determined LD50 values and evaluated potential systemic, neurological, and 
reproductive end points.  These studies have not consistently identified targets of toxicity or adverse 
effect levels.  The available data were considered inadequate for derivation of an acute oral MRL.  
Human data consistently identify the gastrointestinal tract as a target of barium toxicity; most case reports 
of individuals ingesting soluble barium compounds report vomiting, diarrhea, and/or abdominal pain as 
one of the early signs of toxicity.  However, none of the animal studies have adequately investigated this 
end point; rodents are not a good model for examining gastrointestinal irritation.  Animal studies are 
needed to identify the critical targets of barium toxicity and establish dose-response relationships; these 
studies should include a more appropriate animal model for investigating potential gastrointestinal effects.  
Two studies have examined the dermal toxicity of barium.  One is a case report on an individual burned 
with molten barium chloride (Stewart and Hummel 1984); extrapolation of the results of this study to 
environmental exposure scenarios is complicated by the thermal burns.  Tarasenko et al. (1977) examined 
the dermal and ocular toxicity of barium carbonate in several animal species.  Poor reporting of the 
experimental design and results limits the interpretation of the study.  Additional dermal toxicity studies 
are needed for several barium compounds to confirm the Tarasenko et al. (1977) study findings that 
barium is a local irritant and to establish the existence of remote toxicity. 
Intermediate-Duration Exposure.    No human studies have examined the toxicity of barium in 
humans following intermediate-duration inhalation exposure.  Two animal studies have been identified 
81 BARIUM AND BARIUM COMPOUNDS 
3. HEALTH EFFECTS 
(Cullen et al. 2000; Tarasenko et al. 1977).  The Tarasenko et al. (1977) study examined systemic, 
reproductive, and developmental end points.  However, interpretation of the results is limited by poor 
reporting of the study design and results.  The Cullen et al. (2000) study only examined the respiratory 
tract. As these studies were considered inadequate for development of an inhalation MRL, additional 
studies examining a variety of end points are needed to identify the critical targets of barium toxicity and 
to establish concentration-response relationships.   
One human experimental study examined the cardiovascular toxicity of barium (Wones et al. 1990) 
following oral exposure; no adverse effects were found.  Several animal studies also examined the oral 
systemic toxicity (McCauley et al. 1985; NTP 1994; Perry et al. 1983, 1985, 1989; Tardiff et al. 1980), 
neurotoxicity (NTP 1994), reproductive toxicity (Dietz et al. 1992), and developmental toxicity (Dietz et 
al. 1992; Tarasenko et al. 1977) of barium.  The results of these studies suggest that the kidney is the most 
sensitive target of toxicity following intermediate-duration oral exposure.  An intermediate-duration oral 
MRL based on kidney effects in rats exposed to barium chloride for 13 weeks (NTP 1994) has been 
derived. 
Information on the oral toxicity of barium following intermediate-duration exposure comes from a human 
experimental study examining cardiovascular toxicity (Wones et al. 1990) and several animal studies 
examining systemic toxicity (McCauley et al. 1985; NTP 1994; Perry et al. 1983, 1985, 1989; Tardiff et 
al. 1980), neurotoxicity (NTP 1994), reproductive toxicity (Dietz et al. 1992; NTP 1994), and 
developmental toxicity (Dietz et al. 1992).  The human study did not find significant alterations in blood 
pressure or ECG readings in adults exposed to fairly low doses (Wones et al. 1990).  Effects observed in 
the animal studies include increased blood pressure (Perry et al. 1983, 1985, 1989), kidney damage 
(glomerular alterations consisting of fused podocytes and thickening of the capillary basement membrane 
and mild to moderate nephropathy) (McCauley et al. 1985; NTP 1994), and developmental toxicity 
(decreased pup birth weight) (Dietz et al. 1992).  The increase in blood pressure was observed at the 
lowest adverse effect level; however, two other studies (McCauley et al. 1985; NTP 1994) did not find 
significant alterations in blood pressure or ECG readings in rats exposed to higher doses of barium.  The 
low-mineral diet used in the Perry et al. (1983, 1985, 1989) studies may have influenced the results.  The 
calcium content of the rye-based diet was 3.8 mg/kg, which is lower than the concentration recommended 
for maintenance, growth, and reproduction of laboratory rats (NRC 1995).  Additional studies are needed 
to support this hypothesis.  The results of the McCauley et al. (1985) and NTP (1994) studies suggest that 
the kidney is the most sensitive target of toxicity in rats and mice following intermediate-duration oral 
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exposure; an intermediate-duration oral MRL was derived based on kidney effects observed in rats 
exposed to barium chloride for 13 weeks (NTP 1994). 
No studies have examined the toxicity in humans or animals following intermediate-duration dermal 
exposure. Studies are needed to assess the potential toxicity of various barium compounds and to 
establish whether dermal exposure would result in remote toxicity. 
Chronic-Duration Exposure and Cancer.    The toxicity of barium following chronic-duration 
inhalation exposure is limited to three occupational exposure studies (Doig 1976; Essing et al. 1976; 
Seaton et al. 1986). These studies focused on potential respiratory tract effects and are limited by co­
exposure to other compounds, small number of tested workers, and/or lack of a comparison group.  Well-
designed studies examining a number of potential end points are needed to identify the critical targets of 
barium toxicity and establish concentration-response relationships.  These studies would be useful for 
deriving a chronic-duration inhalation MRL for barium. 
Three groups of investigators have examined the effect of living in a community with elevated barium 
levels in the drinking water and the risk of mortality and cardiovascular effects (Brenniman and Levy 
1985; Brenniman et al. 1979a, 1979b, 1981; Elwood et al. 1974; Schroeder and Kraemer 1974).  These 
studies are limited by a number of factors including the lack of information on barium ingestion levels 
and the possible use of water softeners, which may have removed barium from the drinking water and 
increased the sodium content of the water.  Several studies in rats and mice have examined the chronic 
toxicity of barium (NTP 1994; Perry et al. 1989; Schroeder and Mitchener 1975a, 1975b).  The Perry et 
al. (1989) study found significant increases in systolic blood pressure in rats fed a relatively low 
concentration of barium in the diet; however, the contribution of the low mineral basal diet to the 
observed effect is not known. Several rat studies did not find adverse effects at the highest doses tested 
(McCauley et al. 1985; NTP 1994; Schroeder and Mitchener 1975a).  Marked renal nephropathy was 
observed in mice (NTP 1994); this study and effect were the basis of the chronic-duration MRL for 
barium.  The available toxicokinetic data suggest that barium accumulates in bone; it is not known if this 
accumulation would result in adverse effects.  Studies designed to test the possible association between 
high levels of barium in bone and adverse bone effects would be useful. 
Data on the dermal toxicity of barium are limited to a skin tumor promotion study using barium 
hydroxide extract from tobacco plants (Van Duuren et al. 1968); the study did not examine noncancerous 
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end points.  Additional dermal exposure studies are needed to evaluate whether various barium 
compounds are irritants and can cause remote-site toxicity. 
No studies assessing the carcinogenicity of barium following chronic inhalation exposure were identified.  
The carcinogenicity of ingested barium has been assessed in several long-term oral exposure studies in 
rats and mice (McCauley et al. 1985; NTP 1994; Schroeder and Mitchener 1975a, 1975b).  These studies 
did not find significant increases in the incidence of neoplastic lesions in either species.  Although a study 
by Van Duuren et al. (1968) provided evidence suggesting that barium hydroxide extract derived from 
tobacco leaf may act as a tumor-promoting agent when applied with a tumor initiating agent, there are no 
studies to assess barium’s potential to be a complete carcinogen following dermal exposure.  Based on the 
results of the oral study, it can be predicted that inhalation or dermal exposure to barium would not result 
in remote site carcinogenicity; however, it is not known if long-term exposure would result in respiratory 
tract cancer following inhalation exposure or skin cancer following dermal exposure.  Inhalation and 
dermal exposure cancer studies are needed to address these questions.   
Genotoxicity.    The genotoxicity of barium has not been well characterized.  One study used an in vivo 
assay to assess genotoxic potential (Yesilada 2001); increases in somatic mutations were observed in 
D. melanogaster following exposure to high levels of barium nitrate.  The available data utilizing in vitro 
assays have not found significant alterations in gene mutation frequency or DNA damage in non-
mammalian systems (Kanematsu et al. 1980; Monaco et al. 1990, 1991; Nishioka 1975; NTP 1994; 
Rossman et al. 1991; Sirover and Loeb 1976a, 1976b).  In mammalian test systems, barium did not have 
clastogenic effects (NTP 1994), but did increase the frequency of gene mutation (NTP 1994). The 
available data are inadequate to thoroughly assess the genotoxic potential of barium; additionally studies, 
particularly in vivo assays, are needed.  
Reproductive Toxicity.    The reproductive effects of barium have not been thoroughly studied.  There 
are no studies regarding reproductive effects in humans following barium exposure.  Several animal 
studies have examined potential end points of reproductive toxicity.  In the only inhalation exposure study 
(Tarasenko et al. 1977), a number of adverse effects were reported, including disturbances in 
spermatogenesis, shortened estrus cycle, and histological damage to the testes and ovaries.  However, 
limited reporting of the study design and results and the lack of incidence data and statistical analysis 
limit the interpretation of the study results.  Although a 10-day gavage study found significant decreases 
in relative and absolute ovary weights (Borzelleca et al. 1988), other oral exposure studies have not found 
alterations in organ weights or histological alterations in reproductive tissues following acute-, 
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intermediate-, or chronic-duration exposure (McCauley et al. 1985; NTP 1994). Additionally, no 
alterations in sperm morphology, motility, or counts were observed in rats or mice exposed to barium in 
drinking water for 60 days (Dietz et al. 1992).  Only one oral study evaluated reproductive function (Dietz 
et al. 1992) and found no alterations in pregnancy rate or gestation length in rats or mice.  A two-
generation study would be useful for further evaluating the potential reproductive toxicity of barium.  No 
dermal exposure studies examining reproductive end points were identified; based on available 
toxicokinetic data.  Additional studies are needed to further assess if reproductive toxicity is an end point 
of concern for barium.   
Developmental Toxicity.    The developmental effects of barium have not been studied extensively in 
either humans or animals.  One limited statistical study evaluated the degree of correlation between 
barium concentrations in drinking water and human congenital malformation rates of the central nervous 
system (Morton et al. 1976).  Results of the study indicated there was a negative statistical correlation 
between these parameters, implying that a lower risk of congenital abnormalities was found in 
populations with higher barium levels.  Two animal studies evaluated the potential developmental toxicity 
of barium.  Reduced survival, underdevelopment, lowered body weight, decreased lability of the 
peripheral nervous system, and various blood disorders were reportedly noted in the offspring of rats 
following inhalation to barium for an intermediate exposure period (Tarasenko et al. 1977).  The 
investigators also noted increased mortality and systemic toxicity in the offspring of rats orally exposed to 
barium during conception and pregnancy.  As noted previously, interpretation of the results from the 
Tarasenko et al. (1977) studies are limited because the studies were poorly reported and no incidence data 
or statistical analysis were reported.  In a mating study involving oral exposure to barium chloride prior to 
mating (Dietz et al. 1992), decreases in pup birth weight and a nonstatistically significant decrease in live 
litter size were observed in rats; no adverse effects were observed in mice.  It is not known if the decrease 
in body weight observed in the rat offspring was secondary to maternal toxicity or was a direct effect on 
the fetus. Additional developmental toxicity studies, particularly studies involving oral exposure during 
gestation and lactation, would be useful to confirm the results of the Tarasenko et al. (1977) and Dietz et 
al. (1992) studies.  Developmental toxicity studies via dermal exposure are also needed because this end 
point has not been evaluated for this route of exposure.  
Immunotoxicity.    The effect of barium on the immune system has not been well studied.  No studies 
were available regarding immunological effects in humans or animals following inhalation, oral, or 
dermal exposure to barium.  Several oral exposure studies in animals examining lymphoreticular end 
points such as thymus and lymph node histopathology have not reported adverse effects at nonlethal 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
  
  
 
 
   
   
85 BARIUM AND BARIUM COMPOUNDS
3. HEALTH EFFECTS 
doses (Borzelleca et al. 1988; McCauley et al. 1985; NTP 1994).  Screening studies are needed to 
evaluate the potential immunotoxicity of barium following inhalation, oral, or dermal exposure.   
Neurotoxicity.    Exposure to high oral doses of barium is associated with numbness and tingling 
around the mouth and neck (Lewi and Bar-Khayim 1964; Morton 1945); higher doses can result in partial 
or complete paralysis (Das and Singh 1970; Diengott et al. 1964; Gould et al. 1973; Lewi and Bar-
Khayim 1964; Morton 1945; Ogen et al. 1967; Phelan et al. 1984; Wetherill et al. 1981).  Absence of a 
deep tendon reflex has been reported in an individual exposed to airborne barium carbonate powder 
(Shankle and Keane 1988).  Oral exposure of rats and mice to barium has not been associated with 
changes in brain weight or gross or microscopic lesions of the brain (Borzelleca et al. 1988; McCauley et 
al. 1985; NTP 1994; Tardiff et al. 1980).  NTP (1994) evaluated neurobehavioral performance in rats and 
mice exposed to barium chloride in drinking water for acute or intermediate durations.  Decreases in 
spontaneous motor activity were observed in rats exposed for an intermediate duration.  Decreased grip 
strength was also observed in mice; however, this was likely due to debilitation rather than neurotoxicity.  
The human data demonstrate that at presumably high doses, barium affects action potentials of muscles 
and nerve cells by increasing cellular potassium levels.  However, oral studies are needed to establish a 
dose-response relationship for these neurological effects.  No data were available regarding neurological 
effects in animals following inhalation exposure or humans and/or animals following dermal exposure.  
Additional studies would be useful to further evaluate the neurotoxic potential of barium.   
Epidemiological and Human Dosimetry Studies.    A limited number of epidemiological and 
human dosimetry studies evaluating the health effects of barium are available (Brenniman and Levy 1985; 
Brenniman et al. 1979a, 1979b, 1981; Elwood et al. 1974; Schroeder and Kraemer 1974; Wones et al. 
1990). These studies have primarily focused on the potential of barium to adversely affect cardiovascular 
function by altering blood pressure or increasing the risk of death due to cardiovascular disease; 
consistent results have not been found.  However, all of the available human studies on barium have 
limitations and/or confounding variables that make it difficult to draw firm conclusions regarding the 
health effects of barium (see Sections 3.2.2.1 and 3.2.2.2 for discussions on the specific limitations 
associated with available epidemiological and human dosimetry studies).  Several human studies have 
also examined the potential toxicity of inhaled barium to the respiratory tract or cardiovascular system
(Doig 1976; Essing et al. 1976; Seaton et al. 1986). As with the oral studies, limitations in the study
reporting or confounding variables preclude using the studies to establish causal relationships.  In addition 
to these epidemiological or experimental studies, there are numerous case reports of individuals ingesting 
large doses of barium (Das and Singh 1970; Deng et al. 1991; Diengott et al. 1964; Downs et al. 1995; 
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Gould et al. 1973; Koch et al. 2003; Lewi and Bar-Khayim 1964; McNally 1925; Ogen et al. 1967; 
Phelan et al. 1984; Talwar and Sharma 1979; Wetherill et al. 1981) or exposed to airborne barium
carbonate (Shankle and Keane 1988). In general, these studies reported serious health effects such as 
death, ventricular tachycardia, and paralysis.  Animal studies provide evidence that the kidney is a 
sensitive target of toxicity; there is also some evidence that the cardiovascular and neurological systems 
and the developing organisms are targets of barium toxicity (Dietz et al. 1992; McCauley et al. 1985;
NTP 1994; Perry et al. 1983, 1985, 1989).  Additional epidemiological and/or human dosimetry studies 
would be useful to determine the effects of low doses of barium on these end points.  Studies of workers 
exposed to airborne barium would also be useful for establishing the toxicity of barium to the respiratory
tract. 
Biomarkers of Exposure and Effect.
Exposure. There are no established biomarkers of exposure for barium.  Analytical methods exist for 
measuring barium in blood, urine, feces, and biological tissues (Mauras and Allain 1979; Schramel 1988; 
Shiraishi et al. 1987); however, there are no data correlating levels of barium in these tissues and fluids 
with exposure.  Studies associating barium levels in biological media (such as blood or urine) with 
exposure concentrations or doses would be useful for establishing biomarkers of exposure.   
Effect. Symptoms of barium toxicity, such as hypokalemia, gastrointestinal upset, hyper- or hypo-
tension, ventricular tachycardia, and numbness and tingling around the mouth and neck (Das and Singh 
1970; Deng et al. 1991; Diengott et al. 1964; Downs et al. 1995; Gould et al. 1973; Koch et al. 2003; 
Lewi and Bar-Khayim 1964; McNally 1925; Ogen et al. 1967; Phelan et al. 1984; Talwar and Sharma
1979; Wetherill et al. 1981) are well documented.  However, there are no quantitative studies correlating 
these effects with dose and these effects are not specific to barium toxicity.  For purposes of facilitating 
medical surveillance, studies to determine useful biomarkers of effect for barium, particularly effects 
associated with low doses of barium, would be useful. 
Absorption, Distribution, Metabolism, and Excretion.    The database on absorption, distribution, 
metabolism, and excretion of barium is limited.  Existing studies indicate that barium is absorbed from
the respiratory tract (Cuddihy and Griffith 1972; Cuddihy and Ozog 1973b; Morrow et al. 1968) and 
gastrointestinal tract (Cuddihy and Griffith 1972; Harrison et al. 1956; Leggett 1992; LeRoy et al. 1966; 
Schroeder et al. 1972; Taylor et al. 1962;Tipton et al. 1969), primarily deposited in the bones and teeth 
(Bauer et al. 1957; Cuddihy and Griffith 1972; Losee et al. 1974; Miller et al. 1985; Sowden 1958;
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Sowden and Pirie 1958; Sowden and Stitch 1957), and excreted mostly in feces and urine (Cuddihy and 
Griffith 1972; Tipton et al. 1966).  Deposition in bones and teeth and excretion in feces and urine appear 
to be independent of the route of exposure. Essentially no data exist on absorption, distribution, or 
excretion following dermal exposure; however, this route is not considered to be a significant source of 
exposure to barium.  No significant data exist on the metabolism of barium compounds in the body.  
Additional studies evaluating the binding and/or complexing of barium and barium compounds with 
biological macromolecules or organic molecules in the body would be useful.  Studies quantifying the 
extent of absorption following inhalation, oral, and dermal exposure also would be useful because of 
limited absorption data.  A wide variety of individual differences in absorption efficiencies have been 
detected in the available human studies; studies examining factors influencing barium absorption would 
be useful. 
Comparative Toxicokinetics.    Based on available data, there do not appear to be significant 
differences in the toxicokinetics of barium between species (Chou and Chin 1943; Cuddihy and Griffith 
1972; McCauley and Washington 1983), although there is some indication that a larger percentage of 
absorbed barium is excreted in the feces of humans compared to that of experimental animals. However, 
there are not enough similar studies on different species to determine this with certainty.  Studies on 
different species would increase confidence in the reliability of the existing database. 
Methods for Reducing Toxic Effects.    Methods have been reported for limiting oral and dermal 
absorption of barium compounds (Bronstein and Currance 1988; Dreisbach and Robertson 1987; Haddad 
and Winchester 1990) and for counteracting the hypokalemia that is produced by barium in acute high-
level exposure situations (Dreisbach and Robertson 1987; Haddad and Winchester 1990; Proctor et al. 
1988). Contradictions exist in the literature regarding the efficacy or desirability of administering emetics 
(Bronstein and Currance 1988; Ellenhorn and Barceloux 1988; Haddad and Winchester 1990). 
Additional studies clarifying this issue would be helpful.  Also, studies directed at finding a more efficient 
way to remove barium from the body would be useful.  It is unclear whether mechanisms other than 
hypokalemia contribute to the toxic effects produced in acute high-level exposure situations.  Additional 
information on the mechanisms responsible for the toxic effects of barium could aid in the development 
of effective treatments.  Magnesium has been reported to antagonize the neuromuscular effects 
(Dreisbach and Robertson 1987).  Additional studies examining the efficacy of administering soluble 
magnesium salts to antagonize the effects of barium would also be helpful.  No information was located 
on treatment strategies for long-term low-level exposures.  Research on procedures for mitigating such 
chronic exposure situations would be helpful. 
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Children’s Susceptibility.    Data needs relating to both prenatal and childhood exposures, and 
developmental effects expressed either prenatally or during childhood, are discussed in detail in the 
Developmental Toxicity subsection above. 
There is very little information on the toxicity of barium in children.  Two reports of food poisonings with 
barium carbonate (Deng et al. 1991; Lewi and Bar-Khayim 1964) provide some suggestive information 
that children may not be as sensitive as adults to barium carbonate toxicity; however, the lack of detailed 
examination of the exposed children and lack of exposure information limits the interpretation of these 
data. No human or animal toxicity studies have been designed to assess possible differences in the 
toxicity of barium.  There is some information suggesting that infants and young children may have a 
higher barium absorption rate than adults (ICRP 1993; Taylor et al. 1962).  Other potential toxicokinetic 
differences have not been thoroughly investigated.  Additional studies are needed to evaluate potential 
age-specific differences in toxicity and toxicokinetics. 
Child health data needs relating to exposure are discussed in Section 6.8.1, Identification of Data Needs:  
Exposures of Children. 
3.12.3 Ongoing Studies 
No ongoing studies were reported in the FEDRIP (2006) database.   
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4.1 CHEMICAL IDENTITY  
Barium is an alkaline earth metal with an atomic number of 56 and is classified in Group IIA of the 
periodic table of elements. Its outer shell of electrons has a 6s2 configuration.  Because barium is highly 
reactive, it exists in the environment in the +2 oxidation state, which is its only oxidation state.  
Barium forms useful alloys with aluminum and magnesium, which are used as getters in electronic tubes 
to remove residual gases (Genter 2001).  Barium is also used as a deoxidizer for steel and other metals 
(Boffito 2002). 
Barium reacts with several other elements to form commercially-important compounds. Of these, eight 
barium compounds are covered in this chapter:  barium acetate, barium carbonate, barium chloride, 
barium cyanide, barium, hydroxide, barium oxide, barium sulfate, and barium sulfide.  Their chemical 
formulas, structures, synonyms, and identification numbers, in addition to those for barium metal, are 
listed in Table 4-1. 
4.2 PHYSICAL AND CHEMICAL PROPERTIES  
Metallic barium is a silvery-white soft metal, but takes on a silver-yellow color when exposed to air 
(Boffito 2002; Genter 2001).  Like other alkaline earth metals, barium decomposes in water, evolving 
hydrogen gas.  Barium oxidizes readily in moist air.  In powdered form, barium reacts violently with air.  
Because of its high reactivity, barium does not exist as the metal in the environment; it exists in a 
combined state with other elements.  
The barium compounds, barium acetate, barium chloride, barium cyanide, barium hydroxide, and barium 
oxide, are quite soluble in water.  Barium carbonate and sulfate are poorly soluble in water.  Barium oxide 
reacts rapidly with carbon dioxide in water to form barium hydroxide and barium carbonate (Dibello et al. 
2003). Barium sulfide slowly decomposes in water, forming barium hydroxide and barium hydrosulfide. 
Barium sulfide is also known to undergo slow oxidation in solution to form elemental sulfur and various 
oxidized sulfur species including the sulfite, thiosulfate, polythionates, and sulfate.  The water solubility 
of barium compounds increases with decreasing pH (IPCS 1991). 
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Table 4-1. Chemical Identity of Barium and Barium Compoundsa 
Characteristic Barium Barium acetate Barium carbonate 
Synonyms No data Acetic acid, barium salt; Carbonic acid, barium salt; 
barium diacetate barium monocarbonate; 
Pigment White 10; BW-C3; 
BW-P 
Trade names No data No data No data 
Chemical formula Ba Ba(C2H3O2)2 BaCO3 
Chemical structure Ba [Ba2+] [CO32-] 
O 
2+
Ba 
H3C O 2 
Identification numbers: 
 CAS registry 7440-39-3 543-80-6 513-77-9 
 NIOSH RTECS CQ8370000b AF4550000b CQ8600000b
 EPA hazardous D005 No data D005 
waste 
 DOT/UN/NA/IMCO UN1440/IMO 4.3 No data UN 1564/IMO 6.1 
shipping 
HSDB 4481 No data 950 
EINECS 231-149-1 208-849-0 208-167-3 
NCI No data No data No data 
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Table 4-1. Chemical Identity of Barium and Barium Compoundsa 
Characteristic Barium chloride Barium cyanide Barium hydroxide 
Synonyms Barium dichloride; Barium dicyanide Barium dihydroxide; barium 
NCI-C61074; SBa 0108E hydroxide lime; caustic 
baryta 
Trade names No data No data No data 
Chemical formula BaCl2 Ba(CN)2 Ba(OH)2 
Chemical structure [Ba2+] [Cl–]2 [Ba2+] [CN–]2 [Ba2+] [OH–]2 
Identification numbers: 
 CAS registry 10361-37-2 542-62-1 17194-00-2 
 NIOSH RTECS CQ8750000b CQ8785000b CQ9200000b 
 EPA hazardous D005 PO13/D003/D005 D005 
waste 
 DOT/UN/NA/IMCO UN 1564/IMO 6.1 UN 1565/IMO 6.1 UN 1564/IMO 6.1 
shipping 
HSDB 2633 403 1605 
EINECS 233-788-1 208-822-3 241-234-5 
NCI No data No data No data 
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Table 4-1. Chemical Identity of Barium and Barium Compoundsa 
Characteristic Barium oxide Barium sulfate Barium sulfide 
Synonyms 	 Barium monoxide; barium Artificial heavy spar; Barium suphide 
protoxide; baryta; calcined artificial barite; baridol; 
baryta barytes; blanc fixe; C.I. 
Pigment White 21; 
Citobaryum; Enamel 
White; E-Z-Paque; 
Solbar; precipitated 
barium sulphate; sulfuric
acid, barium saltf 
Trade names No data No data No data 
Chemical formula BaO BaSO4 BaS 
Chemical structure 	 [Ba2+] [O2-] [Ba2+] [SO42-] [Ba2+] [S2-] 
Identification numbers: 
 CAS registry 1304-28-5 7727-43-7 21109-95-5 
 NIOSH RTECS CQ9800000b CR0600000b CR0660000b
 EPA hazardous No data D005 No data 
waste 
 DOT/UN/NA/IMCO UN1884 UN1564/IMO6.1 UN1564/IMDG6.1c 
shipping 
EINECS 215-127-9 231-784-4 244-214-4 
HSDB No data 5041 No data 
NCI No data No data No data 
aAll information obtained from HSDB 2007 and ChemIDplus 2007 except where noted 
bRTECS 2007 
cKresse et al. 2007 
CAS = Chemical Abstracts Service; DOT/UN/NA/IMCO = Department of Transportation/United Nations/North 
America/Intergovernmental Maritime Dangerous Goods Code; EINECS = European Inventory of Existing
Commercial chemical Substances; EPA = Environmental Protection Agency; HSDB = Hazardous Substances Data 
Bank; NCI = National Cancer Institute; NIOSH = National Institute for Occupational Safety and Health; 
RTECS = Registry of Toxic Effects of Chemical Substances
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Information regarding the physical and chemical properties of barium and barium compounds is located 
in Table 4-2. 
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Table 4-2. Physical and Chemical Properties of Barium and Barium Compoundsa 
Property Barium Barium acetate Barium carbonate 
Molecular weight 137.327 255.416 (anhydrous) 197.336 
273.431 (monohydrate) 
Physical description Silvery-yellow metal; White powder White orthorhombic crystals 
cubic (anhydrous); white 
crystals (monohydrate) 
Melting point 727 °C Decomposes at 110 °C 1,555 °C 
(monohydrate) 
Boling point 1,897 °C No data No data 
Density 3.62 g/cm3 2.47 g/cm3 4.2865 g/cm3 
(anhydrous); 
2.19 g/cm3 
(monohydrate) 
Specific gravity No data 2.02 (below 24.7 °C)b No data 
Odor No data No data Odorlessc 
Odor threshold No data No data No data 
Solubility: 
Water Reacts with water 79.2 g/100 g water at 0.0014 g/100 g water at 
25 °C 20 °C; soluble in dilute HCl, 
HNO3, and acetic acidd; 
soluble in NH4Cl and NH4NO3 
solutionsd 
Organic solvents Slightly soluble in Slightly soluble in Insoluble in alcohole 
ethanol ethanol (monohydrate) 
Partition coefficients No data No data No data 
Vapor pressure 6.65x10-4 mmHg (at 
630 °C)f; 0.998 mmHg 
(at 1,050 °C)f 
No data Essentially zerog 
Henry’s law coefficients No data No data No data 
Autoignition temperature No data No data Nonflammablec 
Flashpoint No data No data Nonflammablec 
Flammability limits Explosion hazard if No data Nonflammablec 
exposed to moist aird 
Conversion factors No data No data No data 
Explosive limits No data No data No data 
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Table 4-2. Physical and Chemical Properties of Barium and Barium Compoundsa 
Property Barium chloride Barium cyanide Barium hydroxide 
Molecular weight 208.232 (anhydrous); 189.361 171.342 (anhydrous); 189.357 
244.263 (dihydrate)e (monohydrate); 315.464 
(octahydrate) 
Physical description White hygroscopic White crystalline White powder (anhydrous, 
orthorhombic crystals powder monohydrate); white 
(anhydrous); white monoclinic crystals 
monoclinic crystals (octahydrate) 
(dihydrate)  
Melting point  962 °C (anhydrous); No data 408 °C (anhydrous);  
decomposes at decomposes at 78 °C 
approximately 120 °C (octahydrate) 
(dihydrate) 
Boling point 1,560 °C (anhydrous) No data No data 
Density 3.9 g/cm3 (anhydrous); No data 3.743 g/cm3 (monohydrate); 
3.097 g/cm3 2.18 g/cm3 (octahydrate) 
(dihydrate) 
Specific gravity No data No data 4.495 (anhydrous)h 
Odor Odorlessg No data No data 
Odor threshold No data No data No data 
Solubility: 
Water 37.0 g/100 g water at 800 g/L (at 14 °C)e 4.91 g/100 g water at 25 °C 
25 °C 
Organic solvents Insoluble in ethanol 180 g/L (in 70% alcohol Soluble in methanold 
(dehydrate) at 14 °C)e 
Partition coefficients No data No data No data 
Vapor pressure Essentially zerog No data 0 mm Hg at 15 °C 
(monohydrate)i; 11.4 mm Hg 
at 15 °C (water vapor 
pressure of octahydrate)i 
Henry’s law coefficients No data No data No data 
Autoignition temperature No data Nonflammablec No data 
Flashpoint No data Nonflammablec No data 
Flammability limits No data Nonflammablec No data 
Conversion factors No data No data No data 
Explosive limits No data No data Explosive >216 °Cj 
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Table 4-2. Physical and Chemical Properties of Barium and Barium Compoundsa 
Property Barium oxide Barium sulfate Barium sulfide 
Molecular weight 
Physical description 
Melting point 
Boling point 
Density 
Specific gravity 
Odor 
Odor threshold 
Solubility: 
Water 
Organic solvents 
Partition coefficients 
Vapor pressure 
Henry’s law coefficients 
Autoignition temperature 
Flashpoint 
Flammability limits 
Conversion factors 
Explosive limits 
153.326 
White-yellow powder; 
cubic and hexagonal 
crystals 
1,972 °C 
No data 
5.72 g/cm3 (cubic) 
5.32 (hexagonal)b 
Odorlessg 
No data 
1.5 g/100 g water at 
20 °C 
Soluble in ethanol; 
insoluble in acetone 
No data 
Essentially zerog 
No data 
No data 
No data 
Produces heat on 
contact with water or 
steamk 
No data 
Contact with CO2 may 
cause explosionk 
233.391 
White orthorhombic 
crystals 
1,580 °C 
No data 
4.49 g/cm3 
4.50b 
 Odorlessd 
No data 
00.00031 g/100 g water 
at 20 °C 
Insoluble in ethanol 
No data 
No data 
No data 
No data 
No data 
Noncombustiblek 
No data 
Heating with aluminum 
may cause violent 
explosionsk 
169.393 
Colorless cubic crystals or 
gray powder 
2,229 °C 
No data 
4.3 g/cm3 
No data 
 Sulfurous 
No data 
8.94 g/100 g water at 25 °C 
No data 
No data 
No data 
No data 
No data 
No data 
Flammable by spontaneous 
chemical reactionsk 
No data 
Air, moisture, or acid fumes 
may cause it to ignitek 
aAll information obtained from Lide 2005 except where noted
bDibello et al. 2003 
cDOT 2005 
dBudavari et al. 2001 
eWeast 1989 
fBoffito 2002 
gNIOSH/OSHA 1978
hPerry and Chilton 1973 
iPreisman and Davis 1948 
jHSDB 2007 
kLewis 2000 
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5.1 PRODUCTION 
Barium is a dense alkaline earth metal that occurs naturally in ore deposits and makes up 0.05% of the 
Earth's crust (Genter 2001).  Barium and its compounds may be found in nature or produced industrially
for various uses.  The largest natural source of barium is barite ore, which is composed largely of barium
sulfate and is found in beds or masses in limestone, dolomite, shales, and other sedimentary formations 
(Miner 1969b). The major impurities in crude barite ore are iron(III) oxide, aluminum oxide, silica, and 
strontium sulfate (WHO 2001).  Crude barite is turned into crushed barite which not only has its own 
industrial uses but also serves, in turn, as the source for the production of other barium compounds. 
Crushed barite is first converted to barium sulfide by high-temperature, solid-phase reduction with a 
carbonaceous reducing agent.  Barium sulfide is the starting point for the chemical manufacture of most 
other barium compounds (Dibello et al. 2003).  One such useful compound is lithophone consisting of 
28% zinc sulfide (ZnS) and 72% barium sulfate (BaSO4), which is used as a white pigment in paints.  
Barium sulfate is produced from high-grade (75–98%) ore in association with granite and shale, crushed, 
and then beneficiated by washing, jigging, heavy-media separation, tabling, floatation, or magnetic 
separation (Stokinger 1981; USGS 2004).  Barium carbonate (BaCO3) occurs in nature as witherite; 
however, it has little economic significance due to its rareness, impurities, and almost fully depleted 
deposits (Kresse et al. 2007). 
In 2005, the major producer of barite in the United States was from mines in Nevada.  Significantly 
smaller amounts were produced from a single mine in Georgia.  Total U.S. production for 2004 was 
532,000 metric tons, a figure that represented 7.3% of world production.  This production figure is 14%
higher than for 2003.  In 2004, 24 grinding plants within the United States produced 2,440,000 metric 
tons of ground or crushed (processed) barite ore. Fourteen facilities, 6 in Louisiana and 8 in Texas, 
produced American Petroleum Institute (API)-grade barite in 2004.  These stand-alone grinding plants 
received barite from China and India for grinding to API specifications for the oil and gas drilling 
markets. Of the total production of ground and crushed barite ore in 2004, 94% (2,300,000 metric tons) 
was used in well drilling operations.  Louisiana and Texas were the major U.S. consumers of processed 
barite ore (1,803,000 metric tons); much of this consumption was driven by exploration for natural gas.  
The demand for barite in the United States is expected to increase, while the level of drilling activity in 
North America remains high due to a strong demand in the United States for natural gas.  The remaining 
6% (142,000 metric tons) was used as filler and extenders and in the manufacture of glass and barium
chemicals, such as barium sulfide (USGS 2004, 2006).  A list of production and processing facilities for 
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barium and barium compounds in the United States along with the production or processing volume for 
each are provided in Tables 5-1 and 5-2 (TRI04 2006).  A listing of specific manufactures of barite and 
barium compounds is given in Table 5-3. 
5.2 IMPORT/EXPORT 
For the year 2004, U.S. imports of crude barite ore totaled 1,960,000 metric tons, which was a 17%
increase from levels reported in 2003.  Estimates for 2005 predict a 17% increase in imports to 
2,350,000 metric tons.  Export volumes were at 70,000 metric tons, a 37% increase from 2003 levels.  
Estimates indicate a 22% increase in exports to 90,000 metric tons in 2005.  Import of barium chloride, 
barium nitrate, and barium carbonate amounted to 130, 4,300, and 10,200 metric tons in 2004, 
respectively.  Imports of barium oxide, hydroxide, and peroxides were reported to be 3,540 metric tons 
(USGS 2004, 2006).   
5.3 USE 
Barium and its compounds are used in oil and gas drilling muds, automotive paints, stabilizers for 
plastics, case hardening steels, bricks, tiles, lubricating oils, and jet fuel as well as in various types of 
pesticides (Bodek et al. 1988; Venugopal and Luckey 1978; WHO 2001).  The largest use of mined 
barite, which accounts for 94% of the total output, is oil and gas well drilling (USGS 2006). The rest of 
barite ore (or crude barium sulfate) is utilized frequently as a colorant in paint, as a flux to reduce melting 
temperature in the manufacture of glass, and as a filler in plastics, rubber, and brake linings as well as in 
the production of other barium compounds (Dibello et al. 2003).  Such barium compounds as the 
carbonate, chloride, and hydroxide are important in the brick, ceramic, photographic, and chemical 
manufacturing industries (Bodek et al. 1988). 
Industrial uses of barium and its compounds are wide and varied.  Barium metal and its alloys, for 
example, are often used as "getters" to remove gases from vacuum tubes due to their ability to absorb 
gases (Stokinger 1981).  One of barium carbonate's major uses is as a rodenticide (Meister 2004; 
Worthing 1987); however, it also plays an important role in the brick, tile, ceramics, oil drilling, and 
chemical manufacturing industries (Dibello et al. 2003; ILO 1983).  Barium sulfate, in the chemically
treated, blanc fixe form, is used in high-quality paints as well as in glass- and papermaking (ILO 1983; 
Kresse et al. 2007).  Barium sulfate is also added to concrete to increase the radiation shielding of this 
material.  The chloride is used for chlorine and sodium hydroxide manufacture, as a flux for aluminum
alloys, in pigment and textile dye manufacture, and in the treatment of boiler water (Dibello et al. 2003).   
99 BARIUM AND BARIUM COMPOUNDS 
5. PRODUCTION, IMPORT/EXPORT, USE, AND DISPOSAL 
Table 5-1. Facilities that Produce, Process, or Use Barium 
Minimum Maximum 
Number of amount on site amount on site 
Statea facilities in poundsb in poundsb Activities and usesc 
AK 8 0 999,999 1, 5, 12, 13, 14 
AL 23 0 999,999 1, 2, 3, 5, 6, 7, 8, 10, 11, 12, 13, 14 
AR 10 0 49,999,999 1, 3, 5, 7, 8, 11, 12 
AZ 8 0 9,999,999 1, 5, 7, 10, 13 
CA 34 0 9,999,999 1, 2, 3, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14 
CO 8 100 99,999 2, 6, 7, 8, 12, 14 
CT 3 100 999,999 1, 2, 4, 6, 7, 8, 9, 12 
DE 4 100,000 999,999 2, 3, 9, 13, 14 
FL 2 0 999,999 1, 5, 8 
GA 13 0 49,999,999 1, 2, 3, 4, 6, 7, 8, 14 
IA 12 0 999,999 1, 2, 5, 7, 10, 11, 12 
ID 7 10,000 999,999 1, 3, 5, 12, 13 
IL 22 100 49,999,999 1, 2, 3, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14 
IN 19 0 9,999,999 1, 2, 3, 5, 6, 7, 8, 9, 10, 11, 12 
KS 13 0 999,999 1, 2, 3, 4, 5, 6, 7, 8, 9, 12, 13 
KY 14 0 999,999 1, 2, 3, 4, 5, 6, 7, 8, 9 
LA 6 0 99,999 1, 5, 6, 8, 12 
MA 6 1,000 99,999 1, 3, 7, 8, 11 
MD 7 100 999,999 1, 2, 3, 4, 5, 6, 7, 8, 11, 12 
ME 4 100 99,999 1, 5, 8, 13 
MI 36 0 999,999 1, 3, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14 
MN 21 100 999,999 1, 3, 4, 5, 7, 8, 9, 10, 11, 12, 13, 14 
MO 11 0 999,999 1, 3, 4, 5, 6, 7, 8, 9, 13, 14 
MS 10 100 999,999 2, 3, 7, 8, 11 
MT 3 10,000 99,999 1, 5, 8, 9, 12 
NC 18 0 999,999 1, 2, 3, 5, 6, 7, 8, 10, 11, 12, 13 
ND 1 100,000 999,999 1, 5, 9, 12 
NE 14 100 9,999,999 1, 2, 3, 4, 5, 7, 8, 9, 11, 12, 13, 14 
NJ 17 0 999,999 2, 3, 6, 7, 8, 10, 11 
NM 6 0 49,999,999 6, 7, 8, 9, 11, 12, 14 
NV 6 100 9,999,999 1, 5, 6, 7, 10, 13 
NY 20 0 999,999 1, 2, 3, 4, 5, 6, 7, 8, 10, 12, 13 
OH 54 0 999,999 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14 
OK 19 0 999,999 1, 2, 3, 5, 7, 8, 11, 12, 13 
OR 9 0 999,999 1, 2, 3, 5, 6, 7, 12, 13 
PA 27 0 999,999 1, 2, 3, 5, 6, 7, 8, 10, 11, 12, 13 
PR 2 10,000 999,999 12 
RI 3 10,000 99,999 2, 3, 4, 6, 7 
SC 21 0 999,999 1, 2, 3, 4, 5, 6, 7, 8, 11, 12 
SD 2 100,000 999,999 1, 5, 12, 14 
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Table 5-1. Facilities that Produce, Process, or Use Barium 
Minimum Maximum 
Number of amount on site amount on site 
Statea facilities in poundsb in poundsb Activities and usesc 
TN 19 100 999,999 1, 2, 3, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14 
TX 46 0 9,999,999 1, 2, 3, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14 
UT 9 1,000 999,999 1, 2, 3, 5, 7, 8, 11, 12 
VA 15 0 999,999 1, 2, 5, 6, 7, 8, 10, 12 
VT 1 1,000 9,999 11 
WA 3 0 999,999 2, 5, 7, 8, 12, 13, 14 
WI 13 0 999,999 1, 3, 5, 6, 7, 8, 10, 11, 12, 14 
WV 10 0 999,999 2, 3, 7, 8, 10, 12 
WY 2 0 999 1, 2, 13 
aPost office state abbreviations used 
bAmounts on site reported by facilities in each state 
cActivities/Uses: 
1. Produce 
2. Import 
3. Onsite use/processing 
4. Sale/Distribution 
5. Byproduct 
6. Impurity 
7. Reactant 
8. Formulation Component 
9. Article Component 
10. Repackaging 
11. Chemical Processing Aid 
12. Manufacturing Aid  
13. Ancillary/Other Uses 
14. Process Impurity 
Source: TRI04 2006 (Data are from 2004) 
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Table 5-2. Facilities that Produce, Process, or Use Barium Compounds 
Minimum Maximum 
Number of amount on site amount on site 
Statea facilities in poundsb in poundsb Activities and usesc 
AK 4 0 9,999,999 1, 5, 12, 14 
AL 58 0 9,999,999 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14  
AR 47 0 9,999,999 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14  
AZ 41 100 99,999,999 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14  
CA 89 0 99,999,999 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14  
CO 41 0 9,999,999 1, 3, 4, 5, 6, 7, 8, 9, 12, 13, 14  
CT 25 100 999,999 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 12, 13  
DE 17 0 999,999 1, 2, 3, 4, 5, 6, 7, 8, 9, 11, 12, 13  
FL 51 0 999,999 1, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14  
GA 79 0 49,999,999 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14  
HI 2 1,000 99,999 1, 5, 10 
IA 42 100 999,999 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14  
ID 14 0 9,999,999 1, 2, 3, 5, 7, 8, 10, 11, 12, 13, 14  
IL 136 0 999,999,999 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14  
IN 109 0 9,999,999 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14  
KS 48 0 499,999,999 1, 2, 3, 4, 5, 6, 7, 8, 9, 11, 12, 13, 14  
KY 80 0 9,999,999 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14  
LA 56 0 499,999,999 1, 2, 3, 4, 5, 6, 7, 8, 9, 12, 13, 14  
MA 42 0 49,999,999 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13  
MD 52 100 9,999,999 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13  
ME 25 0 99,999 1, 2, 3, 5, 7, 8, 10, 11, 12, 13  
MI 125 0 499,999,999 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14  
MN 46 0 9,999,999 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14  
MO 68 0 499,999,999 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 12, 13, 14  
MS 39 0 9,999,999 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14  
MT 14 100 9,999,999 1, 3, 4, 5, 6, 7, 9, 12, 13, 14  
NC 77 0 49,999,999 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14  
ND 18 0 9,999,999 1, 5, 8, 9, 12, 13, 14  
NE 32 0 9,999,999 1, 3, 4, 5, 6, 7, 8, 9, 11, 12, 13  
NH 10 0 99,999 1, 2, 3, 4, 5, 7, 8, 9, 10, 12 
NJ 103 0 49,999,999 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14  
NM 21 0 9,999,999 1, 3, 4, 5, 6, 7, 8, 9, 11, 12, 13, 14  
NV 19 0 499,999,999 1, 2, 3, 4, 5, 7, 8, 9, 12, 13 
NY 121 0 499,999,999 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14  
OH 169 0 499,999,999 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14  
OK 43 0 9,999,999 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14  
OR 27 0 999,999 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 12, 13  
PA 153 0 9,999,999 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14  
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Table 5-2. Facilities that Produce, Process, or Use Barium Compounds 
Minimum Maximum 
Number of amount on site amount on site 
Statea facilities in poundsb in poundsb Activities and usesc 
PR 3 10,000 999,999 1, 2, 4, 5, 6 
RI 12 100 99,999 2, 3, 4, 6, 7, 8, 11  
SC 50 0 9,999,999 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14  
SD 7 1,000 999,999 1, 5, 7, 8, 9, 12, 13  
TN 71 0 9,999,999 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14  
TX 114 0 499,999,999 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14  
UT 41 0 99,999,999 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14  
VA 44 0 999,999 1, 2, 3, 4, 5, 6, 7, 8, 9, 11, 12, 13, 14  
VT 6 1,000 99,999 1, 5, 7, 8, 11 
WA 26 0 9,999,999 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13  
WI 54 0 9,999,999 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14  
WV 34 0 999,999 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14  
WY 23 0 9,999,999 1, 3, 4, 5, 9, 12, 13, 14  
aPost office state abbreviations used 
bAmounts on site reported by facilities in each state 
cActivities/Uses: 
1. Produce 6. Impurity 11. Chemical Processing Aid 
2. Import 7. Reactant 12. Manufacturing Aid  
3. Onsite use/processing 8. Formulation Component 13. Ancillary/Other Uses 
4. Sale/Distribution 9. Article Component 14. Process Impurity 
5. Byproduct 10. Repackaging 
Source: TRI04 2006 (Data are from 2004) 
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Table 5-3. Current U.S. Manufacturers of Barium Metal and Selected Barium 
Compoundsa 
Company Location 
Barite (barium sulfate, natural): 
CIMBAR Performance Minerals  Cadet, Missouri 
Cartersville, Georgia 
Chatsworth, Georgia 
Elementis Pigments, Inc. East St. Louis, Illinois 
Huber Engineered Materials Division Quincy, Illinois 
M-I, SWACO Amelia, Louisiana 
Battle Mountain, Nevada 
Galveston, Texas 
Westlake, Louisiana 
New Riverdale Ochre Company, Inc. Cartersville, Georgia 
Unimin Corporation Plant location not specified 
Barium sulfate (synthetic): 
Barium and Chemicals, Inc. Steubenville, Ohio 
CIMBAR Performance Minerals Cartersville, Georgia 
GFS Chemicals, Inc. Columbus, Ohio 
Johnson Matthey, Inc. Alfa Aesar Ward Hill, Massachusetts 
Mineral and Pigment Solutions, Inc. South Plainfield, New Jersey 
Barium acetate:  
Barium and Chemicals, Inc. Steubenville, Ohio 
Barium carbonate: 
Barium and Chemicals, Inc. Steubenville, Ohio 
CERAC, Inc. Milwaukee, Wisconsin 
Chemical Products Corporation Cartersville, Georgia 
Johnson Matthey, Inc. Alfa Aesar Ward Hill, Massachusetts 
Mallinckrodt Inc. Pharmaceuticals Group St. Louis, Missouri 
Osram Sylvania Inc. Towanda, Pennsylvania 
Barium chloride:  
Barium and Chemicals, Inc. Steubenville, Ohio 
Chemical Products Corporation Cartersville, Georgia 
GFS Chemical, Inc. Columbus, Ohio 
Johnson Matthey, Inc. Alfa Aesar Ward Hill, Massachusetts 
Mallinckrodt Inc. Pharmaceuticals Group St. Louis, Missouri 
Osram Sylvania Inc. Towanda, Pennsylvania 
Barium hydroxide: 
Barium and Chemicals, Inc.b,c,d Steubenville, Ohio 
Johnson Matthey, Inc. Alfa Aesarb,c Ward Hill, Massachusetts 
Mallinckrodt, Inc. Pharmaceuticals Groupe St. Louis, Missouri 
Barium oxide: 
Barium and Chemicals, Inc. Steubenville, Ohio 
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Table 5-3. Current U.S. Manufacturers of Barium Metal and Selected Barium 
Compoundsa 
Company Location 
Barium sulfide: 
Barium and Chemicals, Inc. Steubenville, Ohio 
Chemical Products Corporation Cartersville, Georgia 
Johnson Matthey, Inc. Alfa Aesar Ward Hill, Massachusetts 
aDerived from SRI 2006 unless otherwise noted.  SRI reports production of chemicals produced in commercial 
quantities (defined as exceeding 5,000 pounds or $10,000 in value annually) by the companies listed. 
bBarium hydroxide, anhydrous [Ba(OH)2]
cBarium hydroxide octahydrate [Ba(OH)2 • 8H2O]
dBarium hydroxide monohydrate [Ba(OH)2• H2O] 
eBarium hydroxide, hydration not specified 
105 BARIUM AND BARIUM COMPOUNDS 
5. PRODUCTION, IMPORT/EXPORT, USE, AND DISPOSAL 
Barium oxide is used to dry gases and solvents, strengthen ceramics, and as a component in some 
specialty cements.  Barium hydroxide plays a role in glass manufacturing, synthetic rubber vulcanization, 
in the production of barium greases and plasticizers, as a component in sealants, pigment dispersion, 
paper manufacturing, sugar refining, in animal and vegetable oil refining, and in the protection of objects 
made of limestone from deterioration.  Barium acetate is used in printing fabrics, in lubricating grease, 
and as a catalyst for organic reactions.  Finally, the main function of barium sulfide is to act as a starting 
point for the production of a number of other barium compounds (Dibello et al. 2003; ILO 1983).  This 
compound is also used in the production of thin-film electroluminescent phosphors and the vulcanization 
of carbon black-filled neoprene rubbers. 
Barium and its compounds have several important medical uses as well.  Barium chloride was formerly 
used in treating complete heart block, because periods of marked bradycardia and asystole were prevented 
through its use.  This use was abandoned, however, mainly due to barium chloride's toxicity (Hayes 
1982).  Characterized by extreme insolubility, chemically pure barium sulfate is non toxic to humans.  It 
is frequently utilized as a benign, radiopaque aid to x-ray diagnosis in colorectal and some upper 
gastrointestinal examinations, because it is normally not absorbed by the body after oral intake (de Zwart 
et al. 2001; Doull et al. 1980; ILO 1983; Lin 1996; Newman 1998; Pijl et al. 2002; Rae 1977). 
5.4 DISPOSAL 
In case of a spill, it is suggested that persons not wearing protective equipment be restricted from the area.  
Furthermore, ventilation should be provided in the room and the spilled material collected in as safe a 
manner as possible. Persons in charge of vessels or facilities are required to notify the National Response 
Center (NRC) immediately, when there is a release of this designated hazardous substance, in an amount 
equal to or greater than its reportable quantity of 1,000 pounds or 454 kg (HSDB 2007).  Barium 
compounds (particularly soluble ones) should be placed in sealed containers and reclaimed or disposed of 
in a secured sanitary landfill (IPCS 1991; NIOSH/OSHA 1978).  It is also suggested that all federal, state, 
and local regulations concerning barium disposal should be followed (HSDB 2007).  No other guidelines 
or regulations concerning disposal of barium and its compounds were found. 
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6.1 OVERVIEW 
Barium has been identified in at least 798 of the 1,684 hazardous waste sites that have been proposed for 
inclusion on the EPA National Priorities List (NPL) (HazDat 2006).  However, the number of sites 
evaluated for barium is not known.  The frequency of these sites can be seen in Figure 6-1. Of these sites, 
794 are located within the United States, 1 is in the Territory of Guam, and 3 are located in the 
Commonwealth of Puerto Rico (the Territory of Guam and the Commonwealth of Puerto Rico are not 
shown). 
Barium is a naturally occurring component of minerals that are found in small but widely distributed 
amounts in the earth's crust, especially in igneous rocks, sandstone, shale, and coal (Kunesh 1978; Miner 
1969a). Barium enters the environment naturally through the weathering of rocks and minerals.  
Anthropogenic releases are primarily associated with industrial processes.  Barium is present in the 
atmosphere, urban and rural surface water, soils, and many foods. 
Under natural conditions, barium is stable in the +2 valence state and is found primarily in the form of 
inorganic complexes.  Conditions such as pH, Eh (oxidation-reduction potential), cation exchange 
capacity, and the presence of sulfate, carbonate, and metal oxides (e.g., oxides of aluminum, manganese, 
silicon, and titanium) will affect the partitioning of barium and its compounds in the environment.  The 
major features of the biogeochemical cycle of barium include wet and dry deposition to land and surface 
water, leaching from geological formations to groundwater, adsorption to soil and sediment particulates, 
and biomagnification in terrestrial and aquatic food chains. 
The general population is exposed to barium through consumption of drinking water and foods, usually at 
low levels. Workers in barium mining or processing industries and individuals who reside near such 
industries might be exposed to relatively high levels, primarily through the inhalation of fugitive dust 
containing barium compounds.  The most recent occupational exposure estimates indicate that about 
10,000 people were potentially exposed to barium and about 474,000 to barium compounds in workplace 
environments in the United States in 1980 (NIOSH 1989a). 
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6.2 RELEASES TO THE ENVIRONMENT 
The Toxics Release Inventory (TRI) data should be used with caution because only certain types of 
facilities are required to report (EPA 2005d). This is not an exhaustive list.  Manufacturing and 
processing facilities are required to report information to the TRI only if they employ 10 or more full-time 
employees; if their facility is included in Standard Industrial Classification (SIC) Codes 10 (except 1011, 
1081, and 1094), 12 (except 1241), 20–39, 4911 (limited to facilities that combust coal and/or oil for the 
purpose of generating electricity for distribution in commerce), 4931 (limited to facilities that combust 
coal and/or oil for the purpose of generating electricity for distribution in commerce), 4939 (limited to 
facilities that combust coal and/or oil for the purpose of generating electricity for distribution in 
commerce), 4953 (limited to facilities regulated under RCRA Subtitle C, 42 U.S.C. section 6921 et seq.), 
5169, 5171, and 7389 (limited S.C. section 6921 et seq.), 5169, 5171, and 7389 (limited to facilities 
primarily engaged in solvents recovery services on a contract or fee basis); and if their facility produces, 
imports, or processes ≥25,000 pounds of any TRI chemical or otherwise uses >10,000 pounds of a TRI 
chemical in a calendar year (EPA 2005d). 
Barium is a highly reactive metal that occurs naturally only in a combined state.  The element is released 
to environmental media by both natural processes and anthropogenic sources. 
According to the SARA Section 313 Toxics Release Inventory (TRI), an estimated total of 230 million 
pounds (105,000 metric tons) of barium and barium compounds were released to the environment from 
manufacturing and processing facilities in the United States in 2004 (TRI04 2006) (see Tables 6-1 and 
6-2). Most of these barium releases were to land.  The TRI data must be viewed with caution since only 
certain types of facilities were required to report.  This is not an exhaustive list. 
6.2.1 Air 
Estimated combined releases of 2.51 million pounds (1,140 metric tons) of barium (0.35 million pounds) 
and barium compounds (2.16 million pounds) to the atmosphere from 1,107 domestic manufacturing and 
processing facilities in 2004, accounted for about 1.09% of the estimated total environmental releases 
from facilities required to report to the TRI (TRI04 2006).  These releases are summarized in Tables 6-1 
and 6-2. 
Barium is released primarily to the atmosphere as a result of industrial emissions during the mining, 
refining, and production of barium and barium chemicals, fossil fuel combustion (Miner 1969a), and  
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Table 6-1. Releases to the Environment from Facilities that Produce, Process, or 
Use Bariuma  
Reported amounts released in pounds per yearb 
Total release 
Statec RFd Aire Waterf UIg Landh Otheri On-sitej Off-sitek 
On- and 
off-site 
AK 3 24,620 0 0 306,812 0 146,620 184,812 331,432 
AL 5 6,963 504 0 39,889 4,748 7,459 44,645 52,104 
AZ 2 1,062 0 0 1,950,946 0 1,823,807 128,201 1,952,008 
CA 2 1,911 0 0 797,507 78 799,418 78 799,496 
CO 1 0 0 No data 0 0 No data 0 0 
CT 1 4 4 0 0 3,515 4 3,519 3,523 
DE 1 20 64 0 0 0 84 0 84 
GA 4 81 0 0 3,757 0 81 3,757 3,837 
IA 4 36,228 0 0 163 0 36,228 163 36,391 
ID 1 14 0 0 130,611 0 130,625 0 130,625 
IL 3 9,428 61 0 45,553 0 9,489 45,553 55,042 
IN 2 10 255 0 18,074 16,900 10 35,229 35,239 
KS 2 7,501 0 0 161,964 526,878 169,465 526,878 696,343 
KY 2 75,258 0 0 0 0 75,258 0 75,258 
MI 5 230 666 0 44,245 271,175 896 315,420 316,316 
MN 2 114,719 0 0 694 0 114,719 694 115,413 
MO 1 0 0 0 0 81 0 81 81 
NC 3 11 0 0 1,559 0 11 1,559 1,570 
NE 6 23,979 3,320 0 37,786 362,667 65,080 362,672 427,752 
NJ 2 89 0 0 30 272 89 302 391 
NM 1 0 0 0 0 0 0 0 0 
NV 2 1,243 0 0 817,749 0 818,992 0 818,992 
NY 5 35,001 137 0 3,073 15,991 35,140 19,062 54,202 
OH 14 866 372 16,649 287,615 6,472 220,822 91,152 311,974 
OK 1 1,906 5 0 250 0 1,906 255 2,161 
OR 1 0 0 0 230,293 1 230,293 1 230,294 
PA 4 756 0 0 344,131 51,746 322,501 74,132 396,633 
SC 2 253 0 0 0 72 253 72 325 
SD 1 500 0 0 39,480 0 39,980 0 39,980 
TN 1 0 0 No data 0 0 No data 0 0 
TX 9 7,392 4,029 0 71,083 7 81,473 1,038 82,511 
UT 2 10 0 0 31,035 0 31,010 35 31,045 
VA 2 0 1,900 0 111,900 0 95,900 17,900 113,800 
WI 1 0 0 0 257,400 0 0 257,400 257,400 
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Table 6-1. Releases to the Environment from Facilities that Produce, Process, or 
Use Bariuma  
Reported amounts released in pounds per yearb 
Total release 
Statec RFd Aire Waterf UIg Landh Otheri On-sitej Off-sitek 
On- and 
off-site 
WV 2 4,214 10 0 77,821 201 82,045 202 82,246 
Total 100 354,269 11,327 16,649 5,811,421 1,260,803 5,339,658 2,114,811 7,454,470 
aThe TRI data should be used with caution since only certain types of facilities are required to report.  This is not an 
exhaustive list.  Data are rounded to nearest whole number.  
bData in TRI are maximum amounts released by each facility.  
cPost office state abbreviations are used. 
dNumber of reporting facilities.  
eThe sum of fugitive and point source releases are included in releases to air by a given facility. 
fSurface water discharges, waste water treatment-(metals only), and publicly owned treatment works (POTWs) (metal 
and metal compounds). 
gClass I wells, Class II-V wells, and underground injection. 
hResource Conservation and Recovery Act (RCRA) subtitle C landfills; other on-site landfills, land treatment, surface 
impoundments, other land disposal, other landfills. 
iStorage only, solidification/stabilization (metals only), other off-site management, transfers to waste broker for 
disposal, unknown 
jThe sum of all releases of the chemical to air, land, water, and underground injection wells. 
kTotal amount of chemical transferred off-site, including to POTWs. 
RF = reporting facilities; UI = underground injection 
Source: TRI04 2006 (Data are from 2004) 
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Table 6-2. Releases to the Environment from Facilities that Produce, Process, or 
Use Barium Compoundsa  
Reported amounts released in pounds per yearb 
Total release 
On- and 
Statec RFd Aire Waterf UIg Landh Otheri On-sitej Off-sitek off-site 
AK 1 16,122 0 0 16,122 0 32,244 0 32,244 
AL 34 69,621 94,049 3,900 11,966,847 67,278 12,062,542 139,153 12,201,695 
AR 16 28,134 107,680 0 2,906,741 44,565 3,038,693 48,427 3,087,120 
AZ 10 11,779 0 0 3,951,882 61 3,962,437 1,285 3,963,722 
CA 14 8,998 514 0 56,003 3,624 20,826 48,313 69,139 
CO 18 14,440 2,232 0 8,687,234 7,500 5,019,424 3,691,982 8,711,406 
CT 4 505 5 0 66,963 22,315 540 89,248 89,788 
DE 3 17,256 9,034 0 480,594 121,025 486,290 141,619 627,909 
FL 22 49,588 9,750 0 2,232,733 216,852 2,134,494 374,429 2,508,924 
GA 29 61,732 112,867 0 8,660,091 19,737 8,798,097 56,330 8,854,427 
HI 1 45 0 0 29,331 0 45 29,331 29,376 
IA 24 142,028 3,709 0 4,358,835 229,865 3,293,915 1,440,522 4,734,437 
ID 6 8,334 11,400 0 137,167 83 98,901 58,083 156,984 
IL 56 218,005 114,459 0 13,593,791 370,276 6,061,909 8,234,621 14,296,530 
IN 45 72,823 31,471 0 8,274,849 82,196 7,095,068 1,366,271 8,461,340 
KS 12 78,277 938 0 4,774,271 250 4,853,486 250 4,853,736 
KY 38 49,663 76,268 0 7,134,938 211,117 5,405,100 2,066,886 7,471,986 
LA 17 70,200 40,931 1,367 4,315,727 8,307 4,411,344 25,188 4,436,532 
MA 14 2,275 1,283 0 257,892 21,982 20,043 263,389 283,432 
MD 18 9,340 1,880 59 468,562 697,038 90,155 1,086,724 1,176,879 
ME 6 1,301 4,100 0 81,692 0 71,193 15,900 87,093 
MI 32 55,968 125,134 56 10,513,385 24,961 7,965,087 2,754,417 10,719,504 
MN 22 48,772 22,540 0 8,233,091 71,522 7,430,251 945,673 8,375,924 
MO 30 231,257 11,722 0 10,226,716 731 10,356,850 113,576 10,470,426 
MS 16 5,973 14,703 0 1,626,877 528 1,627,878 20,203 1,648,081 
MT 6 111,530 781 0 8,892,216 175,814 8,951,015 229,325 9,180,340 
NC 31 30,632 68,807 0 3,082,682 171,007 2,921,804 431,324 3,353,127 
ND 9 39,926 24,052 0 13,826,846 6,786 7,126,843 6,770,767 13,897,610 
NE 11 37,560 52 0 3,982,921 6,350 3,739,570 287,313 4,026,883 
NH 5 1,532 0 0 26,500 1,583 9,632 19,983 29,615 
NJ 20 7,826 9,949 0 96,325 297,053 7,832 403,321 411,153 
NM 6 13,400 250 0 5,210,450 750 5,204,409 20,441 5,224,850 
NV 4 25,974 0 0 1,432,649 37 1,458,623 37 1,458,660 
NY 24 18,085 136,769 0 1,454,199 311,766 790,432 1,130,387 1,920,819 
OH 94 43,103 82,835 319 8,642,836 424,109 5,383,148 3,810,054 9,193,202 
OK 12 25,481 11,600 0 2,005,538 19 1,737,944 304,694 2,042,638 
OR 5 12,393 2,120 0 115,146 0 100,513 29,146 129,659 
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Table 6-2. Releases to the Environment from Facilities that Produce, Process, or 
Use Barium Compoundsa  
Reported amounts released in pounds per yearb 
Total release 
On- and 
Statec RFd Aire Waterf UIg Landh Otheri On-sitej Off-sitek off-site 
PA 72 50,576 40,857 250 3,948,212 422,230 1,469,982 2,992,143 4,462,125 
PR 1 1,542 0 0 91 0 1,633 0 1,633 
RI 3 5 23 0 1,072 477 28 1,549 1,577 
SC 36 27,220 51,763 0 1,313,342 678,479 1,263,992 806,812 2,070,803 
SD 2 1,057 36 0 731,856 0 681,949 51,000 732,949 
TN 24 64,154 106,884 0 4,653,790 334 4,240,684 584,478 4,825,162 
TX 48 158,316 67,044 0 16,122,300 3,011,576 16,164,215 3,195,022 19,359,236 
UT 9 5,422 100 0 3,661,314 3,902 3,510,292 160,446 3,670,738 
VA 28 25,919 26,448 0 2,006,961 189,025 1,704,517 543,836 2,248,353 
VT 1 250 5 0 0 28,667 250 28,672 28,922 
WA 11 1,318 3,118 0 2,274,705 42 2,119,156 160,027 2,279,183 
WI 30 37,077 20,145 0 890,567 1,023,144 342,849 1,628,084 1,970,933 
WV 20 75,248 18,436 0 5,243,526 78,000 4,479,752 935,458 5,415,210 
WY 7 68,528 3,229 0 7,343,092 0 6,751,399 663,450 7,414,849 
Total 1,007 2,156,511 1,471,972 5,951 210,011,467 9,052,963 174,499,278 48,199,586 222,698,864 
aThe TRI data should be used with caution since only certain types of facilities are required to report.  This is not an 
exhaustive list.  Data are rounded to nearest whole number.  
bData in TRI are maximum amounts released by each facility.  
cPost office state abbreviations are used. 
dNumber of reporting facilities.  
eThe sum of fugitive and point source releases are included in releases to air by a given facility. 
fSurface water discharges, waste water treatment-(metals only), and publicly owned treatment works (POTWs) (metal 
and metal compounds). 
gClass I wells, Class II-V wells, and underground injection. 
hResource Conservation and Recovery Act (RCRA) subtitle C landfills; other on-site landfills, land treatment, surface 
impoundments, other land disposal, other landfills. 
iStorage only, solidification/stabilization (metals only), other off-site management, transfers to waste broker for 
disposal, unknown 
jThe sum of all releases of the chemical to air, land, water, and underground injection wells. 
kTotal amount of chemical transferred off-site, including to POTWs. 
RF = reporting facilities; UI = underground injection 
Source: TRI04 2006 (Data are from 2004) 
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entrainment of soil and rock dust into the air (Schroeder 1970).  In addition, coal ash, containing widely 
variable amounts of barium, is also a source of airborne barium particulates (Miner 1969a; Schroeder 
1970).  In 1969, an estimated 18% of the total U.S. barium emissions to the atmosphere resulted from the 
processing of barite ore, and more than 28% of the total was estimated to be from the production of 
barium chemicals.  The manufacture of various end products (e.g., drilling well muds, and glass, paint, 
and rubber products) and the combustion of coal were estimated to account for an additional 23 and 26% 
of the total barium emissions for 1969, respectively (Davis 1972). 
Estimates of barium releases from individual industrial processes are available for particulate emissions 
from the drying and calcining of barium compounds and for fugitive dust emissions during the processing 
of barite ore.  Soluble barium compounds (unspecified) are emitted as particulates from barium chemical 
dryers and calciners to the atmosphere during the processing of barium carbonate, barium chloride, and 
barium hydroxide (Reznik and Toy 1978).  Uncontrolled particulate emissions of soluble barium 
compounds from chemical dryers and calciners during barium processing operations may range from 
0.04 to 10 g/kg of final product.  Controlled particulate emissions are less than 0.25 g/kg of final product.  
Based on an uncontrolled emission factor of 5 g/kg and a controlled emission factor of 0.25 g/kg, total 
particulate emissions from the drying and calcining of barium carbonate, barium chloride, and barium 
hydroxide are estimated to be 160 metric tons (352,800 pounds) per year (Reznik and Toy 1978).  
Fugitive dust emissions occur during processing (grinding and mixing) of barite ore and may also occur 
during the loading of bulk product of various barium compounds into railroad hopper cars (Reznik and 
Toy 1978). Based on an emission factor of 1 g/kg, total emissions of fugitive dust from the domestic 
barium chemicals industry during the grinding of barite ore have been estimated to be approximately 
90 metric tons (198,450 pounds) per year (Reznik and Toy 1978). Other particulate emissions from the 
industrial production of barium compounds include an estimated 820 metric tons (1.8 million pounds) per 
year from uncontrolled kilns during the processing of barite ore and 8 metric tons (17,640 pounds) per 
year from black ash (i.e., barium sulfide) rotary kilns during the production of barium hydroxide (Reznik 
and Toy 1978).  Electric utilities that burn bituminous coal emit a small fraction of the barium contained 
in coal into the air.  For example, it is estimated that 830 pounds/year of barium are released to air from a 
650 megawatt (MW) plant, in comparison to 270,000 pounds/year released as ash to land-based waste 
sites (Rubin 1999).  
The use of barium in the form of organometallic compounds as a smoke suppressant in diesel fuels results 
in the release of solids to the atmosphere (Miner 1969a; Ng and Patterson 1982; Schroeder 1970).  The 
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maximum concentration of soluble barium in exhaust gases containing barium-based smoke suppressants 
released from test diesel engines and operating diesel vehicles is estimated to be 12,000 μg/m3, when the 
barium concentration in the diesel fuel is 0.075% by weight and 25% of the exhausted barium (at a 
sampling point 10 feet from the engine and upstream from the muffler) is soluble (Golothan 1967).  Thus, 
1 L of this exhaust gas contains an estimated 12 μg soluble barium or 48 μg total barium (Schroeder 
1970). However, recent legislation requiring the use of low-sulfur fuel in diesel engines has eliminated 
the need for barium as a sulfur-scavenging additive and, therefore, has greatly reduced the emissions of 
barium from diesel engine exhaust (Schauer et al. 1999; Winkler 2002). 
6.2.2 Water 
Estimated combined releases of 1.48 million pounds (674 metric tons) of barium (0.01 million pounds) 
and barium compounds (1.47 million pounds) to surface water from 1,107 domestic manufacturing and 
processing facilities in 2004, accounted for about 0.64% of the estimated total environmental releases 
from facilities required to report to the TRI (TRI04 2006).   
The primary source of naturally occurring barium in drinking water results from the leaching and eroding 
of sedimentary rocks into groundwater (Kojola et al. 1978).  Although barium occurs naturally in most 
surface water bodies (i.e., approximately 99% of those examined) (DOI 1970), releases of barium to 
surface waters from natural sources are much lower than those to groundwater (Kojola et al. 1978). 
About 80% of the barium produced is used as barite to make high-density oil and gas well drilling muds, 
and during offshore drilling operations there are periodic discharges of drilling wastes in the form of 
cuttings and muds into the ocean (Ng and Patterson 1982).  For example, in the Santa Barbara Channel 
region, about 10% of the muds used are lost into the ocean (Ng and Patterson 1982).  Operations 
involving three drilling platforms in the Santa Maria Basin off the coast of central California released 
approximately 1.8x106 kg of barium to the ocean in discharged muds, cuttings, and waste water from 
1986 to 1994 (Phillips et al. 1998).  The use of barium in offshore drilling operations may increase 
barium pollution, especially in coastal sediments (Ng and Patterson 1982). 
6.2.3 Soil 
Estimated combined releases of 216 million pounds (98,095 metric tons) of barium (5.81 million pounds) 
and barium compounds (210 million pounds) to soils from 1,107 domestic manufacturing and processing 
facilities in 2004, accounted for about 93.7% of the estimated total environmental releases from facilities 
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required to report to the TRI (TRI04 2006).  An additional combined total of 0.023 million pounds 
(10 metric tons) from barium (0.017 million pounds) and barium compounds (0.006 million pounds), 
constituting about 0.01% of the total environmental emissions, were released via underground injection 
(TRI04 2006). These releases are summarized in Tables 6-1 and 6-2. 
The process of drilling for crude oil and natural gas generates waste drilling fluids or muds, which are 
often disposed of by land farming.  Most of these fluids are water based and contain barite and other 
metal salts.  Thus, barium may be introduced into soils as the result of land farming these slurried reserve 
pit wastes (Bates 1988). 
The use of barium fluorosilicate and carbonate as insecticides (Beliles 1979; Meister 2004) might also 
contribute to the presence of barium in agricultural soils. 
Barium has been detected with a positive geometric mean concentration of 100.5 ppm in soil samples 
from approximately 52% of the hazardous waste sites that have had samples analyzed by the CLP 
(CLPSD 1989). Note that these data from the CLPSD represent frequency of occurrence and
concentration data for NPL sites only. 
6.3 ENVIRONMENTAL FATE
6.3.1 Transport and Partitioning 
Most barium released to the environment from industrial sources is in forms that do not become widely
dispersed (Ng and Patterson 1982). In the atmosphere, barium is likely to be present in particulate form
(EPA 1984). Although chemical reactions may cause changes in speciation of barium in air, the main 
mechanisms for the removal of barium compounds from the atmosphere are likely to be wet and dry 
deposition (EPA 1984). 
In aquatic media, barium is likely to precipitate out of solution as an insoluble salt (i.e., as BaSO4 or 
BaCO3). Waterborne barium may also adsorb to suspended particulate matter through the formation of 
ion pairs with natural anions such as bicarbonate or sulfate in the matter (Bodek et al. 1988; EPA 1984; 
Giusti et al. 1993; Lagas et al. 1984; Tanizaki et al. 1992).  Precipitation of barium sulfate salts is 
accelerated when rivers enter the ocean because of the high sulfate content (905 mg/L) in the ocean 
(Bowen 1966; WHO 2001).  It is estimated that only 0.006% of the total barium input into oceans from
freshwater sources remains in solution (Chow et al. 1978; WHO 2001).  Sedimentation of suspended 
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solids removes a large portion of the barium content from surface waters (Benes et al. 1983).  There is 
evidence to suggest that the precipitation of barium from the surface of fresh and marine waters occurs, in 
part, as the result of the barite crystal formation in microorganisms (González-Muñoz et al. 2003).  
Barium in sediments is found largely in the form of barium sulfate (barite).  Coarse silt sediment in a 
turbulent environment will often grind and cleave the barium sulfate from the sediment particles leaving a 
buildup of dense barites (Merefield 1987).  Estimated soil:water distribution coefficients (Kd) (i.e., the 
ratio of the quantity of barium sorbed per gram of sorbent to the concentration of barium remaining in 
solution at equilibrium) range from 200 to 2,800 for sediments and sandy loam soils (DOE 1984; Rai et 
al. 1984). 
The uptake of barium by fish and marine organisms is also an important removal mechanism (Bowen 
1966; Schroeder 1970).  Barium levels in sea water range from 2 to 63 μg/L with a mean concentration of 
about 13 μg/L (Bowen 1979).  Barium was found to bioconcentrate in marine plants by a factor of 400– 
4,000 times the level present in the water (Bowen 1966).  Bioconcentration factors in marine animals, 
plankton, and brown algae of 100, 120, and 260, respectively, have been reported (Schroeder 1970).  In 
freshwater, a bioconcentration factor of 129 was estimated in fish where the barium in water was 
0.07 mg/L (Hope et al. 1996). 
Barium added to soils (e.g., from the land farming of waste drilling muds) may either be taken up by 
vegetation or transported through soil with precipitation (Bates 1988).  Relative to the amount of barium 
found in soils, little is typically bioconcentrated by plants (Schroeder 1970).  For example, a 
bioconcentration factor of 0.4 has been estimated for plants in a Virginia floodplain with a barium soil 
concentration of 104.2 mg/kg (Hope et al. 1996).  However, there are some plants, such as legumes, 
forage plants, Brazil nuts, and mushrooms that accumulate barium (Aruguete et al. 1998; IPCS 1991; 
WHO 2001).  Bioconcentration factors from 2 to 20 have been reported for tomatoes and soybeans (WHO 
2001). 
Barium is not very mobile in most soil systems, due to the formation of water-insoluble salts and an 
inability of the barium ion to form soluble complexes with fulvic and humic acids (WHO 2001).  The rate 
of transportation of barium in soil is dependent on the characteristics of the soil material.  Soil properties 
that influence the transportation of barium to groundwater are cation exchange capacity, calcium 
carbonate (CaCO3) content and pH.  In soil with a high cation exchange capacity (e.g., fine textured 
mineral soils or soils with high organic matter content), barium mobility will be limited by adsorption 
(Bates 1988; Kabata-Pendias and Pendias 1984).  High CaCO3 content limits mobility by precipitation of 
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the element as BaCO3 (Lagas et al. 1984). Barium will also precipitate as barium sulfate in the presence 
of sulfate ions (Bodek et al. 1988; Lagas et al. 1984). Barium is more mobile and is more likely to be 
leached from soils in the presence of chloride due to the high solubility of barium chloride as compared to 
other chemical forms of barium (Bates 1988; Lagas et al. 1984).  Barium may become more mobile in 
soils under acid conditions as barium in water-insoluble salts, such as barium sulfate and carbonate, 
becomes more soluble (WHO 2001).  Barium complexes with fatty acids (e.g., in acidic landfill leachate) 
will be much more mobile in the soil due to the lower charge of these complexes and subsequent 
reduction in adsorption capacity (Lagas et al. 1984). 
Barium mobility in soil is reduced by the precipitation of barium carbonate and sulfate.  Humic and fulvic 
acid have not been found to increase the mobility of barium (EPA 1984). 
6.3.2 Transformation and Degradation  
6.3.2.1 Air 
Elemental barium undergoes oxidation in air and is oxidized readily in moist air (Boffito 2002; EPA 
1983; Kresse et al. 2007; Kunesh 1978).  The residence time of barium in the atmosphere may be several 
days, depending on the size of the particulate formed, the chemical nature of the particulate, and 
environmental factors such as rainfall (EPA 1984; WHO 2001). 
6.3.2.2 Water 
Under natural conditions, barium will form compounds in the +2 oxidation state.  Barium does not 
hydrolyze appreciably except in highly alkaline environments (i.e., at pH levels ≥10) (Bodek et al. 1988).
Appreciable levels of barium sulfate occur because natural water often contains high sulfate 
concentrations, especially ocean water.  Since the solubility of barium sulfate is low, only trace amounts 
of barium dissolve in surface water (Bodek et al. 1988; NAS 1977).  At pH levels of 9.3 or below, barium
sulfate may limit barium concentrations in natural waters (Bodek et al. 1988).  The solubility of barium
-sulfate increases considerably in the presence of chloride (Cl-) and other anions (e.g., NO3 and CO3-2), 
and at pH levels of 9.3 or below, the barium ion (Ba2+) is the dominant species (Bodek et al. 1988; NAS 
1977).  The Ba2+ ion is stable under the pH-Eh range of natural systems.  However, natural and treated 
waters usually contain sufficient sulfate so that a barium ion concentration of more than 1,000– 
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1,500 μg/L cannot be maintained in solution (EPA 1983; Hem 1959; Lagas et al. 1984; McCabe et al. 
1970). 
As pH levels increase above 9.3 and in the presence of carbonate, barium carbonate becomes the 
dominant species (Bodek et al. 1988; Singer 1974).  Barium carbonate also exhibits fast precipitation 
kinetics and very low solubility and in alkaline environments limits the soluble barium concentration 
(Faust and Aly 1981; Hem 1959; Rai et al. 1984; Singer 1974).  Barium forms salts of low solubility with 
arsenate, chromate, fluoride, oxalate, and phosphate ions (Bodek et al. 1988; EPA 1983; Kunesh 1978). 
The chloride, hydroxide, and nitrate of barium are water-soluble (Bodek et al. 1988; EPA 1983; 
Kirkpatrick 1978) and are frequently detected in aqueous environments (Rai et al. 1984). 
Barium also forms complexes with natural organics in water (e.g., fatty acids in acidic landfill leachates) 
to a limited extent (Lagas et al. 1984; Morel 1983; Rai et al. 1984). 
6.3.2.3 Sediment and Soil 
Barium reacts with metal oxides and hydroxides in soil and is subsequently adsorbed onto soil 
particulates (Hem 1959; Rai et al. 1984).  Adsorption onto metal oxides in soils and sediments probably 
acts as a control over the concentration of barium in natural waters (Bodek et al. 1988).  Under typical 
environmental conditions, barium displaces other adsorbed alkaline earth metals from MnO2, SiO2, and 
TiO2 (Rai et al. 1984).  However, barium is displaced from Al2O3 by other alkaline earth metals (Rai et al. 
1984).  The ionic radius of the barium 2+ ion, its typical oxidation state, makes isomorphous substitution 
possible only with strontium, and generally not with the other members of the alkaline earth elements 
(Kirkpatrick 1978).  Among the other elements that occur with barium in nature, substitution is common 
only with potassium but not with the smaller ions of sodium, iron, manganese, aluminum, and silicon 
(Kirkpatrick 1978). 
Barium is also adsorbed onto soil and subsoil through electrostatic interactions (Bodek et al. 1988; Singer 
1974).  The cation exchange capacity of the sorbent largely controls the retention of barium in soils 
(Bodek et al. 1988).  Barium is strongly adsorbed by clay minerals (Kabata-Pendias and Pendias 1984; 
Lagas et al. 1984). 
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Barium can also form salts with acetate, nitrate, chloride, and hydroxide ions in soil.  The mobility of 
barium in soils increases upon formation of these water soluble salts (Bodek et al. 1988).  In general, the 
solubility of barium compounds increases with decreasing pH. 
6.4 LEVELS MONITORED OR ESTIMATED IN THE ENVIRONMENT  
Reliable evaluation of the potential for human exposure to barium depends in part on the reliability of 
supporting analytical data from environmental samples and biological specimens.  Concentrations of 
barium in unpolluted atmospheres and in pristine surface waters are often so low as to be near the limits 
of current analytical methods.  In reviewing data on barium levels monitored or estimated in the 
environment, it should also be noted that the amount of chemical identified analytically is not necessarily 
equivalent to the amount that is bioavailable.  The analytical methods available for monitoring barium in 
a variety of environmental media are detailed in Chapter 7. 
6.4.1 Air 
The concentration of barium in ambient air is estimated to be <0.05 μg/m3 (IPCS 1991).  Airborne barium 
likely exists as the carbonate or sulfate salts and is carried on particulate matter that results as a 
consequence of natural processes (e.g., suspension of soil dust) or anthropogenic activities (e.g., 
combustion process, mining and calcining of barium ores) (WHO 2001).  However, there is no apparent 
correlation between the degree of industrialization and barium concentrations in ambient air (Winkler 
2002).  Particulate matter from diesel exhaust was once a source of barium in ambient air.  However, 
barium emissions from diesel engines has been greatly diminished to near zero emissions with the current 
use of low-sulfur diesel fuels, which do not require the addition of barium as a sulfur-scavenging agent 
(Hildemann et al. 1991; Schauer et al. 1999; Shahin et al. 2000; Winkler 2002).  
Tabor and Warren (1958) report urban and suburban air concentrations of barium ranging from <0.005 to 
1.5 μg/m3. In another study of barium concentrations in ambient air, values ranged from 0.0015 to 
0.95 mg/m3 (EPA 1984). No distinct pattern related to industrialization appeared in the results reported 
on 754 samples from 18 cities and four suburban areas in the United States.  For example, in Houston, 
Texas and its suburbs, 76% of the samples contained barium at levels ranging from 0.005 to 1.5 μg/m3, 
whereas in Fort Worth, Texas, 66% of the samples had values <0.005 μg/m3 (Tabor and Warren 1958). 
Another compilation of atmospheric data shows barium concentrations in urban atmospheres of North 
America ranging from 2x10-4 to 2.8x10-2 μg/m3 with a mean concentration of 1.2x10-2 μg/m3 (Bowen 
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1979).  In contrast, barium levels in samples from the South Pole and northern Norway were 1.6x10-5 and 
7.3x19-4 μg/m3, respectively (Bowen 1979).  Mean barium concentrations in background air collected 
between April and October 2002 on the campus of the University of Birmingham, United Kingdom, were 
0.32 and 1.4 ng/m3 in the <0.5 and 3.0–7.2 μm particular matter fractions, respectively (Birmili et al. 
2006). 
Maximum ground-level barium concentrations (as soluble compounds) associated with uncontrolled 
atmospheric particulate emissions from chemical dryers and calciners at barium-processing plants have 
been estimated (using dispersion modeling) to range from 1.3 to 330 μg/m3 over a 24-hour averaging time 
at locations along facility boundaries (i.e., away from the source of emission) (Reznik and Toy 1978). 
Barium has been measured in dust samples taken from 49 residences in Ottawa, Canada.  Mean and 
median concentrations of 405.56 and 222.22 mg barium/kg dust, respectively, were measured within a 
sub-fraction of the dust samples where the particulate sizes ranged from 100 to 250 μm (Butte and 
Heinzow 2002; Rasmussen et al. 2001). 
Barium has been measured in rain and snow collected near Claremont, New Hampshire in 1996–1997 
(Feng et al. 2000).  Barium concentrations in rain ranged from 0.22 to 0.84 μg/L with a mean 
concentration of 0.39 μg/L.  In snow, barium concentrations ranged from 0.64 to 7.44 μg/L with a mean 
concentration of 1.5 μg/L. 
Barium has been detected in air samples collected at 24 of the 798 hazardous waste sites where barium 
has been detected in some environmental medium (HazDat 2006).  The HazDat information includes data 
from both NPL and other Superfund sites.  Concentrations of barium in air ranged from 0.015 to 
327,000,000 μg/m3 in 16 onsite (HazDat 2006).  In comparison, concentrations of barium in air ranged 
from 0.0135 to 561,000,000 μg/m3 in 12 offsite samples (HazDat 2006). 
6.4.2 Water 
Barium has been found in almost all raw surface waters and public drinking water supplies sampled (i.e., 
approximately 99%) (Kopp 1969) at concentrations ranging from ≤5 to 15,000 μg/L with mean 
concentrations generally on the order of 10–60 μg/L (Barnett et al. 1969; Bowen 1979; DOI 1970; Durfor 
and Becker 1964; Durum and Haffty 1961; Elinder and Zenz 1994; EPA 2005c; Kopp 1969; Longerich et 
al. 1991; McCabe et al. 1970; Neal et al. 1996; Saleh and Wilson 1999; Tuovinen et al. 1980).  Barium 
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concentrations are lowest (mean value of 15 μg/L) in the drainage basins of the western Great Lakes and 
highest (mean value of 90 μg/L) in the southwestern drainage basins of the lower Mississippi Valley 
(EPA 2005c).  Barium concentrations in the shallow aquifer below Denver, Colorado, have been reported 
to range from 18 to 594 μg/L with a median value of 104 μg/L (Bruce and McMahon 1996).  Barium 
concentrations in most drinking water supplies are <200 μg/L with a mean concentration of 28.6 μg/L 
(EPA 2005c).  In California, mean and median values of 302 and 160 μg/L, respectively, were measured 
for barium concentrations in drinking water supplies (Storm 1994). 
Barium concentrations in groundwater supplies have been known to exceed EPA's maximum contaminant 
level (MCL) of 2.0 mg/L (2,000 μg/L) (EPA 2002a); this may be due to leaching and erosion of barium 
from sedimentary rocks (Calabrese 1977; Kojola et al. 1978).  For example, community water supplies 
from deep rock and drift wells in northeastern Illinois have been found to have barium concentrations 
ranging from 1,100 to 10,000 μg/L (Calabrese 1977).  Many communities in Kentucky, Pennsylvania, and 
New Mexico have drinking water where the barium content is up to ten times higher than the MCL (EPA 
2005c). Water samples taken from groundwater wells in Texas that are within 750 m of brine injection, 
dry, or plugged gas/oil wells contain barium ranging in concentration from 1.2 to 2,300 μg/L (Hudak and 
Wachal 2001). 
A mean concentration of 167 μg/L for barium was measured in influent streams of a public waste water 
treatment plant in Melbourne, Australia (Wilkie et al. 1996).  The amount of barium in the influent 
streams could not be accounted for based on the mean concentrations of barium in domestic water 
supplies (20 μg/L) or domestic sewage (38 μg/L). Instead, it is likely that the barium unaccounted for in 
the influent stream is the result of barium carried in effluents from industries that are discharged into the 
catchment area of the treatment plant. 
Barium has also been found in sea water at concentrations ranging from 2 to 63 μg/L with a mean 
concentration of 13 μg/L (Bowen 1979). 
Barium has been detected in surface water and groundwater samples collected at 257 and 561 of the 
798 hazardous waste sites, respectively, where barium has been detected in some environmental medium 
(HazDat 2006). The HazDat information includes data from both NPL and other Superfund sites.  
Maximum concentrations of barium in surface water (lakes, streams, ponds, etc.) ranged from 0.33 to 
18,100,000 μg/L in 77 onsite samples (HazDat 2006).  In comparison, maximum concentrations of 
barium in surface water (lakes, streams, ponds, etc.) ranged from 10 to 73,8000 μg/L in 112 offsite 
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samples (HazDat 2006).  The maximum concentrations of barium in groundwater ranged from 0.064 to 
2,100,000 μg/L in 442 onsite samples (HazDat 2006).  In comparison, maximum concentrations of 
barium in groundwater ranged from 0.05 to 803,000 μg/L in 260 offsite samples (HazDat 2006).  
6.4.3 Sediment and Soil 
Barium is relatively abundant in the earth's crust and is found in most soils at concentrations (Table 6-3) 
ranging from about 15 to 3,500 ppm (dry weight) and mean values ranging between 265 and 835 ppm, 
depending on soil type (EPA 1995a; Kabata-Pendias and Pendias 1984; Lide 2005; Zenz et al. 1994).  
The barium content in cultivated and uncultivated soil samples collected during a number of field studies 
ranged from 15 to 1,000 ppm (mean concentration of 300 ppm) for B horizon soils (subsurface soils) in 
the eastern United States and from 70 to 5,000 ppm (mean concentration of 560 ppm) for B horizon soils 
in the western United States (Bowen 1979; Schroeder 1970; Shacklette and Boerngen 1984). Barium 
content ranged from 150 to 1,500 ppm for surface horizon soils collected in Colorado (mean 
concentration of 550 ppm) (Connor and Shacklette 1975).  Soil samples (0–6 inch depth) taken from three 
New England cities, Boston, Providence and Springfield, were reported to have mean barium 
concentrations of 53.95, 45.29 and 45.17 mg/kg, respectively, and upper 95% interval values of 66.25, 
59.43, and 51.03 mg/kg, respectively (Bradley et al. 1994).  Soil samples were obtained from areas that 
were not influenced by industrial activity, such as along roads and sidewalks, parks and open lots, and 
may account for why the mean values for barium concentration were well below a mean value of 
420 mg/kg for the United States.   
Geometric mean concentrations of barium in sediments taken from 16 sampling sites along the southern 
shore of Lake Ontario and southeastern shore of Lake Erie ranged from 6.0 to 143.6 μg/g (dry weight) 
(Lowe and Day 2002).  Thirteen of the 16 sites had mean barium concentrations that exceeded EPA’s 
guidelines (20–60 μg barium/g dry weight) for defining moderately polluted harbor sediments for this 
metal. However, these concentrations are lower than the mean barium concentration of 482.1 μg/g in 
sediments collected from Lake Pontchartrain near New Orleans, Louisiana (USGS 2002c).  The barium 
content in total suspended solids collected from the Mississippi River before it enters Lake Pontchartrain 
was 599 μg/g. 
Barium concentrations in sediments near offshore drilling platforms are typically higher than unaffected 
sediments.  Surficial and suspended sediments collected within 500 m of a drilling platform in the Santa 
Maria Basin offshore of central California contained barium at concentrations of 923 and 736 mg/kg dry 
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Table 6-3. Concentrations of Barium in Surface Soils of the United Statesa,b 
Concentrationc 
Soil Mean Range 
Sandy and lithosols on sandstone 400 20–1,500 
Light loamy soils 555 70–1,000 
Loess and soils on silt deposits 675 200–1,500 
Clay and clay loamy soils 535 150–1,500 
Alluvial soils 660 200–1,500 
Soils over granite and gneisses 785 300–1,500 
Soils over volcanic rocks 770 500–1,500 
Soils over limestones and calcareous rocks 520 150–1,500 
Soils on glacial till and drift 765 300–1,500 
Light desert soils 835 300–2,000 
Silty prairie soils 765 200–1,500 
Chernozems and dark prairie soils 595 100–1,000 
Organic light soils 265 10–700 
Forest soils 505 150–2,000 
Various soils 560 70–3,000 
Mean concentration in Earth’s crustd 500 — 
Mean concentration in Earth’s cruste 425 — 
aData obtained from Kabata-Pendias and Pendias (1984) unless indicated otherwise
bData are for whole soil profiles 
cConcentrations expressed as ppm dry weight
dZenz et al. 1994 
eLide 2000 
Source: Adapted from EPA 1995a 
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weight, respectively (Phillips et al. 1998).  These values were higher (although not statistically 
significant) than the values of 869 and 687 mg/kg dry weight measured in surficial and suspended 
sediments, respectively, collected at a distance of 1,000 meters from the platform and are similar to the 
predrilling concentrations of barium in these sediments.  In other California coastal sediments, for 
example the Southern California Bight, barium concentrations range from 145 to 1,259 ppm with an 
average of 720 ppm (Chow et al. 1978).  Median barium concentration ranges in sediments from the lake 
system in Chiapas, Mexico were 54.4–121.2 and 50.3–155.3 μg/g dry weight in three lakes during the dry 
(June 2002) and rainy (September 2000) seasons, respectively (Pascual-Barrera et al. 2004).  This lake 
system is an area of petroleum extraction and processing.  Barium concentrations ranging from 180 to 
2,800 μg/g dry weight (mean 729 μg/g dry weight) were reported in surface sediments (<63 μm fraction) 
collected in April 2002 from eight stations in Izmit Bay, Turkey (Pekey 2006). 
Barium has been detected in soil and sediment samples collected at 369 and 260 of the 798 hazardous 
waste sites, respectively, where barium has been detected in some environmental medium (HazDat 2006).  
The HazDat information includes data from both NPL and other Superfund sites.  Maximum 
concentrations of barium in soil (topsoil, <3 inches depth) ranged from 1.59 to 13,000 ppm in 84 onsite 
samples (HazDat 2006).  In comparison, maximum concentrations of barium in soil (topsoil, <3 inches 
depth) ranged from 3 to 54,700 ppm in 28 offsite samples (HazDat 2006).  Maximum concentrations of 
barium in sediment (lakes, streams, ponds, etc.) ranged from 13.1 to 17,600 ppm in 36 onsite samples 
(HazDat 2006). In comparison, maximum concentrations of barium in sediment (lakes, streams, ponds, 
etc.) ranged from 0.156 to 26,400 ppm in 92 offsite samples (HazDat 2006). 
6.4.4 Other Environmental Media 
Barium occurs in many foods at generally low levels (Table 6-4).  In the Canadian Total Diet Study, the 
concentrations of barium were found to be less than 4 ppm (4,000 ng/g) in a variety of foods (Health 
Canada 2005).  However, Brazil nuts have notably high concentrations of barium (3,000–4,000 ppm) 
(Beliles 1979). Some plants bioconcentrate barium from the soil (Beliles 1979; Reeves 1979; Schroeder 
1970).  The barium content in corn samples from Georgia, Missouri, and Wisconsin collected during a 
number of field studies ranged from 5 to 150 ppm with mean concentrations ranging from 15 to 54 ppm 
(Connor and Shacklette 1975).  The barium content in other cultivated plants (e.g., lima beans, cabbage, 
soybeans, and tomatoes) from Georgia, Missouri, and Wisconsin ranged from 7 to 1,500 ppm with mean 
concentrations in various plants ranging between 38 and 450 ppm.  The highest levels occurred in  
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Table 6-4. Concentrations of Barium in Food Obtained from the Canadian Total 
Diet Study Between 1993 and 1999  
Concentration (ng/g) 
Food Categories Averagea Rangeb 
Milk 71.22 67.96–73.24 
Dairy produce (ice cream, yogurt, cheese, cream) 332.37 70.61–962.93c 
Meats (beef, pork veal, lamb, organ meats) 131.82 12.06–237.57 
Eggs 456.69 456.69 
Poultry (chicken, turkey) 52.53 52.53 
Fish (marine, fresh water, canned) and shellfish 137.28 36.17–481.34 
Soups (meat, cream, tomato, dehydrated) 130.01 119.66–154.53 
Breads, cereals, pasta, rice, pastries (cake, pies) 891.16 45.86–3,840.40d 
Vegetables 425.69 47.99–2,282.23e 
Fruits 570.33 57.62–3,750.03f 
Oils, fats, butter 32.45 20.67–53.08 
Candy, syrups, jams, gelatin, puddings, honey, sugar 300.60 4.86–903.07g 
Peanut butter and peanuts 2,919.11 2,919.11 
Beverages (beer, wine, coffee, tea, soft drinks, tap water) 70.94 13.05–151.82 
Baby foods and formula 196.46 46.98–481.85 
Frozen entrees 457.76 393.57–594.11 
Processed foods (pizza, burgers, French fries, hot dog, etc.) 516.96 278.43–864.58 
aValues represent the average barium concentration in the foods covered under the individual food categories. 
bValues represent the range of average concentrations of the food items covered under the individual food  
categories. 
cThe highest barium concentrations were found in unprocessed cheeses (962.93 ng/g). 
dThe highest barium concentrations were found in wheat and bran cereals (3,840.40 ng/g), whole wheat bread 
(1,494.06 ng/g), muffins (1,434.30 ng/g), and cookies (1,029.13 ng/g). 
eThe highest barium concentrations were found in beets (2,282.23 ng/g) and carrots (1,309.25 ng/g). 
fThe highest barium concentrations were found in raspberries (3,750.03 ng/g) and strawberries (1,176.48 ng/g). 
gThe highest barium concentrations were found in chocolate candy bars (903.07 ng/g). 
Source: Health Canada (2005) 
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cabbage from Georgia and soybeans from Missouri and the lowest levels occurring in Georgia tomatoes 
(Connor and Shacklette 1975). 
Grippo et al. (2006) measured various metal concentrations in dietary supplements purchased from 
random local vendors in the Little Rock, Arkansas area between 2002 and 2003.  Barium concentrations 
in botanicals were 0.0200 and 15.4 ng/g in samples of milk thistle and kava kava, respectively.  Barium 
concentrations in ephedra-containing supplements were 0.0400 and 93.3 ng/g in Virgin Earth and 
Xenadrine RFA-1, respectively.  The authors noted that all metals measured in this study were detected at 
concentrations below toxic levels or physiological limits for daily intake, where such limits have been 
identified (Grippo et al. 2006).   
The Wyoming Game and Fish Department collected game fish during the 2000–2001 season to survey the 
state’s fisheries for metal contamination.  Ninety-six fish composites (fillets) were collected, representing 
11 species, from 28 lakes and reservoirs across Wyoming.  In this study, barium concentrations were at or 
below the method detection limit of 0.05 mg/kg (Dailey et al. 2005).  Mean barium concentrations 
ranging from 0.057 to 0.255 mg/kg wet weight were reported in muscle tissue of five species of sturgeons 
collected from the Caspian Sea (Pourang et al. 2005).   
Barium is also found in anaerobic sewage sludge at concentrations ranging from 100 to 9,000 ppm (mean 
concentration of 800 ppm) and in aerobic sewage sludge at concentrations ranging from 100 to 300 ppm 
(mean concentration of 200 ppm) (Sommers 1977). 
Barium concentrations in leachates from municipal landfills range from 0.11 to 9,220 μg/L (EPA 1990, 
1991; Roy 1994). 
Barium concentrations in fertilizers and soil amendments range from <0.2 to 669 μg/g mean (Raven and 
Loeppert 1997). The highest levels are in tilemsi phosphate rock (669 μg/g), austenite (408 μg/g), 
milorganite (165 μg/g), manure (153 μg/g), and compost (131 μg/g). There is some concern that 
continued use of fertilizers and soil amendments, which contain high amounts of barium and other metals, 
may result in an accumulation of barium in agricultural soils.  The accumulation of barium in soils that is 
due to the continued use of fertilizers and soil amendments and the potential for increased content of 
barium in agricultural products and potential harm to the environment have not yet been assessed (Raven 
and Loeppert 1997). 
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6.5 GENERAL POPULATION AND OCCUPATIONAL EXPOSURE  
The primary routes of exposure of humans to barium are consumption of food and water and inhalation of 
ambient air (ICRP 1974; Reeves 1979; WHO 2001).  Based on compliance monitoring data from the 
Federal Reporting Data System (FRDS), of the approximately 214 million people in the United States 
who are connected to a public water supply, it is estimated that about 150,000 people are exposed to 
barium concentrations greater than EPA's MCL of 2.0 mg/L (2,000 μg/L) (EPA 2002a). However, since 
94% of all samples collected from public water supplies of the 100 largest cities in the United States had 
barium concentrations <100 μg/L (Durfor and Becker 1964), it is likely that most of the people connected 
to a public water supply receive drinking water with barium concentrations below the MCL.  In a survey 
of drinking water from residences in EPA Region V (Indiana, Illinois, Michigan, Minnesota, Ohio, and 
Wisconsin) taken from the National Human Exposure Assessment Survey (NHEXAS) in 1995, an 
average barium concentration of 30 μg/L was obtained, with a 90th percentile value of 77 μg/L (Thomas et 
al. 1999).  Assuming an average adult drinking water consumption rate of 2 L/day and that barium is 
present at concentrations of 30 μg/L, the average adult daily intake of barium through the consumption of 
drinking water would be 60 μg/day (0.86 μg/kg/day for a 70-kg adult).  However, the International 
Commission for Radiation Protection (ICRP) estimates that the gastrointestinal absorption of barium is 
<5% (ICRP 1973). 
The International Commission on Radiological Protection (ICRP 1974) has estimated that intake of 
barium through inhalation ranges from 0.09 to 26 μg/day.  Based on reported urban air concentrations for 
barium (<0.005–1.5 μg/m3) (Tabor and Warren 1958) and assuming an average adult ventilation rate of 
20 m3/day (EPA 1989), the calculated daily respiratory intake of barium ranges from <0.1 to 30 μg, which 
is comparable to the ICRP estimated intake range above.  Based on the 8-hour time-weighted average 
threshold limit value (TLV) in workplace air of 500 μg/m3 (ACGIH 2004), and assuming an 8-hour 
inhalation of 10 m3 of air, a daily barium workplace intake of 5,000 μg can be calculated. NAS (1977) 
estimated that 75% of inhaled barium could be absorbed into the bloodstream if soluble barium salts were 
involved. 
Since average ground level concentrations of an emission vary with the distance from the emission point, 
the population around a source site will be exposed to differing emission levels.  Using an average 
population density of 27 persons/km2 (based on actual population data from areas surrounding barium 
production and processing plants), it has been estimated that approximately 0–886 persons within an area 
of up to 32.8 km2 around a source site could be exposed to soluble barium compound concentrations of 
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>1.67 μg/m3 in ambient air (Reznik and Toy 1978). Assuming that the average adult daily ventilation rate 
is 20 m3 (EPA 1989), breathing these ambient air barium concentrations would result in daily respiratory 
intakes of >32 μg. No other correlations have been established between barium concentrations in air and 
geographical areas or land-use types. 
The day-to-day intake of barium is likely to vary with the quantity and types of food ingested since the 
barium content in foods varies widely (Schroeder 1970).  Based on consumption of food and beverages in 
long-term balance studies of four individuals, daily barium intake was estimated to range from 650 to 
1,770 μg/day, or from 9.30 to 25.3 μg/kg body weight/day based on an adult weight of 70 kg (Tipton et al. 
1966, 1969).  Assuming an estimated average barium intake of 60 μg/day from drinking water that is 
based on the barium concentrations in drinking water obtained in the NHEXAS EPA Region V study 
(Thomas et al. 1999) and a consumption of 2 L of water per day, the barium intake from the consumption 
of non-drinking water dietary sources alone would range from 590 to 1,710 μg/day.  Thus, food is 
typically the primary source of barium exposure for the general population.  Gastrointestinal absorption of 
barium from food was reported to be approximately 6% (ranging from 1 to 15%) (ICRP 1974).  However, 
reevaluation of this ICRP data and the data from other studies (Harrison et al. 1956; LeRoy et al. 1966); 
Tipton et al. 1969, Schroeder et al. 1972) using the methods of re-estimating barium absorption, which are 
based on current information of systemic kinetics of barium (Leggett 1992), suggest that gastrointestinal 
absorption of barium may be higher, generally ranging between 7 and 30% and could be as high as 95% 
in some individuals.  
In the Canadian Total Diet Study (TDS) of 1993–1999, the average barium intake in individuals surveyed 
was found to be highest in young children (Health Canada 2005).  The average barium intake ranged from 
20.760 to 25.251 μg/kg body weight/day for children ages 0–4 years old (Table 6-5).  For individuals 
older than 4 years, the average barium intake decreased for both males and females with increasing age to 
values of 9.704 (20–39 years) and 7.839 (>65 years) μg/kg body weight/day in males and 8.418 (20– 
39 years) and 7.546 (>65 years) μg/kg body weight) in females.  The average daily barium intakes from 
the Canadian TDS for males and females of all ages (8.817 μg/kg body weight/day) is in reasonable 
agreement with the low end of the daily intake range for barium of 9.30 μg/kg body weight/day 
determined by Tipton et al. (1966, 1969). 
Mean daily balances (excluding loss via hair and sweat) determined from long-term balance studies of 
four adult subjects ranged from a negative balance of 800 μg to a positive balance of 890 μg (Tipton et 
al. 1966, 1969). Based on data from these studies, Schroeder (1970) estimated that human daily intake  
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Table 6-5. Average Dietary Intake of Barium in Different Age/Sex Groups from 
the Canadian Total Diet Study (1993–1999) 
Sex Age Intakea 
Male and female 0–1 months 20.760 
Male and female 2–3 months 23.350 
Male and female 4–6 months 21.414 
Male and female 7–9 months 21.213 
Male and female 10–12 months 22.823 
Male and female 1–4 years 25.251 
Male and female 5–11 years 18.741 
Male 12–19 years 11.759 
Male 20–39 years 9.704 
Male 40–64 years 8.976 
Male ≥65 years 7.839 
Female 12–19 years 9.280 
Female 20–39 years 8.418 
Female 40–64 years 7.855 
Female ≥65 years 7.546 
Male and female All ages 8.817 
amicrograms barium per kilogram body weight per day 
Source: Health Canada (2005) 
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from food (1,160 μg), water (80 μg), and air (10 μg) would be approximately 1,250 μg, and that loss from 
urine (180 μg), feces (1,010 μg) and other sources (e.g., sweat and hair) (85 μg) would be 1,275 μg. 
Using these latter estimates of barium intake and loss, a negative barium balance of 25 μg would occur.  
According to ICRP, the average daily intake of barium from food and fluids (750 μg) and ambient air 
(0.09–26 μg) ranges from 750 to 776 μg.  In addition, ICRP (1974) estimated that approximately 825 μg 
of barium is lost daily through the urine (50 μg), feces (690 μg), sweat (10 μg), and hair (75 μg). These 
intake and loss estimates indicate a negative daily balance of up to 75 μg. However, these negative daily 
balance values of 25 and 75 μg are not significant.  Also, it is not expected that a negative daily balance 
would maintain a total body content of barium for a 70-kg adult of 22,000 μg, a value that was estimated 
from a study of barium content in major human organs and tissues (ICRP 1974; Schroeder et al. 1972).  
Ninety-three percent of this barium was found in bone and connective tissue.  The remaining 7% of 
barium exists largely in fat, skin, and lungs. 
Barium content in the human population has been determined in urine and major organs and tissues in 
more current studies.  Barium concentrations in urine for the United States population aged 6 years and 
older were measured in the Third National Health and Nutrition Examination Survey (NHANES).  The 
geometric mean (95% confidence interval) for the creatinine-adjusted levels of barium in urines for all 
ages was 1.44 (1.31–1.58) μg per gram of creatinine (CDC 2005).  Within age groups, the geometric 
means for the barium concentration in urine decreased as a function of age, from 2.20 μg per gram of 
creatinine (6–11 years) to 1.45 μg per gram of creatinine (12–19 years) and 1.37 μg per gram of creatinine 
(20 years and older).  The geometric mean concentration of barium in females (1.59 μg per gram of 
creatinine) was slightly higher than in males (1.30 μg per gram of creatinine).  As a function of ethnicity, 
non-Hispanic whites had the highest geometric mean barium concentrations (1.62 μg per gram of 
creatinine) followed by Mexican Americans (1.18 μg per gram of creatinine) and non-Hispanic African 
Americans (0.891 μg per gram of creatinine).  A median urinary concentration of 1,146 ng/L (range 295– 
5,250 ng/L) was reported in urine of 50 healthy individuals, aged 20–68 years, in central Italy (Alimonti 
et al. 2005). 
Occupational exposure to barium primarily occurs in workers and miners who inhale barium sulfate (or 
the ore, barite) and barium carbonate dust during the mining of barite and the manufacturing and 
processing (e.g., mixing, grinding, and loading) of barium compounds (Beliles 1979; Reznik and Toy 
1978; Schroeder 1970).  Inhalation exposure to barium is also known to occur for industrial welders, 
especially those using barium-containing stick electrodes and self-shielded flux core wires, and those 
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working in ceramic factories (Ramakrishna et al. 1996; Roig-Navarro et al. 1997; WHO 2001; Zschiesche 
et al. 1992). 
Data from a workplace survey, the National Occupational Exposure Survey (NOES), conducted by 
NIOSH from 1980 to 1983, estimated the number of workers potentially exposed to various chemicals in 
the workplace in 1980 (NIOSH 1989a), including a separate tally of female workers.  The data for barium 
and barium compounds included in the survey are summarized in Table 6-6.  The NOES database does 
not contain information on the frequency, concentration, or duration of exposure of workers to any of the 
chemicals listed therein.  This is a survey that provides only estimates of the number of workers 
potentially exposed to chemicals in the workplace. 
6.6 EXPOSURES OF CHILDREN  
This section focuses on exposures from conception to maturity at 18 years in humans.  Differences from 
adults in susceptibility to hazardous substances are discussed in Section 3.7, Children’s Susceptibility. 
Children are not small adults.  A child’s exposure may differ from an adult’s exposure in many ways. 
Children drink more fluids, eat more food, breathe more air per kilogram of body weight, and have a 
larger skin surface in proportion to their body volume.  A child’s diet often differs from that of adults.  
The developing human’s source of nutrition changes with age:  from placental nourishment to breast milk 
or formula to the diet of older children who eat more of certain types of foods than adults.  A child’s 
behavior and lifestyle also influence exposure.  Children crawl on the floor, put things in their mouths, 
sometimes eat inappropriate things (such as dirt or paint chips), and spend more time outdoors.  Children 
also are closer to the ground, and they do not use the judgment of adults to avoid hazards (NRC 1993). 
The main exposures of children to barium are expected to occur mainly from the diet or by dermal contact 
with barium-containing dust, with minor exposures through barium in air.  Data on the daily intake of 
barium in the total diet of children in the United States were not located in the available literature.  
However, the average daily intake of barium in children has been determined in a Canadian Total Diet 
Study (1993–1999), showing that children ages 0–48 months have the highest barium intake through their 
diet in comparison to older children (>4 years) and adults (Health Canada 2005).  The average barium 
intake in young male and female children increased from 20.760 for infants (0–1 month) to 25.251 μg/kg 
body weight/day for children ages 1–4 years (Table 6-5).  For older children (>4 years), there is a 
continual decrease in the average daily barium intake, with values of 18.741 μg/kg body weight/day for  
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Table 6-6. Number of Workers Potentially Exposed to Barium and Barium 
Compounds 
Total workers (female 
Chemical Number of plants workers) 
Barium 815 10,308 (3,598) 
Barium carbonate 4,494 61,019 (6,889) 
Barium chloride 4,293 57,767 (15,249) 
Barium hydroxide 1,423 35,351 (12,208) 
Barium oxide (BaO2) 46 511 (325) 
Barium nitrate 353 9,625 (2,699) 
Barium sulfate 20,089 305,887 (83,800) 
Barium sulfide 7 7 (0) 
Chromic acid (H2CrO4), barium salt (1:1) 20 3,546 (1,984) 
Source: NIOSH 1989a 
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individuals aged 5–11 years and then down to 11.759 μg/kg body weight/day for males and 9.280 μg/kg 
body weight/day for females aged 12–19 years.  It is expected that the data obtained from the Canadian 
Total Diet Study will reasonably approximate the daily barium intake for children living in the United 
States. It is estimated that for children in the United States, the barium intake through drinking water will 
range between 36 and 60 μg/day.  This estimate is based on an average concentration of 30 μg barium/L 
in drinking water within the United States (Thomas et al. 1999) and the consumption of 1.2–2.0 L 
water/day.  A factor to be taken into account is that fractional intestinal absorption of metals in young 
children, as in young mammals, may be higher than in adults (Foulkes and Bergman 1993).  Dermal 
contact with barium in household dust is not expected to result in uptake of barium through the skin.  Oral 
intake of barium through hand-to-mouth exposures to barium-containing dust is likely to occur.  
However, it is not known how much barium is taken in through this route of exposure.  There is also the 
potential of oral intake of barium through the licking or ingestion of crayons or water colors, but it is not 
known how much barium is ingested or how much is bioavailable (Rastogi and Pritzl 1996). 
Dietary intake of barium in 3-month-old infants has been given by Biego et al. (1998) for exclusive 
consumption of various types of milk.  The average barium intake from the consumption of breast milk 
only was determined to be 4 μg/day.  Barium intake increases with exclusive consumption of bottled milk 
(39 μg/day), evaporated milk (42 μg/day), formula (44 μg/day), and dried milk (59 μg/day). The highest 
average intake of barium occurred with exclusive consumption of soya milk (91 μg/day).  These intakes 
are based on an average daily intake of milk of 700 mL. 
6.7 POPULATIONS WITH POTENTIALLY HIGH EXPOSURES  
The general population is commonly exposed to barium primarily through ingestion of drinking water and 
consumption of food and beverages.  However, certain populations face greater than average exposures to 
this element due to environmental sources, such as drinking water (EPA 1987). High levels of barium 
have been reported in groundwater from deep rock and drift wells in several communities in northeastern 
Illinois (Brenniman et al. 1981; Calabrese 1977) where barium is a naturally occurring geochemical 
pollutant found almost exclusively in the Cambrian-Ordovician Aquifer (Gilkeson et al. 1978).  Other 
populations that might receive increased exposure to barium are consumers of crops grown on soils that 
have been used for the land farming of waste oil-well drilling muds (Bates 1988).  Individuals who work 
at or live near barium mining, manufacturing, or processing plants might inhale higher ambient air 
concentrations or increased amounts of fugitive dust containing barium particulates.  Populations living in 
the vicinity of the NPL sites known to be contaminated with barium may also be exposed to higher than 
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background levels of the compound through contact with contaminated waste site media or barium in 
offsite air or water. Barium has been measured in air, surface water, and groundwater collected offsite of 
some NPL sites (HazDat 2006).  No information was found regarding the sizes of these populations or 
their intake levels of barium. 
6.8 ADEQUACY OF THE DATABASE
Section 104(i)(5) of CERCLA, as amended, directs the Administrator of ATSDR (in consultation with the 
Administrator of EPA and agencies and programs of the Public Health Service) to assess whether 
adequate information on the health effects of barium is available.  Where adequate information is not 
available, ATSDR, in conjunction with NTP, is required to assure the initiation of a program of research 
designed to determine the health effects (and techniques for developing methods to determine such health 
effects) of barium. 
The following categories of possible data needs have been identified by a joint team of scientists from
ATSDR, NTP, and EPA. They are defined as substance-specific informational needs that if met would 
reduce the uncertainties of human health assessment.  This definition should not be interpreted to mean 
that all data needs discussed in this section must be filled.  In the future, the identified data needs will be 
evaluated and prioritized, and a substance-specific research agenda will be proposed.  
6.8.1 Identification of Data Needs 
Physical and Chemical Properties.    The physical and chemical properties of metallic barium and 
its inorganic compounds have been well characterized (Boffito 2002; CHRIS Manual 2005; Dibello et al. 
2003; DOT 2004; Genter 2001; HSDB 2007; Kresse et al. 2007; Lewis 1997; Lide 2005; NIOSH/OSHA 
1978; NIOSH 1999; Budavari et al. 2001; OHM/TADS 1989; Parmeggiani 1983; Perry and Chilton 1973;
RTECS 2007; Lewis 2000; Stokinger 1981; Weast 1989).  Physical and chemical properties of organic 
compounds of barium have not been comprehensively examined probably due to the limited extent of 
formation of these compounds.  However, further study of the properties of these compounds would help 
in understanding their role in the environmental fate and transport of barium, particularly at hazardous 
waste sites where high levels of organic contaminants might be present. 
Production, Import/Export, Use, Release, and Disposal.    According to the Emergency 
Planning and Community Right-to-Know Act of 1986, 42 U.S.C. Section 11023, industries are required 
to submit substance release and off-site transfer information to the EPA.  The TRI, which contains this 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
     
 
 
 
 
 
136 BARIUM AND BARIUM COMPOUNDS
6. POTENTIAL FOR HUMAN EXPOSURE 
information for 2004, became available in May of 2006.  This database is updated yearly and should 
provide a list of industrial production facilities and emissions. 
Because barium compounds occur naturally and are widely used in oil well drilling muds, in steel, rubber 
and plastic products, glass and ceramics, chemical, and pyrotechnics industries, in insecticides, and as a 
smoke suppressant in diesel fuels (Bodek et al. 1988; Dibello et al. 2003; ILO 1983; Kirkpatrick 1985; 
Meister 2004; Stokinger 1981; Venugopal and Luckey 1978; WHO 2001; Worthing 1987), the potential 
for human exposure to these compounds, such as through ingestion of food and water or inhalation of 
ambient air, is substantial.  Recent data on production volumes and import and export of barite and some
barium compounds (e.g., barium chloride, barium carbonate, barium hydroxide, and barium oxide) are 
available (USGS 2006).  In addition, only limited information on disposal of barium compounds was 
available (HSDB 2007; IPCS 1991; NIOSH/OSHA 1978). Additional information on production, import, 
export, and disposal would be useful in assessing the potential for the release of, and exposure to, barium
compounds. 
Environmental Fate. The partitioning of barium in environmental media is influenced by the specific 
form of the compound and such site-specific conditions as pH and cation exchange capacity (Bates 1988; 
Bodek et al. 1988; Bowen 1966; Giusti et al. 1993; Kabata-Pendias and Pendias 1984; Lagas et al. 1984; 
Tanizaki et al. 1992).  Upon release to the environment, barium is most likely to partition to soils and 
sediments (Chow et al. 1978; DOE 1984; Rai et al. 1984; WHO 2001).  Barium is transported in the 
atmosphere, surface waters, soil runoff, and groundwater.  In surface waters and soils, barium may ionize 
and form various salts depending on the pH and the availability of anions (Bates 1988; Bodek et al. 1988; 
Bowen 1966; Kabata-Pendias and Pendias 1984; Lagas et al. 1984; WHO 2001).  Additional information 
on the transport and transformation of barium in the atmosphere would be useful in developing a more 
complete understanding of the environmental fate of barium compounds. 
Bioavailability from Environmental Media.    Barium is absorbed following ingestion (Chou and 
Chin 1943; Cuddihy and Griffith 1972; McCauley and Washington 1983; Taylor et al. 1962) and 
inhalation (Cuddihy and Ozog 1973b). The bioavailability of barium from air, water, and food has been 
examined rather extensively in animals (Chou and Chin 1943; Cuddihy and Griffith 1972; McCauley and
Washington 1983; Taylor et al. 1962) and humans (Tipton et al. 1969).  However, bioavailability from
soil has not been studied.  Since soil is an important repository for barium, information on barium
absorption from ingested soil would be useful in developing an understanding of the potential for 
exposure following ingestion of contaminated soils, particularly at hazardous waste sites. 
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Food Chain Bioaccumulation.    There is information that barium bioconcentrates in certain plants 
and aquatic organisms (Aruguete et al. 1998; Bowen 1966; Hope et al. 1996; IPCS 1991; Schroeder 1970;
WHO 2001).  However, the extent to which plants bioconcentrate barium from soil or to which uptake 
occurs in terrestrial animals is not well characterized.  Further studies on the bioconcentration of barium
by plants and terrestrial animals and on the biomagnification of barium in terrestrial and aquatic food 
chains would be useful to better characterize the environmental fate of barium and define the importance 
of food chain accumulation as a source of human exposure. 
Exposure Levels in Environmental Media. Reliable monitoring data for the levels of barium in 
contaminated media at hazardous waste sites are needed so that the information obtained on levels of 
barium in the environment can be used in combination with the known body burden of barium to assess 
the potential risk of adverse health effects in populations living in the vicinity of hazardous waste sites.  
The need for additional information on the relationship between barium exposure and levels of barium
achieved in vivo is essential if such concentrations are to be used as biomonitors of exposure. 
Barium has been detected in the atmosphere (Bowen 1979; EPA 1984; Hildemann et al. 1991; IPCS 
1991; Schauer et al. 1999; Shahin et al. 2000; WHO 2001; Winkler 2002), surface water (Barnett et al. 
1969; Bowen 1979; DOI 1970; Durfor and Becker 1964; Durum and Haffty 1961; Elinder and Zenz 
1994; EPA 2005c; Kopp 1969; Longerich et al. 1991; McCabe et al. 1970; Neal et al. 1996; Saleh and 
Wilson 1999; Tuovinen et al. 1980), groundwater (Bruce and McMahon 1996; Calabrese 1977; Hudak 
and Wachal 2001; Kojola et al. 1978), soils (Bowen 1979; Bradley et al. 1994; EPA 1995a; Kabata-
Pendias and Pendias 1984; Lide 2005; Schroeder 1970; Shacklette and Boerngen 1984; Zenz et al. 1994),
and foodstuffs (Beliles 1979; Connor and Shacklette 1975; Health Canada 2005; Schroeder 1970).  There 
are reliable data to characterize the potential for human exposure via intake of drinking water (Durfor and 
Becker 1964; Hadjimarkos 1967; Thomas et al. 1999), and foods (Health Canada 2005; Tipton et al. 
1966, 1969).  Recent data on barium levels in plants and ambient air, soils, and groundwater, particularly
from hazardous waste sites, would be useful in helping to develop a more complete understanding of the 
potential for human exposure. 
Exposure Levels in Humans. Barium can be detected in blood, urine, feces, and biological tissues 
(CDC 2001, 2003; Mauras and Allain 1979; Schramel 1988; Shiraishi et al. 1987).  However, there are no 
data correlating barium levels in tissues and fluids with exposure levels.  Recent biomonitoring data exist 
for the U.S. general population (CDC 2005), although there are limited monitoring data for occupational 
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exposure and for populations living near hazardous waste sites.  This information is necessary for 
assessing the need to conduct health studies on these populations. 
Exposures of Children.   Child health data needs relating to susceptibility are discussed in 
Section 3.12.2, Identification of Data Needs: Children’s Susceptibility. 
Data on the exposure of children in the United States to barium are very limited.  It is expected that the 
largest exposure to barium will be through the diet.  Therefore, market basket surveys or total diet studies 
similar to those conducted by the U.S. Food and Drug Administration would be useful for providing data 
on typical levels of exposure via dietary intake for children in the United States.  Data are available for 
barium intake in Canadian children obtained from a 1993–1999 total diet study (Health Canada 2005) and 
in a separate study (Biego et al. 1998) in infants (3 months old) from the exclusive consumption of breast 
milk and other types of milk.  
Exposure Registries.   No exposure registries for barium were located.  This substance is not 
currently one of the compounds for which a sub-registry has been established in the National Exposure 
Registry.  The substance will be considered in the future when chemical selection is made for sub-
registries to be established.  The information that is amassed in the National Exposure Registry facilitates 
the epidemiological research needed to assess adverse health outcomes that may be related to exposure to 
this substance. 
6.8.2 Ongoing Studies 
Three ongoing studies concerning the fate/transport of barium and measurement of barium in 
environmental media were identified in the Federal Research in Progress database (FEDRIP 2005).  
These studies are summarized in Table 6-7.  No other pertinent ongoing studies were identified. 
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Table 6-7. Ongoing Studies on Environmental Fate and the Potential for Human 
Exposure to Barium and Barium Compounds 
Investigator Affiliation Research description Sponsor 
Batiza, R Oregon State University The proposed research will attempt to NSF 
quantify the cold seep barite contribution to 
the marine sediment record by first 
quantifying the cold seep barite (an 
important carrier of barium) contribution to 
barium and radon fluxes within the San 
Clemente basin and then, secondly, 
quantify the effects of this source on the 
chemical signature of barite in the basin 
sediments. 
Naehr, TM; Texas A&M University Acquisition of a basic powder x-ray NSF 
MacDonald, IR Corpus Christi difractometer system for qualitative and 
quantitative phase analysis in studies of 
(1) geologic materials to enhance research 
into the formation of diagenetic barite and 
silicate minerals in sediments from the 
Peruvian Continental Margin, (2) the 
authigenic seafloor deposits at sites of 
active submarine fluid expulsion in the Gulf 
of Mexico region to elucidate the geo­
chemical environment at these sites, and 
(3) barium and other metals in soil and 
sediment samples. 
Odom, JW Auburn University Develop analytical techniques for total and Hatch 
plant-available forms of barium and other 
metals in soils and for total analysis of 
these metals in plant material; determine 
the normal occurrence of both total and 
extractable forms of these elements in 
selected soil profiles; and ascertain the 
availability of soil test calibration data and 
soil test procedures for these elements. 
NSF = National Science Foundation 
Source: FEDRIP 2005 
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The purpose of this chapter is to describe the analytical methods that are available for detecting, 
measuring, and/or monitoring barium, its metabolites, and other biomarkers of exposure and effect to 
barium.  The intent is not to provide an exhaustive list of analytical methods.  Rather, the intention is to 
identify well-established methods that are used as the standard methods of analysis.  Many of the 
analytical methods used for environmental samples are the methods approved by federal agencies and 
organizations such as EPA and the National Institute for Occupational Safety and Health (NIOSH).  Other 
methods presented in this chapter are those that are approved by groups such as the Association of 
Official Analytical Chemists (AOAC) and the American Public Health Association (APHA).  
Additionally, analytical methods are included that modify previously used methods to obtain lower 
detection limits and/or to improve accuracy and precision. 
7.1 BIOLOGICAL MATERIALS  
Inductively coupled plasma-atomic emission spectrometry (ICP-AES) has been used for measuring low 
levels of barium in the blood, urine, and bones of humans and animals (Mauras and Allain 1979; 
Schramel 1988; Shiraishi et al. 1987) (see Table 7-1).  In general, biological samples are nebulized and 
the resulting aerosol is transported to the plasma torch.  Atomic-line emission spectra are produced by the 
inductively coupled plasma for specific element and the intensities of the lines (bands) are monitored by a 
photomultiplier tube.  A line emission at 455.50 nm was observed for barium (Mauras and Allain 1979; 
Oppenheimer et al. 1984).  Detection limits of 0.25 μg barium/L of urine, 0.6 μg barium/L of blood, and 
0.0005 μg of barium per gram of bone were achieved (Mauras and Allain 1979; Shiraishi et al. 1987).  
Advantages of ICP-AES technique include moderate costs, fairly rapid analysis time, and high sensitivity 
(Mauras and Allain 1979; Oppenheimer et al. 1984).  The presence of spectral interferences is a 
disadvantage of ICP-AES technique. These interferences are caused when a sample contains elements or 
compounds that have analytical emission lines (bands) that overlap the line chosen for the analyte. Boric 
acid or sodium borate (at a concentration of >100 mg boron/L of sample) was reported to interfere with 
the line emission spectra of barium at 455.50 nm (Mauras and Allain 1979). 
Neutron activation analysis (NAA) technique has also been used for determining low levels of barium in 
human blood (Olehy et al. 1966).  This technique is based on the interaction of the nuclei of individual 
barium atoms with neutron irradiation, resulting in the emission of x-rays (photons).  Detection limits of 
7 μg barium/L of erythrocyte and 66 μg barium/L of plasma were obtained (Olehy et al. 1966).  The 
advantages of the NAA technique include minimal sample preparation and the fact that destruction of the  
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Table 7-1. Analytical Methods for Determining Barium in Biological Materials 
Preparation Analytical Sample Percent 
Sample matrix method method detection limit recovery Reference 
Urine and blood Dilute sample with ICP-AES 0.25 μg/L (urine); 3–7% Mauras and 
demineralized water, 0.6 μg/L (blood) coefficient of Allain 1979 
introduce into the variation 
plasma and analyze 
Urine Dilute sample with ICP-AES 0.2 μg/L No data Schramel 
demineralized water, 1988 
introduce into the 
plasma and analyze 
Erythrocyte and Ash sample, digest NAA 7 μg/L 28.5% RSD Olehy et al. 
plasma with acid and (erythrocyte); (erythrocyte) 1966 
irradiate 66 μg/L (plasma) 7.6% RSD 
(plasma) 
Biological tissues Digest sample in Gravimetry No data No data Borchardt et 
acid; precipitate as al. 1961 
the sulfate and 
analyze 
Visceral materials Ash sample and AES No data 86.8–130.5% Baisane et al. 
(intestine, analyze 1979 
stomach, liver, 
spleen, and 
kidney) 
Fetus bones Ash sample and ICP-AES 0.0005 μg/g 0.5% RSD Shiraishi et al. 
digest with acid 1987 
AES = atomic emission spectroscopy; ICP-AES = inductively coupled plasma-atomic emission spectrometry; 
NAA = neutron activation analysis; RSD = relative standard deviation 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
   
  
 
 
 
 
 
 
     
143 BARIUM AND BARIUM COMPOUNDS
7. ANALYTICAL METHODS 
sample is not needed to conduct the analysis.  Disadvantages of this technique include its high costs and a 
nuclear reactor may not be readily available to many laboratories. 
Gravimetric and spectrometric techniques have also been described for quantifying barium in tissues.  
Borchardt et al. (1961) measured barium in tissues gravimetrically following digestion of 15–20 grams of 
sample in a 2:1 (by volume) mixture of sulfuric and nitric acids.  The barium in the samples was 
precipitated out as the sulfate, dried, and weighed.  No limits of detection were given.  Recovery of 
barium from acid-digested tissues can be impaired when organic ions react with barium and interfere with 
the formation of the barium sulfate precipitate.  However, Borchardt et al. (1961) reported that no such 
interferences were observed in their assay and that complete recovery of barium from the sample was 
obtained. In another method, Baisane et al. (1979) used atomic emission spectroscopy to measure barium
in visceral material.  The method required ashing of tissue samples by heating with a burner or a muffle 
furnace and then fusing the ash with graphite and lithium carbonate.  The barium in the fused ash was 
quantified by using an electric arc as an excitation source and monitoring the barium emission at 2,335 Å.  
Limits of detection were not given, but recoveries ranged from 86.8 to 130.5%. 
7.2 ENVIRONMENTAL SAMPLES 
Atomic absorption spectroscopy (AAS) is the most prevalent analytical technique for measuring low 
levels of barium in air, water, waste water, geological materials (calcium carbonate), unused lubricating 
oil, and diagnostic meals containing barium sulfate (see Table 7-2). 
Samples may be prepared for AAS in a variety of ways (EPA 1974, 1994a, 1994b, 1996; Hui-Ming and 
Yao-Han 1984; Johnson et al. 1983; Murata and Noguchi 1974; Pierce and Brown 1977; Renshaw 1973; 
Sharp and Knevel 1971; Sugiyama et al. 1984).  Acid digestion with nitric acid is the most common 
method of preparation.  Sample dilution with nitric acid or other agents to solubilize barium from the 
matrix can also be employed.  If the concentration of barium in the dissolved sample is very low, 
preconcentration techniques such as chelation or extraction may be employed. 
Flame atomic absorption spectroscopy (FAAS) (Methods 208.1 and 7080) and graphite furnace atomic
absorption spectroscopy (GFAAS) (Methods 208.2 and 7081) are the techniques recommended by the 
Office of Solid Waste and Emergency Response of EPA for determining ppb (μg/L) levels of barium in 
water and waste water (EPA 1974, 1979, 1992, 1994a, 1994b).  Parts-per-trillion (sub μg/L) levels of 
barium in seawater and freshwater have been detected by GFAAS (Epstein and Zander 1979; Roe and Froelich 
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Table 7-2. Analytical Methods for Determining Barium in Environmental Samples 
Sample Analytical Sample Percent 
matrix Preparation method method detection limit recovery Reference 
Air Collect sample on FAAS 2 μg per sample  102% NIOSH 1994 
cellulose membrane and (Method 7056) 
extract with hot acid; 
evaporate extract to 
dryness and dissolve 
residue in acid 
Air 	 Collect sample on ICP-AES 0.005 μg per 97.7– NIOSH 2003 
cellulose or PVC sample 102.4% (Method 7300) 
membrane; extract with 
hot acid and evaporate at 
150 °C to near dryness; 
dissolve residue in acid 
Water 	 Reflux with addition of ICP-MS 0.8 μg/L 95% EPA 1994a 
HNO3 and HCl; filter (Method 200.8) 
Reflux with addition of ICP-AES 1 μg/L 92% EPA 1994b 
HNO3 and HCl; filter (Method 200.7) 
Acidify with HNO3; filter FAAS 100 μg/L 94% EPA 1974 
(Method 208.1) 
Reflux with addition of FAAS 33.5–132 μg/L 104.5– ASTM 2000 
HNO3 and HCl (working range) 106.9% (Method D4382) 
(33.5 μg/L) 
Acidify sample and pass FAAS 3 μg/L 11.6% Pierce and 
through ion-exchange RSD Brown 1977 
resin 
Pass sample through ion- FAES μg/L levels No data Johnson et al. 
exchange resin 1983 
Extract sample with FAAS 5 μg/L No data Edelbeck and 
buffered HFA solution West 1970 
 No data GFAAS 7 μg/L 90–110% Fagioli et al. 
1988 
Inject sample directly into GFAAS 0.6 μg/L 13% RSD Roe and 
graphite furnace (seawater); Froelich 1984 
0.2 μg/L 
(freshwater) 
Seawater and Acidify and inject DCAP-AES 10–20 mg/L 108.8% ASTM 1999 
brackish (working range) (10 mg/L) (Method D3986) 
water 
Water and Digest sample and FAAS, 100 μg/L (FAAS); 94–113% EPA 1974, 
waste water evaporate to dryness; GFAAS 2 μg/L (GFAAS) (FAAS); 1979, 1992, 
dissolve residue in acid 	 96–102% 1994 (Methods 
(GFAAS) 208.1, 208.2, 
7080, and 7081) 
Industrial Digest sample; mix with XFS 290 μg/L (in 5.1% RSD Murata and 
waste water cation-exchange resin; 500 mL samples) Noguchi 1974 
dry and analyze 
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Table 7-2. Analytical Methods for Determining Barium in Environmental Samples 
Sample Analytical Sample Percent 
matrix Preparation method method detection limit recovery Reference 
Unused Dissolve sample in FAAS No data No data Holding and 
lubricating oil 2-methyl- Rowson 1975 
propan-2-ol:toluene (3:2); 
add potassium 
naphthenate solution 
Rocks and Precipitate barium from FAAS Low μg/g levels 118% Bano 1973 
minerals sample; dissolve in 
(calcium ammoniacal solution of 
carbonate) EDTA 
Soil Digest sample in HNO3 GFAAS 0.2 μg/g dry 96% EPA 1978, 1996 
and H2O2, filter, dilute with weight (Methods 3050B 
acid and 208.2) 
Sediment, Digest sample in a ICP-MS 0.15 ppm 96–102% USGS 2002a 
soil, rocks mixture of HCl, HNO3, and (Method T20) 
HClO4 by heating to 
dryness; resuspend 
residue in HNO3 and H2O2 
and heat; cool and dilute 
in 1% HNO3 
Sediment, Digest sample in a ICP-AES 0.3 ppm 95–106% USGS 2002b 
rocks, plants mixture of HF, HNO3, and (Methods E011 
HClO4 by heating to and T01) 
dryness; resuspend 
residue in HClO4 and heat 
to dryness; resuspend in 
aqua regia, dilute with  
1% HNO3, and reheat 
Food, Homogenize sample; ICP-AES 0.03 mg/kg (food) 86–94% EPA 1995b 
beverage microwave digestion of 0.004 mg/kg (food) 
sample in HNO3; (beverage) 86–92% 
centrifuge (beverage) 
Diagnostic Add sample to EDTA FAAS No data 98.6– Sharp and 
meals solution and warm 102.5% Knevel 1971 
containing 
barium sulfate 
Compound Prepare solution of Scintillation No data No data Larsen 1973 
formulation 
(Ba14CO3) 
sample in EDTA and 
count 
spectrometry 
Ba14CO3 = radiolabeled barium carbonate; DCAP-AES = direct-current argon plasma-atomic emission spectroscopy; 
EDTA = ethylenediamine tetraacetic acid; FAAS = flame atomic absorption spectroscopy; FAES = flame atomic 
emission spectroscopy; GFAAS = graphite furnace atomic absorption spectroscopy; HCl = hydrochloric acid; 
HClO4 = perchloric acid; HF = hydrofluoric acid; HFA = hexafluoroacetylacetone; HNO3 = nitric acid; 
H2O2 = hydrogen peroxide; ICP-AES = inductively coupled plasma-atomic emission spectroscopy; 
ICP-MS = inductively coupled plasma-mass spectrometry; PVC = polyvinyl chloride; RSD = relative standard 
deviation; XFS = x-ray fluorescence spectroscopy  
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1984).  The advantages that GFAAS and FAAS techniques offer are that they are sensitive techniques, 
use relatively simple and inexpensive instrumentation, and have high accuracy and precision. In addition, 
GFAAS technique requires a small amount of sample and is more sensitive than FAAS methodology for 
determining barium in aqueous media (Edelbeck and West 1970; Oppenheimer et al. 1984). 
FAAS (Method 7056) is the technique recommended by NIOSH for detecting soluble barium compounds 
in air (NIOSH 1994).  AAS has also been employed for detecting barium in air at 20 ppb (Miner 1969a). 
Other analytical techniques that have been employed for measuring barium and its compounds in 
environmental media include x-ray fluorescence spectroscopy (XFS), neutron activation analysis (NAA), 
direct current argon plasma-atomic emission spectroscopy (DCAP-AES), inductively coupled plasma-
mass spectrometry (ICP-MS), inductively coupled plasma-atomic emission spectroscopy (ICP-AES), 
scintillation spectroscopy, and spectrography (Boothe and James 1985; Landis and Coons 1954; Larsen 
1973; Murata and Noguchi 1974; Oppenheimer et al. 1984).  XFS and NAA methods are less sensitive 
than other available analytical methods for measuring barium in environmental media.  Scintillation 
spectroscopy and spectrography are less commonly used to measure barium in the environment relative to 
other analytical methods.  ICP-MS and ICP-AES offer low detection sensitivities that are typically at the 
ppb level and are becoming more routinely used for analysis of samples with complex mixtures of metals 
and metal complexes.  For example, ICP-AES (Method 7300) is a technique recommended by NIOSH for 
analyzing soluble barium compounds in air with a limit of detection of 0.005 μg per sample 
(approximately 0.005 μg/m3), which is 400 times less than the detection limit for another NIOSH method 
(7056) that uses FAAS as the technique to quantify barium in air (NIOSH 1994, 2003).  ICP-AES 
(Methods E011 and T01) and ICP-MS (Method T20) are recommended by the U.S. Geological Survey 
(USGS) for measuring the barium content in sediments and rocks (USGS 2002a, 2002b).  ICP-AES is 
also used to quantify barium and other trace metals in food and beverages with minimum detection limits 
of 0.004–0.3 mg/kg (ppm) and recoveries of 86–94% (EPA 1995b).  ICP-MS is a useful technique for 
isotopic analysis of barium to determine sources of environmental emissions of barium compounds. 
7.3 ADEQUACY OF THE DATABASE 
Section 104(i)(5) of CERCLA, as amended, directs the Administrator of ATSDR (in consultation with the 
Administrator of EPA and agencies and programs of the Public Health Service) to assess whether 
adequate information on the health effects of barium is available.  Where adequate information is not 
available, ATSDR, in conjunction with NTP, is required to assure the initiation of a program of research 
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designed to determine the health effects (and techniques for developing methods to determine such health 
effects) of barium.  
The following categories of possible data needs have been identified by a joint team of scientists from
ATSDR, NTP, and EPA. They are defined as substance-specific informational needs that if met would 
reduce the uncertainties of human health assessment.  This definition should not be interpreted to mean 
that all data needs discussed in this section must be filled.  In the future, the identified data needs will be 
evaluated and prioritized, and a substance-specific research agenda will be proposed.  
7.3.1 Identification of Data Needs 
Methods for Determining Biomarkers of Exposure and Effect.     
Exposure. Several methods are available for measuring biomarkers of exposure.  ICP-AES is the 
analytical method used for measuring barium in blood, urine and bone of humans and animals at ppt (sub 
μg/L) levels (Mauras and Allain 1979; Schramel 1988; Shiraishi et al. 1987).  NAA technique has also 
been employed for measuring barium in blood of humans and animals at ppb (μg/L) levels (Olehy et al. 
1966). These techniques are sensitive for measuring background levels of barium in the population.  
However, information is needed on whether data collected using these techniques can be used to correlate 
the levels of barium in biological tissues and fluids with exposure levels. 
Effect. At present, no biomarkers of effect are available for barium.  There are no data to indicate 
whether a biomarker, if available, would be preferred over chemical analysis for monitoring effects from
long- and short-term exposure to barium. 
Methods for Determining Parent Compounds and Degradation Products in Environmental 
Media.    GFAAS and FAAS are the most widely used analytical techniques for measuring barium and 
its compounds in air (NIOSH 1987), water (ASTM 2000; Edelbeck and West 1970; EPA 1974, 1994a, 
1994b; Fagioli et al. 1988; Johnson et al. 1983; Pierce and Brown 1977; Roe and Froelich 1984), seawater 
and brackish water (ASTM 1999), waste water (EPA 1974, 1979, 1992, 1994b), rocks and minerals 
(Bano 1973), unused lubricating oil (Holding and Rowson 1975), soil (EPA 1978, 1996), and diagnostic 
meals (Sharp and Knevel 1971).  The media of most concern for potential human exposure to barium is 
water. GFAAS and FAAS techniques are sensitive for measuring background levels of barium in 
aqueous media (Epstein and Zander 1979; Roe and Froelich 1984).  However, it is not known whether 
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these techniques are sensitive for measuring levels of barium at which health effects might begin to occur. 
FAAS and GFAAS are the methods (Methods 208.1, 208.2, 7080, and 7081) recommended by EPA for 
detecting ppb levels of barium in water and waste water (EPA 1974, 1979, 1992, 1994c).  GFAAS has 
also been employed to detect ppt levels of barium in aqueous media (Epstein and Zander 1979; Roe and 
Froelich 1984). ICP-MS and ICP-AES quantitative methods are increasing in use for routine analysis of 
barium at ppb levels and are capable of ppt levels of detection when ion chromatographic and other 
prepurification methods are used in sample preparation and analysis.  Therefore, analytical methods are 
available that are sufficiently specific and sensitive to measure barium in the environment, and no data 
needs have been identified at this time. 
7.3.2 Ongoing Studies 
No ongoing studies regarding techniques for measuring and determining barium in biological and 
environmental samples were located. 

149 BARIUM AND BARIUM COMPOUNDS 
8. REGULATIONS AND ADVISORIES 
The international and national regulations and guidelines regarding barium and barium compounds in air, 
water, and other media are summarized in Table 8-1. 
ATSDR has derived an intermediate-duration oral MRL of 0.2 mg barium/kg/day for barium.  This MRL 
is based on a NOAEL of 65 mg barium/kg/day and a LOAEL of 115 mg barium/kg/day for increased 
kidney weight in female rats (NTP 1994) and an uncertainty factor of 100 (10 to account for animal to 
human extrapolation, and 10 for human variability) and modifying factor of 3 to account for the lack of an 
adequate developmental toxicity study 
ATSDR has derived a chronic-duration oral MRL of 0.2 mg barium/kg/day for barium.  The MRL is 
based on a BMDL05 of 61 mg barium/kg/day for nephropathy in male mice (NTP 1994) and an 
uncertainty factor of 100 (10 to account for animal to human extrapolation and 10 for human variability) 
and modifying factor of 3 to account for the lack of an adequate developmental toxicity study. 
EPA (IRIS 2006) has derived an oral reference dose (RfD) for barium of 0.2 mg/kg/day, based on a 
BMDL05 of 63 mg/kg/day for nephropathy in male mice (NTP 1994) and an uncertainty factor of 300 
(10 to account for animal to human extrapolation, 10 for human variability, and 3 for database 
deficiencies, particularly the lack of a two-generation reproductive toxicity study and an adequate 
investigation of developmental toxicity).  EPA (IRIS 2006) has not recommended an inhalation reference 
concentration (RfC) for barium at this time. 
Using their 1986 guidelines, EPA has determined that barium is not classifiable as a human carcinogen 
and has assigned it the cancer classification, Group D (IRIS 2006). Using their recent guidelines, EPA 
determined that barium is considered not likely to be carcinogenic to humans following oral exposure and 
its carcinogenic potential cannot be determined following inhalation exposure (IRIS 2006). 
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8. REGULATIONS AND ADVISORIES 
Table 8-1. Regulations and Guidelines Applicable to Barium and 
Barium Compounds 
Agency Description Information Reference 
INTERNATIONAL 
Guidelines: 
IARC Carcinogenicity classification No data IARC 2004 
WHO Air quality guidelines No data WHO 2000 
Drinking water quality guidelines 0.7 mg/L WHO 2004 
NATIONAL 
Regulations and Guidelines: 
a. Air 
ACGIH TLV (TWA) ACGIH 2004 
Barium and soluble compounds 0.5 mg/m3  
(as Ba) 
Barium sulfate 10 mg/m3  
NIOSH REL (TWA) NIOSH 2005a, 
Barium chloridea 0.5 mg/m3 2005b 
Barium sulfate 10 mg/m3 (total) 
5.0 mg/m3 (respiratory) 
IDLH  
Barium chloride 50 mg/m3  
Barium sulfate No data 
OSHA PEL (8-hour TWA) for general industry OSHA 2005c 
Barium, soluble compounds (as Ba) 0.5 mg/m3 29 CFR 1910.1000 
Barium sulfate 15 mg/m3 (total dust) 
5.0 mg/m3 (respirable 
fraction) 
PEL (8-hour TWA) for construction OSHA 2005b 
industry 29 CFR 1926.55 
Barium, soluble compounds (as Ba) 0.5 mg/m3 
PEL (8-hour TWA) for shipyard OSHA 2005a 
industry 29 CFR 1915.1000 
Barium, soluble compounds (as Ba) 0.5 mg/m3 
Barium sulfate 15 mg/m3 (total dust) 
5.0 mg/m3 (respirable 
fraction) 
b. Water 
EPA Drinking water standards and health EPA 2004 
advisories 
1-day health advisory for a 10-kg 0.7 mg/L 
child 
10-day health advisory for a 10-kg 0.7 mg/L 
child 
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8. REGULATIONS AND ADVISORIES 
Table 8-1. Regulations and Guidelines Applicable to Barium and 
Barium Compounds 
Agency Description Information Reference 
NATIONAL (cont.) 
National primary drinking water EPA 2002a 
standards  
MCLG 2.0 mg/L 
MCL 2.0 mg/L 
Reportable quantities of hazardous 10 pounds EPA 2005b 
substances (barium cyanide) 40 CFR 117.3 
designated pursuant to Section 311 of 
the Clean Water Act 
Water quality criteria for human health EPA 2002b 
consumption of: 
Water + organism 1.0 mg/L 
Organism only No data 
c. Food 
FDA Bottled drinking water 2.0 mg/L FDA 2004 
21 CFR 165.110 
d. Other 
 ACGIH Carcinogenicity classification A4b ACGIH 2004
 EPA Carcinogenicity classification Group Dc IRIS 2006 
RfC Not recommended at this 
time 
RfD 0.2 mg/kg/day 
NTP Carcinogenicity classification No data NTP 2005 
aThe REL also applies to other soluble barium compounds (as Ba) except barium sulfate.
bA4: not classifiable as a human carcinogen 
cGroup D: not classifiable as to human carcinogenicity 
ACGIH = American Conference of Governmental Industrial Hygienists; CFR = Code of Federal Regulations; 
DWEL = drinking water equivalent level; EPA = Environmental Protection Agency; FDA = Food and Drug 
Administration; IARC = International Agency for Research on Cancer; IDLH = immediately dangerous to life or health; 
MCL = maximum contaminant level; MCLG = maximum contaminant level goal; NIOSH = National Institute for 
Occupational Safety and Health; NTP = National Toxicology Program; OSHA = Occupational Safety and Health 
Administration; PEL = permissible exposure limit; REL = recommended exposure limit; RfC = inhalation reference 
concentration; RfD = oral reference dose; TLV = threshold limit values; TWA = time-weighted average; WHO = World 
Health Organization 
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Absorption—The taking up of liquids by solids, or of gases by solids or liquids. 
Acute Exposure—Exposure to a chemical for a duration of 14 days or less, as specified in the 
Toxicological Profiles. 
Adsorption—The adhesion in an extremely thin layer of molecules (as of gases, solutes, or liquids) to the 
surfaces of solid bodies or liquids with which they are in contact. 
Adsorption Coefficient (Koc)—The ratio of the amount of a chemical adsorbed per unit weight of 
organic carbon in the soil or sediment to the concentration of the chemical in solution at equilibrium. 
Adsorption Ratio (Kd)—The amount of a chemical adsorbed by sediment or soil (i.e., the solid phase) 
divided by the amount of chemical in the solution phase, which is in equilibrium with the solid phase, at a 
fixed solid/solution ratio. It is generally expressed in micrograms of chemical sorbed per gram of soil or 
sediment. 
Benchmark Dose (BMD)—Usually defined as the lower confidence limit on the dose that produces a 
specified magnitude of changes in a specified adverse response.  For example, a BMD10 would be the 
dose at the 95% lower confidence limit on a 10% response, and the benchmark response (BMR) would be 
10%.  The BMD is determined by modeling the dose response curve in the region of the dose response 
relationship where biologically observable data are feasible.    
Benchmark Dose Model—A statistical dose-response model applied to either experimental toxicological 
or epidemiological data to calculate a BMD. 
Bioconcentration Factor (BCF)—The quotient of the concentration of a chemical in aquatic organisms 
at a specific time or during a discrete time period of exposure divided by the concentration in the 
surrounding water at the same time or during the same period. 
Biomarkers—Broadly defined as indicators signaling events in biologic systems or samples. They have 
been classified as markers of exposure, markers of effect, and markers of susceptibility. 
Cancer Effect Level (CEL)—The lowest dose of chemical in a study, or group of studies, that produces 
significant increases in the incidence of cancer (or tumors) between the exposed population and its 
appropriate control. 
Carcinogen—A chemical capable of inducing cancer. 
Case-Control Study—A type of epidemiological study that examines the relationship between a 
particular outcome (disease or condition) and a variety of potential causative agents (such as toxic 
chemicals).  In a case-controlled study, a group of people with a specified and well-defined outcome is 
identified and compared to a similar group of people without outcome. 
Case Report—Describes a single individual with a particular disease or exposure.  These may suggest 
some potential topics for scientific research, but are not actual research studies. 
Case Series—Describes the experience of a small number of individuals with the same disease or 
exposure. These may suggest potential topics for scientific research, but are not actual research studies. 
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Ceiling Value—A concentration of a substance that should not be exceeded, even instantaneously. 
Chronic Exposure—Exposure to a chemical for 365 days or more, as specified in the Toxicological 
Profiles. 
Cohort Study—A type of epidemiological study of a specific group or groups of people who have had a 
common insult (e.g., exposure to an agent suspected of causing disease or a common disease) and are 
followed forward from exposure to outcome.  At least one exposed group is compared to one unexposed 
group. 
Cross-sectional Study—A type of epidemiological study of a group or groups of people that examines 
the relationship between exposure and outcome to a chemical or to chemicals at one point in time. 
Data Needs—Substance-specific informational needs that if met would reduce the uncertainties of human 
health assessment. 
Developmental Toxicity—The occurrence of adverse effects on the developing organism that may result 
from exposure to a chemical prior to conception (either parent), during prenatal development, or 
postnatally to the time of sexual maturation.  Adverse developmental effects may be detected at any point 
in the life span of the organism. 
Dose-Response Relationship—The quantitative relationship between the amount of exposure to a 
toxicant and the incidence of the adverse effects. 
Embryotoxicity and Fetotoxicity—Any toxic effect on the conceptus as a result of prenatal exposure to 
a chemical; the distinguishing feature between the two terms is the stage of development during which the 
insult occurs.  The terms, as used here, include malformations and variations, altered growth, and in utero 
death. 
Environmental Protection Agency (EPA) Health Advisory—An estimate of acceptable drinking water 
levels for a chemical substance based on health effects information.  A health advisory is not a legally 
enforceable federal standard, but serves as technical guidance to assist federal, state, and local officials. 
Epidemiology—Refers to the investigation of factors that determine the frequency and distribution of 
disease or other health-related conditions within a defined human population during a specified period.   
Genotoxicity—A specific adverse effect on the genome of living cells that, upon the duplication of 
affected cells, can be expressed as a mutagenic, clastogenic, or carcinogenic event because of specific 
alteration of the molecular structure of the genome. 
Half-life—A measure of rate for the time required to eliminate one half of a quantity of a chemical from 
the body or environmental media. 
Immediately Dangerous to Life or Health (IDLH)—The maximum environmental concentration of a 
contaminant from which one could escape within 30 minutes without any escape-impairing symptoms or 
irreversible health effects. 
Immunologic Toxicity—The occurrence of adverse effects on the immune system that may result from 
exposure to environmental agents such as chemicals. 
Immunological Effects—Functional changes in the immune response. 
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Incidence—The ratio of individuals in a population who develop a specified condition to the total 
number of individuals in that population who could have developed that condition in a specified time 
period. 
Intermediate Exposure—Exposure to a chemical for a duration of 15–364 days, as specified in the 
Toxicological Profiles. 
In Vitro—Isolated from the living organism and artificially maintained, as in a test tube. 
In Vivo—Occurring within the living organism. 
Lethal Concentration(LO) (LCLO)—The lowest concentration of a chemical in air that has been reported 
to have caused death in humans or animals. 
Lethal Concentration(50) (LC50)—A calculated concentration of a chemical in air to which exposure for 
a specific length of time is expected to cause death in 50% of a defined experimental animal population. 
Lethal Dose(LO) (LDLo)—The lowest dose of a chemical introduced by a route other than inhalation that 
has been reported to have caused death in humans or animals. 
Lethal Dose(50) (LD50)—The dose of a chemical that has been calculated to cause death in 50% of a 
defined experimental animal population. 
Lethal Time(50) (LT50)—A calculated period of time within which a specific concentration of a chemical 
is expected to cause death in 50% of a defined experimental animal population. 
Lowest-Observed-Adverse-Effect Level (LOAEL)—The lowest exposure level of chemical in a study, 
or group of studies, that produces statistically or biologically significant increases in frequency or severity 
of adverse effects between the exposed population and its appropriate control. 
Lymphoreticular Effects—Represent morphological effects involving lymphatic tissues such as the 
lymph nodes, spleen, and thymus. 
Malformations—Permanent structural changes that may adversely affect survival, development, or 
function. 
Minimal Risk Level (MRL)—An estimate of daily human exposure to a hazardous substance that is 
likely to be without an appreciable risk of adverse noncancer health effects over a specified route and 
duration of exposure. 
Modifying Factor (MF)—A value (greater than zero) that is applied to the derivation of a Minimal Risk 
Level (MRL) to reflect additional concerns about the database that are not covered by the uncertainty 
factors. The default value for a MF is 1. 
Morbidity—State of being diseased; morbidity rate is the incidence or prevalence of disease in a specific 
population. 
Mortality—Death; mortality rate is a measure of the number of deaths in a population during a specified 
interval of time. 
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Mutagen—A substance that causes mutations.  A mutation is a change in the DNA sequence of a cell’s 
DNA. Mutations can lead to birth defects, miscarriages, or cancer. 
Necropsy—The gross examination of the organs and tissues of a dead body to determine the cause of 
death or pathological conditions. 
Neurotoxicity—The occurrence of adverse effects on the nervous system following exposure to a 
chemical. 
No-Observed-Adverse-Effect Level (NOAEL)—The dose of a chemical at which there were no 
statistically or biologically significant increases in frequency or severity of adverse effects seen between 
the exposed population and its appropriate control.  Effects may be produced at this dose, but they are not 
considered to be adverse. 
Octanol-Water Partition Coefficient (Kow)—The equilibrium ratio of the concentrations of a chemical 
in n-octanol and water, in dilute solution. 
Odds Ratio (OR)—A means of measuring the association between an exposure (such as toxic substances 
and a disease or condition) that represents the best estimate of relative risk (risk as a ratio of the incidence 
among subjects exposed to a particular risk factor divided by the incidence among subjects who were not 
exposed to the risk factor). An OR of greater than 1 is considered to indicate greater risk of disease in the 
exposed group compared to the unexposed group. 
Organophosphate or Organophosphorus Compound—A phosphorus-containing organic compound 
and especially a pesticide that acts by inhibiting cholinesterase. 
Permissible Exposure Limit (PEL)—An Occupational Safety and Health Administration (OSHA) 
allowable exposure level in workplace air averaged over an 8-hour shift of a 40-hour workweek. 
Pesticide—General classification of chemicals specifically developed and produced for use in the control 
of agricultural and public health pests. 
Pharmacokinetics—The dynamic behavior of a material in the body, used to predict the fate 
(disposition) of an exogenous substance in an organism.  Utilizing computational techniques, it provides 
the means of studying the absorption, distribution, metabolism, and excretion of chemicals by the body. 
Pharmacokinetic Model—A set of equations that can be used to describe the time course of a parent 
chemical or metabolite in an animal system.  There are two types of pharmacokinetic models:  data-based 
and physiologically-based.  A data-based model divides the animal system into a series of compartments, 
which, in general, do not represent real, identifiable anatomic regions of the body, whereas the 
physiologically-based model compartments represent real anatomic regions of the body. 
Physiologically Based Pharmacodynamic (PBPD) Model—A type of physiologically based dose-
response model that quantitatively describes the relationship between target tissue dose and toxic end 
points. These models advance the importance of physiologically based models in that they clearly 
describe the biological effect (response) produced by the system following exposure to an exogenous 
substance. 
Physiologically Based Pharmacokinetic (PBPK) Model—Comprised of a series of compartments 
representing organs or tissue groups with realistic weights and blood flows.  These models require a 
variety of physiological information:  tissue volumes, blood flow rates to tissues, cardiac output, alveolar 
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ventilation rates, and possibly membrane permeabilities.  The models also utilize biochemical 
information, such as air/blood partition coefficients, and metabolic parameters.  PBPK models are also 
called biologically based tissue dosimetry models. 
Prevalence—The number of cases of a disease or condition in a population at one point in time.  
Prospective Study—A type of cohort study in which the pertinent observations are made on events 
occurring after the start of the study.  A group is followed over time. 
q1*—The upper-bound estimate of the low-dose slope of the dose-response curve as determined by the 
multistage procedure.  The q1* can be used to calculate an estimate of carcinogenic potency, the 
incremental excess cancer risk per unit of exposure (usually μg/L for water, mg/kg/day for food, and 
μg/m3 for air). 
Recommended Exposure Limit (REL)—A National Institute for Occupational Safety and Health 
(NIOSH) time-weighted average (TWA) concentration for up to a 10-hour workday during a 40-hour 
workweek. 
Reference Concentration (RfC)—An estimate (with uncertainty spanning perhaps an order of 
magnitude) of a continuous inhalation exposure to the human population (including sensitive subgroups) 
that is likely to be without an appreciable risk of deleterious noncancer health effects during a lifetime.  
The inhalation reference concentration is for continuous inhalation exposures and is appropriately 
expressed in units of mg/m3 or ppm. 
Reference Dose (RfD)—An estimate (with uncertainty spanning perhaps an order of magnitude) of the 
daily exposure of the human population to a potential hazard that is likely to be without risk of deleterious 
effects during a lifetime.  The RfD is operationally derived from the no-observed-adverse-effect level 
(NOAEL, from animal and human studies) by a consistent application of uncertainty factors that reflect 
various types of data used to estimate RfDs and an additional modifying factor, which is based on a 
professional judgment of the entire database on the chemical.  The RfDs are not applicable to 
nonthreshold effects such as cancer. 
Reportable Quantity (RQ)—The quantity of a hazardous substance that is considered reportable under 
the Comprehensive Environmental Response, Compensation, and Liability Act (CERCLA).  Reportable 
quantities are (1) 1 pound or greater or (2) for selected substances, an amount established by regulation 
either under CERCLA or under Section 311 of the Clean Water Act.  Quantities are measured over a 
24-hour period. 
Reproductive Toxicity—The occurrence of adverse effects on the reproductive system that may result 
from exposure to a chemical.  The toxicity may be directed to the reproductive organs and/or the related 
endocrine system.  The manifestation of such toxicity may be noted as alterations in sexual behavior, 
fertility, pregnancy outcomes, or modifications in other functions that are dependent on the integrity of 
this system. 
Retrospective Study—A type of cohort study based on a group of persons known to have been exposed 
at some time in the past.  Data are collected from routinely recorded events, up to the time the study is 
undertaken. Retrospective studies are limited to causal factors that can be ascertained from existing 
records and/or examining survivors of the cohort. 
Risk—The possibility or chance that some adverse effect will result from a given exposure to a chemical. 
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Risk Factor—An aspect of personal behavior or lifestyle, an environmental exposure, or an inborn or 
inherited characteristic that is associated with an increased occurrence of disease or other health-related 
event or condition. 
Risk Ratio—The ratio of the risk among persons with specific risk factors compared to the risk among 
persons without risk factors. A risk ratio greater than 1 indicates greater risk of disease in the exposed 
group compared to the unexposed group. 
Short-Term Exposure Limit (STEL)—The American Conference of Governmental Industrial 
Hygienists (ACGIH) maximum concentration to which workers can be exposed for up to 15 minutes 
continually. No more than four excursions are allowed per day, and there must be at least 60 minutes 
between exposure periods. The daily Threshold Limit Value-Time Weighted Average (TLV-TWA) may 
not be exceeded. 
Standardized Mortality Ratio (SMR)—A ratio of the observed number of deaths and the expected 
number of deaths in a specific standard population. 
Target Organ Toxicity—This term covers a broad range of adverse effects on target organs or 
physiological systems (e.g., renal, cardiovascular) extending from those arising through a single limited 
exposure to those assumed over a lifetime of exposure to a chemical. 
Teratogen—A chemical that causes structural defects that affect the development of an organism. 
Threshold Limit Value (TLV)—An American Conference of Governmental Industrial Hygienists 
(ACGIH) concentration of a substance to which most workers can be exposed without adverse effect.  
The TLV may be expressed as a Time Weighted Average (TWA), as a Short-Term Exposure Limit 
(STEL), or as a ceiling limit (CL). 
Time-Weighted Average (TWA)—An allowable exposure concentration averaged over a normal 8-hour 
workday or 40-hour workweek. 
Toxic Dose(50) (TD50)—A calculated dose of a chemical, introduced by a route other than inhalation, 
which is expected to cause a specific toxic effect in 50% of a defined experimental animal population. 
Toxicokinetic—The absorption, distribution, and elimination of toxic compounds in the living organism. 
Uncertainty Factor (UF)—A factor used in operationally deriving the Minimal Risk Level (MRL) or 
Reference Dose (RfD) or Reference Concentration (RfC) from experimental data.  UFs are intended to 
account for (1) the variation in sensitivity among the members of the human population, (2) the 
uncertainty in extrapolating animal data to the case of human, (3) the uncertainty in extrapolating from 
data obtained in a study that is of less than lifetime exposure, and (4) the uncertainty in using lowest­
observed-adverse-effect level (LOAEL) data rather than no-observed-adverse-effect level (NOAEL) data. 
A default for each individual UF is 10; if complete certainty in data exists, a value of 1 can be used; 
however, a reduced UF of 3 may be used on a case-by-case basis, 3 being the approximate logarithmic 
average of 10 and 1. 
Xenobiotic—Any chemical that is foreign to the biological system. 
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APPENDIX A.  ATSDR MINIMAL RISK LEVELS AND WORKSHEETS 
The Comprehensive Environmental Response, Compensation, and Liability Act (CERCLA) [42 U.S.C. 
9601 et seq.], as amended by the Superfund Amendments and Reauthorization Act (SARA) [Pub. L. 99– 
499], requires that the Agency for Toxic Substances and Disease Registry (ATSDR) develop jointly with 
the U.S. Environmental Protection Agency (EPA), in order of priority, a list of hazardous substances most 
commonly found at facilities on the CERCLA National Priorities List (NPL); prepare toxicological 
profiles for each substance included on the priority list of hazardous substances; and assure the initiation 
of a research program to fill identified data needs associated with the substances. 
The toxicological profiles include an examination, summary, and interpretation of available toxicological 
information and epidemiologic evaluations of a hazardous substance.  During the development of 
toxicological profiles, Minimal Risk Levels (MRLs) are derived when reliable and sufficient data exist to 
identify the target organ(s) of effect or the most sensitive health effect(s) for a specific duration for a 
given route of exposure. An MRL is an estimate of the daily human exposure to a hazardous substance 
that is likely to be without appreciable risk of adverse noncancer health effects over a specified duration 
of exposure. MRLs are based on noncancer health effects only and are not based on a consideration of 
cancer effects.  These substance-specific estimates, which are intended to serve as screening levels, are 
used by ATSDR health assessors to identify contaminants and potential health effects that may be of 
concern at hazardous waste sites.  It is important to note that MRLs are not intended to define clean-up or 
action levels. 
MRLs are derived for hazardous substances using the no-observed-adverse-effect level/uncertainty factor 
approach. They are below levels that might cause adverse health effects in the people most sensitive to 
such chemical-induced effects.  MRLs are derived for acute (1–14 days), intermediate (15–364 days), and 
chronic (365 days and longer) durations and for the oral and inhalation routes of exposure.  Currently, 
MRLs for the dermal route of exposure are not derived because ATSDR has not yet identified a method 
suitable for this route of exposure. MRLs are generally based on the most sensitive chemical-induced end 
point considered to be of relevance to humans.  Serious health effects (such as irreparable damage to the 
liver or kidneys, or birth defects) are not used as a basis for establishing MRLs.  Exposure to a level 
above the MRL does not mean that adverse health effects will occur. 
MRLs are intended only to serve as a screening tool to help public health professionals decide where to 
look more closely.  They may also be viewed as a mechanism to identify those hazardous waste sites that 
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are not expected to cause adverse health effects.  Most MRLs contain a degree of uncertainty because of 
the lack of precise toxicological information on the people who might be most sensitive (e.g., infants, 
elderly, nutritionally or immunologically compromised) to the effects of hazardous substances.  ATSDR 
uses a conservative (i.e., protective) approach to address this uncertainty consistent with the public health 
principle of prevention. Although human data are preferred, MRLs often must be based on animal studies 
because relevant human studies are lacking.  In the absence of evidence to the contrary, ATSDR assumes 
that humans are more sensitive to the effects of hazardous substance than animals and that certain persons 
may be particularly sensitive.  Thus, the resulting MRL may be as much as 100-fold below levels that 
have been shown to be nontoxic in laboratory animals. 
Proposed MRLs undergo a rigorous review process:  Health Effects/MRL Workgroup reviews within the 
Division of Toxicology and Environmental Medicine, expert panel peer reviews, and agency-wide MRL 
Workgroup reviews, with participation from other federal agencies and comments from the public.  They 
are subject to change as new information becomes available concomitant with updating the toxicological 
profiles. Thus, MRLs in the most recent toxicological profiles supersede previously published levels.  
For additional information regarding MRLs, please contact the Division of Toxicology and 
Environmental Medicine, Agency for Toxic Substances and Disease Registry, 1600 Clifton Road NE, 
Mailstop F-32, Atlanta, Georgia 30333. 
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MINIMAL RISK LEVEL (MRL) WORKSHEET 
Chemical Name: Barium, Soluble Salts 
CAS Numbers: 
Date:   August 2007 
Profile Status: Final 
Route: [ ] Inhalation  [X] Oral 
Duration: [ ] Acute  [X] Intermediate   [ ] Chronic 
Graph Key: 23 
Species: Rat 
Minimal Risk Level: 0.2 [X] mg/kg/day  [ ] ppm 
Reference: NTP. 1994.  Toxicology and carcinogenesis studies of barium chloride dihydrate (CAS No. 
10326-27-9) in F344/N rats and B6C3F1 mice (drinking water studies).  Research Triangle Park, NC: 
U.S. Department of Health and Human Services, Public Health Service, National Institutes of Health, 
National Toxicology Program.  NTP TR 432. 
Experimental design: Groups of 10 male and 10 female F344/N rats were administered 0, 125, 500, 
1,000, 2,000, or 4,000 ppm barium chloride dihydrate in drinking water for 90 days.  Using measured 
body weights and water consumption, the investigators estimated the daily barium doses to be 0, 10, 30, 
65, 110, and 200 mg barium/kg/day for males and 0, 10, 35, 65, 115, and 180 mg barium/kg/day for 
females.  Neurobehavioral tests (spontaneous motor activity, grip strength, tail flick latency, startle 
response, hindlimb foot splay) were performed prior to exposure and after 45 and 90 days of exposure.  
Cardiovascular testing (heart rate, blood pressure, and electrocardiogram) was conducted prior to 
exposure and after 45 and 91 days of exposure.  Organ weights (adrenal gland, brain, heart, liver, kidney, 
lung, testis, thymus), blood analysis for hematological and clinical chemistry (barium, sodium, potassium, 
calcium, and phosphorus levels) alterations, and histological examination of major tissues and organs 
(only in the 200/180 mg/kg/day group) were conducted at termination; kidney, liver, spleen, and thymus 
of male and female rats in the 110/115 mg/kg/day groups and adrenal gland, heart, and salivary gland of 
female rats in the 115 mg/kg/day group were also examined microscopically. 
Effect noted in study and corresponding doses: Exposure-related deaths were observed during the last 
week in 30% of the males and 10% of the females exposed to 200/180 mg barium/kg/day.  Significant 
decreases in final body weights were also observed in the 200 mg barium/kg/day males (13% lower than 
controls) and 180 mg barium/kg/day females (8% lower than controls); significant decreases in water 
consumption (approximately 30% lower than controls) were also observed at this dose level.  Marginal, 
but statistically significant, decreases in undifferentiated motor activity was observed in all groups of rats 
exposed to barium for 90 days, except females exposed to 115 mg barium/kg/day; no other alterations in 
neurobehavioral performance were observed.  No significant alterations in heart rate, blood pressure, or 
EKG readings were observed.  Significant increases in serum phosphorus levels were observed in males 
in the 110 and 200 mg barium/kg/day groups and females in the 35, 65, 115, and 180 mg barium/kg/day 
groups; however, the investigators noted that these increases were probably an artifact from hemolysis of 
collected blood samples.  Significant increases in absolute and relative kidney weights were observed in 
females exposed to 115 or 180 mg barium/kg/day and increases in relative kidney weights were also 
observed in males at 200 mg barium/kg/day.  An increase in relative kidney weight was also observed in 
the females exposed to 65 mg barium/kg/day.  The magnitude of the increases in relative kidney weights 
were 7, 14, and 19% in the females exposed to 65, 115, and 180 mg barium/kg/day and 12% in males 
exposed to 200 mg barium/kg/day.  ;Minimal to mild, focal to multifocal dilatation of the proximal 
convoluted tubules of the outer medulla and renal cortex was observed in three male and three female rats 
in the 200/180 mg barium/kg/day group.  The small increase in relative kidney weight (7%) observed in 
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the female rats exposed to 65 mg barium/kg/day was not considered biologically significant because it is 
not supported by an increase in histological alterations in the kidney at 65 or 115 mg barium/kg/day or in 
rats exposed to 75 mg barium/kg/day for 2 years (NTP 1994). 
Dose and end point used for MRL derivation: The MRL is based on a NOAEL of 65 mg barium/kg/day 
for increased absolute and relative kidney weight.  The increased kidney weight was considered an early 
indicator of potentially more serious effects in the kidney.  A NOAEL/LOAEL approach was used to 
derive the MRL because none of the available benchmark dose models provided an adequate fit to the 
absolute or relative kidney weight data.  
[X] NOAEL [ ] LOAEL 
Uncertainty Factors used in MRL derivation: 100 
[ ]  10 for use of a LOAEL 
[X]  10 for extrapolation from animals to humans 
[X]  10 for human variability 
Modifying Factor used in MRL derivation: 3 
[X]  3 for database deficiences 
A modifying factor of 3 was included to account for deficiencies in the oral toxicity database, particularly 
the need for an additional developmental toxicity study.  Decreases in pup birth weight and a 
nonstatistically significant decrease in live litter size were observed in the offspring of rats exposed to 
180/200 mg Ba/kg/day as barium chloride in drinking water prior to mating (Dietz et al. 1992).  Maternal 
body weight gain and water consumption were not reported, thus it is not known if the decreases in pup 
body weight were secondary to maternal toxicity or direct effect on the fetus.  No developmental effects 
were observed in mice at the highest dose tested (200 mg Ba/kg/day) (Dietz et al. 1992).  One other study 
examined the potential for developmental toxicity in orally exposed animals (Tarasenko et al. 1977). 
However, because the study was poorly reported and no incidence data or statistical analysis were 
presented in the published paper, the reported findings of increased mortality and systemic toxicity in the 
offspring of an unspecified species orally exposed to barium during conception and pregnancy can not be 
adequately evaluated.  The Dietz et al. (1992) study was designed to be a mating trial and did not expose 
the animals during gestation; thus, database is lacking an adequate study to evaluate the potential for 
barium to induce developmental effects.  
Was a conversion factor used from ppm in food or water to a mg/body weight dose?  No. Doses were 
calculated by the investigators using measured drinking water consumption and body weight data. 
If an inhalation study in animals, list conversion factors used in determining human equivalent dose: Not 
applicable. 
Was a conversion used from intermittent to continuous exposure? Not applicable. 
Other additional studies or pertinent information that lend support to this MRL: There are limited data on 
the toxicity of barium in humans following repeated doses.  Wones et al. (1990) found no significant 
alterations in blood pressure or ECG readings, relative to initial baseline measurements in men 
experimentally exposed to up to 0.2 mg barium/kg/day as barium chloride in drinking water for 4 week 
(Wones et al. 1990). These findings are supported by several animal studies that did not find significant 
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alterations in blood pressure or ECG readings in rats exposed to 150–180 mg barium/kg/day in drinking 
water for 13 or 16 weeks, respectively (McCauley et al. 1985; NTP 1994).  A study by Perry et al. (1983, 
1985, 1989) found significant increases in blood pressure in rats administered 8.6 or 11 mg barium/kg/day 
as barium chloride in drinking water for 1 or 4 months, respectively.  The reason for the differences 
between the results from the Perry et al. (1983, 1985, 1989) study and the NTP (1994) and McCauley et 
al. (1985) studies is not known.  It is possible that the diet used in the Perry et al. (1983, 1985, 1989) 
study influenced the results.  In this study, the rats were fed a low-mineral diet; the calcium content of the 
rye-based diet was 3.8 mg/kg, which is lower than the concentration recommended for maintenance, 
growth, and reproduction of laboratory rats (NRC 1995b).   
The results of studies by McCauley et al. (1985) and NTP (1994) suggest that the kidney is the most 
sensitive target of toxicity in rats and mice.  In the McCauley et al. (1985) study, glomerular alterations 
consisting of fused podocytes and thickening of the capillary basement membrane were found in rats 
exposed to 150 mg barium/kg/day in drinking water for 16 weeks.  This lesion was found in 
uninephrectomized Sprague Dawley rats, Dahl salt-sensitive rats, and Dahl salt-resistant rats.  In the NTP 
(1994) rat study, significant increases in absolute and relative kidney weights were observed in female 
rats exposed to 115 or 180 mg barium/kg/day and in males exposed to 200 mg barium/kg/day.  A 
statistically significant increase in relative kidney weight was also observed in the females exposed to 
65 mg barium/kg/day; however, the increase was small (7%) and was not considered biologically 
significant. At 200 and 180 mg barium/kg/day, minimal to mild dilatation of the proximal renal cortex 
was observed in the males and females, respectively; an increase in mortality (30%) was also observed in 
the males exposed to 200 mg barium/kg/day.  In mice, mild to moderate nephropathy (characterized as 
tubule dilatation, regeneration, and atrophy) was observed in 100% of the males exposed to 450 mg 
barium/kg/day and 90% of the females exposed to 495 mg barium/kg/day; no renal lesions were observed 
at the next lowest dose level (205 and 200 mg barium/kg/day in males and females, respectively).  Other 
effects observed at the 450/495 mg barium/kg/day dose level included weight loss, spleen and thymus 
atrophy, and increased mortality (60% of the males and 70% of females died after 5 weeks of exposure).   
Other end points that have been examined in rats and mice include neurotoxicity, reproductive toxicity, 
and developmental toxicity. In male and female rats, slight decreases in undifferentiated motor activity 
were observed at 10 mg barium/kg/day and higher.  However, with the exception of female rats exposed 
to 200 mg barium/kg/day, the difference between motor activity in the barium-exposed rats and the 
controls was less than 20%; this was not considered to be biologically significant.  At 200 mg 
barium/kg/day, the difference was 30%, which was considered to be adverse.  No significant alterations 
were found in performance on the remaining neurobehavioral tests (grip strength, tail flick latency, startle 
response, and hindlimb foot splay).  In mice, a significant decrease in forelimb grip strength was observed 
in females exposed to 495 mg barium/kg/day; this may have been due to debilitation.  No other alterations 
in neurobehavioral performance were found.  No effects on reproductive tissues or reproductive 
performance were observed in rats or mice exposed to approximately 200 mg barium/kg/day (Dietz et al. 
1992; NTP 1994).  Pre-mating exposure to 180/200 mg barium/kg/day resulted in decreased litter size and 
body weight in rat offspring; the NOAEL for these effects was 110/115 mg barium/kg/day (Dietz et al. 
1992).  No developmental effects were observed in mice exposed to 200 mg barium/kg/day (Dietz et al. 
1992). 
Agency Contacts (Chemical Managers):  Cassandra Smith and Yee-Wan Stevens 
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MINIMAL RISK LEVEL (MRL) WORKSHEET 
Chemical Name: Barium, Soluble Salts 
CAS Numbers: 
Date:   August 2007 
Profile Status: Final 
Route: [ ] Inhalation  [X] Oral 
Duration: [ ] Acute  [ ] Intermediate  [X] Chronic 
Graph Key: 49 
Species: Mouse 
Minimal Risk Level: 0.2 [X] mg barium/kg/day   [ ] ppm 
Reference: NTP. 1994.  Toxicology and carcinogenesis studies of barium chloride dihydrate (CAS No. 
10326-27-9) in F344/N rats and B6C3F1 mice (drinking water studies).  U.S. Department of Health and 
Human Services, Public Health Service, National Institutes of Health, National Toxicology Program, 
Research Triangle Park, NC. NTP TR 432. 
Experimental design: Groups of 60 male and 60 female B6C3F1 mice were administered 0, 500, 1,250, 
or 2,500 ppm barium chloride dehydrate in drinking water for 2 years.  Using measured body weights and 
water consumption, the investigators estimated the daily barium doses to be 0, 30, 75, and 160 mg 
barium/kg/day for males and 0, 40, 90, and 200 mg barium/kg/day for females.  Organ weights, blood 
analysis for hematological and clinical chemistry (barium, sodium, potassium, calcium, and phosphorus 
levels, and alanine aminotransferase, creatine kinase, lactate dehydrogenase, and gamma­
glutamyltransferase activities) alterations (measured after 15 months), and histological examination of 
major tissues and organs were conducted at termination.   
Effect noted in study and corresponding doses: Increased mortality attributed to renal lesions was 
observed in the 160/200 mg/kg/day group.  Decreased body weights (<7%) were observed in the barium-
exposed mice.  The investigators noted that a moderate to marked weight loss was observed in animals 
dying early. No significant alterations in hematology or clinical chemistry parameters were observed.  A 
significant increase in the incidence of nephropathy was observed in male and female mice exposed to 
160/200 mg/kg/day.  The nephropathy was characterized by extensive regeneration of cortical and 
medullary tubule epithelium, tubule dilatation, hyaline cast formation, multifocal interstitial fibrosis, and 
glomerulosclerosis in some kidneys.  The incidence of nephropathy was 1/50, 0/50, 2/48, and 19/50 in the 
males and 0/50, 2/53, 1/50, and 37/50 in the females, respectively.  The average severity of the 
nephropathy was 3.6 (moderate to marked) for both the males and females in the 160/200 mg/kg/day 
group.  An increased incidence of lymphoid depletion in the spleen and decreased relative and absolute 
spleen were also observed in the 160/200 mg/kg/day group; however, this was attributed to debilitation 
associated with nephropathy rather than a direct effect on the spleen.  No significant increases in the 
incidences of neoplasms were observed. 
Dose and end point used for MRL derivation: Benchmark dose analysis of the dose-response data 
(Table A-1) for nephropathy in male and female mice exposed to barium chloride in drinking water for 
2 years (NTP 1994) was conducted.  EPA’s Benchmark Dose Software (version 1.3.2) was used to fit 
nine mathematical models to the incidence data.  Model fit was judged by the p-values associated with the 
chi-square goodness-of-fit statistic generated by the models and visual inspection of the plot of observed 
and predicted values. As assessed by the chi-square goodness-of-fit test, several models in the software 
provided adequate fits to the data for the incidence of nephropathy in male and female mice (x2 p-value 
≥0.1). As assessed by lowest Akaike Information Criterion (AIC), the logistic model for the male mouse 
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data and the gamma model for the female mouse data provide the greatest fit.  The results of the 
benchmark dose analysis are presented in Table A-2. 
Table A-1. Incidence of Nephropathy in Male and Female Mice Exposed to 
Barium Chloride in Drinking Water for 2 Years (NTP 1994) 
Water concentration Dose 
(ppm) (mg barium/kg/day) Incidence 
Males 
0 0 1/50 
500 30 0/50 
1,250 75 2/48 
2,500 160 19/50 
Females 
0 0 0/50 
500 40 2/53 
1,250 90 1/50 
2,500 200 37/50 
Table A-2. Predictions from Models for Doses Associated with 10 and 5% Extra 
Risk for the Incidence of Nephropathy in Male and Female Mice Exposed to 
Barium in Drinking Water for 2 Years (NTP 1994) 
BMD10 BMDL10 BMD5 BMDL5 
Model mg/kg/day mg/kg/day mg/kg/day mg/kg/day x2 p-value AIC 
Male mice 
Logistic 103.96 87.26 80.06 61.13 0.28 99.34 
Probit 96.13 80.07 71.96 54.66 0.13 100.11 
Log-probita 99.73 77.90 83.39 59.54 0.31 100.25 
Gammab 102.31 80.06 84.94 59.65 0.31 100.28 
 Log-logistica 104.44 80.50 86.43 59.69 0.31 100.32 
 Weibullb 106.59 81.79 87.63 59.54 0.31 100.35 
 Quantal quadratic 82.83 69.51 57.80 48.5 0.14 101.89 
Multi-stagec 82.83 69.14 57.80 44.97 0.14 101.89 
 Quantal linear NA NA NA NA 0.0032 111.94 
Female mice 
Gammab 125.59 101.49 113.96 87.66 0.34 90.89 
Log-probita 134.85 100.63 125.10 88.39 0.17 92.84 
 Log-logistica 147.43 101.75 137.35 87.01 0.17 92.84 
 Weibullb 153.60 102.66 142.51 84.95 0.17 92.84 
 Logistic NA NA NA NA 0.08 92.35 
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Table A-2. Predictions from Models for Doses Associated with 10 and 5% Extra 
Risk for the Incidence of Nephropathy in Male and Female Mice Exposed to 
Barium in Drinking Water for 2 Years (NTP 1994) 
BMD10 BMDL10 BMD5 BMDL5 
Model mg/kg/day mg/kg/day mg/kg/day mg/kg/day x2 p-value AIC 
Probit NA NA NA NA 0.03 94.03 
 Quantal quadratic NA NA NA NA 0.01 102.21 
Multi-stagec NA NA NA NA 0.01 102.21 
 Quantal linear NA NA NA NA 0.00 126.61 
aslope restricted to >1
brestrict power ≥1 
crestrict betas ≥0 
degree of polynomial = 2; NA = not applicable 
The BMDL05 for male mice was selected as the point of departure for deriving the chronic-duration oral 
MRL. Data from the male mice were used because they identify a lower BMDL than the female data.  
The predicted 5% incidence approach was selected over the other two approaches as a precaution due to 
the severity of the observed effects (moderate to marked severity nephropathy), which resulted in marked 
weight loss and increased mortality.   
[ ] NOAEL   [ ] LOAEL   [X] BMDL 
Uncertainty Factors used in MRL derivation: 300 
[ ]  10 for use of a LOAEL 
[X]  10 for extrapolation from animals to humans 
[X]  10 for human variability 
Modifying Factor used in MRL derivation: 3 
[X]  3 for database deficiences 
A modifying factor of 3 was included to account for deficiencies in the oral toxicity database, particularly 
the need for an additional developmental toxicity study.  Decreases in pup birth weight and a 
nonstatistically significant decrease in live litter size were observed in the offspring of rats exposed to 
180/200 mg Ba/kg/day as barium chloride in drinking water prior to mating (Dietz et al. 1992).  Maternal 
body weight gain and water consumption were not reported, thus it is not known if the decreases in pup 
body weight were secondary to maternal toxicity or direct effect on the fetus.  No developmental effects 
were observed in mice at the highest dose tested (200 mg Ba/kg/day) (Dietz et al. 1992).  One other study 
examined the potential for developmental toxicity in orally exposed animals (Tarasenko et al. 1977). 
However, because the study was poorly reported and no incidence data or statistical analysis were 
presented in the published paper, the reported findings of increased mortality and systemic toxicity in the 
offspring of an unspecified species orally exposed to barium during conception and pregnancy can not be 
adequately evaluated.  The Dietz et al. (1992) study was designed to be a mating trial and did not expose 
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the animals during gestation; thus, database is lacking an adequate study to evaluate the potential for 
barium to induce developmental effects.  
Was a conversion factor used from ppm in food or water to a mg/body weight dose?  No. Doses were 
calculated by the investigators using measured drinking water consumption and body weight data. 
Was a conversion used from intermittent to continuous exposure? Not applicable. 
Other additional studies or pertinent information that lend support to this MRL: Several studies have 
examined the toxicity of barium following chronic-duration exposure.  Significant increases in blood 
pressure were observed in rats exposed to 0.8 mg barium/kg/day as barium chloride in drinking water for 
16 months (Perry et al. 1983, 1985, 1989); the NOAEL for this effect was 0.17 mg barium/kg/day.  At 
higher doses (7.2 mg barium/kg/day), depressed rates of cardiac contraction, reduced cardiac electrical 
conductivity, and decreased cardiac ATP levels were observed.  As noted in the discussion of the 
intermediate-duration oral MRL, interpretation of the results of this study is limited due to the low 
mineral diet which may have supplied inadequate levels of calcium.   
No adverse effects were observed in rats exposed to 60 mg barium/kg/day as barium chloride in drinking 
water for 2 years (NTP 1994), 15 mg barium/kg/day to an unspecified barium compound in drinking 
water for 68 weeks (McCauley et al. 1985), or 0.7 mg barium/kg/day as barium acetate in drinking water 
for a lifetime (Schroeder and Mitchener 1975a).  In mice exposed to barium chloride in drinking water for 
2 years, marked renal nephropathy was observed at 160 mg barium/kg/day; the increased incidence of 
nephropathy in the next lowest dose group (75 mg barium/kg/day) was not statistically significant.  Other 
adverse effects observed at 160 mg barium/kg/day included weight loss and increased mortality. 
The animal data provide suggestive evidence that the kidney is the most sensitive target of toxicity.  A 
serious LOAEL of 160 mg barium/kg/day was identified for nephropathy in mice (NTP 1994); the 
NOAEL identified in this study is 75 mg/kg/day. Although no kidney lesions were observed in rats 
exposed to doses as high as 60 mg barium/kg/day (NTP 1994), the doses utilized in the study may not 
have been high enough to cause kidney damage.  Biologically significant kidney alterations were 
observed at 115 mg barium/kg/day and higher in rats exposed for an intermediate duration (NTP 1994). 
Agency Contacts (Chemical Managers):  Cassandra Smith and Yee-Wan Stevens  
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APPENDIX B.  USER'S GUIDE 
Chapter 1 
Public Health Statement 
This chapter of the profile is a health effects summary written in non-technical language.  Its intended 
audience is the general public, especially people living in the vicinity of a hazardous waste site or 
chemical release.  If the Public Health Statement were removed from the rest of the document, it would 
still communicate to the lay public essential information about the chemical. 
The major headings in the Public Health Statement are useful to find specific topics of concern.  The 
topics are written in a question and answer format.  The answer to each question includes a sentence that 
will direct the reader to chapters in the profile that will provide more information on the given topic. 
Chapter 2 
Relevance to Public Health 
This chapter provides a health effects summary based on evaluations of existing toxicologic, 
epidemiologic, and toxicokinetic information.  This summary is designed to present interpretive, weight­
of-evidence discussions for human health end points by addressing the following questions: 
1.  What effects are known to occur in humans? 
2. What effects observed in animals are likely to be of concern to humans? 
3. What exposure conditions are likely to be of concern to humans, especially around hazardous 
waste sites? 
The chapter covers end points in the same order that they appear within the Discussion of Health Effects 
by Route of Exposure section, by route (inhalation, oral, and dermal) and within route by effect.  Human 
data are presented first, then animal data.  Both are organized by duration (acute, intermediate, chronic).  
In vitro data and data from parenteral routes (intramuscular, intravenous, subcutaneous, etc.) are also 
considered in this chapter. 
The carcinogenic potential of the profiled substance is qualitatively evaluated, when appropriate, using 
existing toxicokinetic, genotoxic, and carcinogenic data.  ATSDR does not currently assess cancer 
potency or perform cancer risk assessments.  Minimal Risk Levels (MRLs) for noncancer end points (if 
derived) and the end points from which they were derived are indicated and discussed. 
Limitations to existing scientific literature that prevent a satisfactory evaluation of the relevance to public 
health are identified in the Chapter 3 Data Needs section. 
Interpretation of Minimal Risk Levels 
Where sufficient toxicologic information is available, ATSDR has derived MRLs for inhalation and oral 
routes of entry at each duration of exposure (acute, intermediate, and chronic).  These MRLs are not 
meant to support regulatory action, but to acquaint health professionals with exposure levels at which 
adverse health effects are not expected to occur in humans. 
B-2 BARIUM AND BARIUM COMPOUNDS 
APPENDIX B 
MRLs should help physicians and public health officials determine the safety of a community living near 
a chemical emission, given the concentration of a contaminant in air or the estimated daily dose in water.  
MRLs are based largely on toxicological studies in animals and on reports of human occupational 
exposure. 
MRL users should be familiar with the toxicologic information on which the number is based.  Chapter 2, 
"Relevance to Public Health," contains basic information known about the substance.  Other sections such 
as Chapter 3 Section 3.9, "Interactions with Other Substances,” and Section 3.10, "Populations that are 
Unusually Susceptible" provide important supplemental information. 
MRL users should also understand the MRL derivation methodology.  MRLs are derived using a 
modified version of the risk assessment methodology that the Environmental Protection Agency (EPA) 
provides (Barnes and Dourson 1988) to determine reference doses (RfDs) for lifetime exposure.   
To derive an MRL, ATSDR generally selects the most sensitive end point which, in its best judgement, 
represents the most sensitive human health effect for a given exposure route and duration.  ATSDR 
cannot make this judgement or derive an MRL unless information (quantitative or qualitative) is available 
for all potential systemic, neurological, and developmental effects.  If this information and reliable 
quantitative data on the chosen end point are available, ATSDR derives an MRL using the most sensitive 
species (when information from multiple species is available) with the highest no-observed-adverse-effect 
level (NOAEL) that does not exceed any adverse effect levels.  When a NOAEL is not available, a 
lowest-observed-adverse-effect level (LOAEL) can be used to derive an MRL, and an uncertainty factor 
(UF) of 10 must be employed.  Additional uncertainty factors of 10 must be used both for human 
variability to protect sensitive subpopulations (people who are most susceptible to the health effects 
caused by the substance) and for interspecies variability (extrapolation from animals to humans).  In 
deriving an MRL, these individual uncertainty factors are multiplied together.  The product is then 
divided into the inhalation concentration or oral dosage selected from the study. Uncertainty factors used 
in developing a substance-specific MRL are provided in the footnotes of the levels of significant exposure 
(LSE) tables. 
Chapter 3 
Health Effects 
Tables and Figures for Levels of Significant Exposure (LSE) 
Tables and figures are used to summarize health effects and illustrate graphically levels of exposure 
associated with those effects.  These levels cover health effects observed at increasing dose 
concentrations and durations, differences in response by species, MRLs to humans for noncancer end 
points, and EPA's estimated range associated with an upper- bound individual lifetime cancer risk of 1 in 
10,000 to 1 in 10,000,000. Use the LSE tables and figures for a quick review of the health effects and to 
locate data for a specific exposure scenario.  The LSE tables and figures should always be used in 
conjunction with the text.  All entries in these tables and figures represent studies that provide reliable, 
quantitative estimates of NOAELs, LOAELs, or Cancer Effect Levels (CELs). 
The legends presented below demonstrate the application of these tables and figures.  Representative 
examples of LSE Table 3-1 and Figure 3-1 are shown.  The numbers in the left column of the legends 
correspond to the numbers in the example table and figure. 
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LEGEND 
See Sample LSE Table 3-1 (page B-6) 
(1) Route of Exposure. One of the first considerations when reviewing the toxicity of a substance 
using these tables and figures should be the relevant and appropriate route of exposure.  Typically 
when sufficient data exist, three LSE tables and two LSE figures are presented in the document.  
The three LSE tables present data on the three principal routes of exposure, i.e., inhalation, oral, 
and dermal (LSE Tables 3-1, 3-2, and 3-3, respectively).  LSE figures are limited to the inhalation 
(LSE Figure 3-1) and oral (LSE Figure 3-2) routes.  Not all substances will have data on each 
route of exposure and will not, therefore, have all five of the tables and figures. 
(2) Exposure Period. Three exposure periods—acute (less than 15 days), intermediate (15– 
364 days), and chronic (365 days or more)—are presented within each relevant route of exposure.  
In this example, an inhalation study of intermediate exposure duration is reported.  For quick 
reference to health effects occurring from a known length of exposure, locate the applicable 
exposure period within the LSE table and figure. 
(3) Health Effect. The major categories of health effects included in LSE tables and figures are 
death, systemic, immunological, neurological, developmental, reproductive, and cancer.  
NOAELs and LOAELs can be reported in the tables and figures for all effects but cancer.  
Systemic effects are further defined in the "System" column of the LSE table (see key number 
18). 
(4) Key to Figure. Each key number in the LSE table links study information to one or more data 
points using the same key number in the corresponding LSE figure.  In this example, the study 
represented by key number 18 has been used to derive a NOAEL and a Less Serious LOAEL 
(also see the two "18r" data points in sample Figure 3-1). 
(5) Species. The test species, whether animal or human, are identified in this column.  Chapter 2, 
"Relevance to Public Health," covers the relevance of animal data to human toxicity and 
Section 3.4, "Toxicokinetics," contains any available information on comparative toxicokinetics.  
Although NOAELs and LOAELs are species specific, the levels are extrapolated to equivalent 
human doses to derive an MRL. 
(6) Exposure Frequency/Duration. The duration of the study and the weekly and daily exposure 
regimens are provided in this column.  This permits comparison of NOAELs and LOAELs from 
different studies. In this case (key number 18), rats were exposed to “Chemical x” via inhalation 
for 6 hours/day, 5 days/week, for 13 weeks.  For a more complete review of the dosing regimen, 
refer to the appropriate sections of the text or the original reference paper (i.e., Nitschke et al. 
1981). 
(7) System. This column further defines the systemic effects.  These systems include respiratory, 
cardiovascular, gastrointestinal, hematological, musculoskeletal, hepatic, renal, and 
dermal/ocular.  "Other" refers to any systemic effect (e.g., a decrease in body weight) not covered 
in these systems.  In the example of key number 18, one systemic effect (respiratory) was 
investigated. 
(8) NOAEL. A NOAEL is the highest exposure level at which no harmful effects were seen in the 
organ system studied.  Key number 18 reports a NOAEL of 3 ppm for the respiratory system, 
which was used to derive an intermediate exposure, inhalation MRL of 0.005 ppm (see 
footnote "b"). 
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(9) LOAEL. A LOAEL is the lowest dose used in the study that caused a harmful health effect. 
LOAELs have been classified into "Less Serious" and "Serious" effects.  These distinctions help 
readers identify the levels of exposure at which adverse health effects first appear and the 
gradation of effects with increasing dose.  A brief description of the specific end point used to 
quantify the adverse effect accompanies the LOAEL.  The respiratory effect reported in key 
number 18 (hyperplasia) is a Less Serious LOAEL of 10 ppm.  MRLs are not derived from 
Serious LOAELs. 
(10) Reference. The complete reference citation is given in Chapter 9 of the profile. 
(11) CEL. A CEL is the lowest exposure level associated with the onset of carcinogenesis in 
experimental or epidemiologic studies.  CELs are always considered serious effects.  The LSE 
tables and figures do not contain NOAELs for cancer, but the text may report doses not causing 
measurable cancer increases. 
(12) Footnotes. Explanations of abbreviations or reference notes for data in the LSE tables are found 
in the footnotes.  Footnote "b" indicates that the NOAEL of 3 ppm in key number 18 was used to 
derive an MRL of 0.005 ppm. 
LEGEND 
See Sample Figure 3-1 (page B-7) 
LSE figures graphically illustrate the data presented in the corresponding LSE tables.  Figures help the 
reader quickly compare health effects according to exposure concentrations for particular exposure 
periods. 
(13) Exposure Period. The same exposure periods appear as in the LSE table.  In this example, health 
effects observed within the acute and intermediate exposure periods are illustrated. 
(14) Health Effect. These are the categories of health effects for which reliable quantitative data 
exists. The same health effects appear in the LSE table. 
(15)  Levels of Exposure. Concentrations or doses for each health effect in the LSE tables are 
graphically displayed in the LSE figures.  Exposure concentration or dose is measured on the log 
scale "y" axis.  Inhalation exposure is reported in mg/m3 or ppm and oral exposure is reported in 
mg/kg/day. 
(16) NOAEL. In this example, the open circle designated 18r identifies a NOAEL critical end point in 
the rat upon which an intermediate inhalation exposure MRL is based.  The key number 18 
corresponds to the entry in the LSE table.  The dashed descending arrow indicates the 
extrapolation from the exposure level of 3 ppm (see entry 18 in the table) to the MRL of 
0.005 ppm (see footnote "b" in the LSE table). 
(17) CEL. Key number 38m is one of three studies for which CELs were derived.  The diamond 
symbol refers to a CEL for the test species-mouse.  The number 38 corresponds to the entry in the 
LSE table. 
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(18)  Estimated Upper-Bound Human Cancer Risk Levels. This is the range associated with the upper-
bound for lifetime cancer risk of 1 in 10,000 to 1 in 10,000,000.  These risk levels are derived 
from the EPA's Human Health Assessment Group's upper-bound estimates of the slope of the 
cancer dose response curve at low dose levels (q1*). 
(19)  Key to LSE Figure. The Key explains the abbreviations and symbols used in the figure. 
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1 →  Table 3-1. Levels of Significant Exposure to [Chemical x] – Inhalation 
LOAEL (effect) Exposure 
Key to 	 frequency/ NOAEL Less serious Serious (ppm) 
figurea Species duration System (ppm) (ppm) 	 Reference 
2 → INTERMEDIATE EXPOSURE 

5 
→ Systemic ↓ 
18 Rat 
→ 
CHRONIC EXPOSURE 
Cancer 
38 Rat 
39 Rat 
40 Mouse 
6
 
↓ 
13 wk 
5 d/wk 
6 hr/d 
18 mo 
5 d/wk 
7 hr/d 
89–104 wk 
5 d/wk 
6 hr/d 
79–103 wk 
5 d/wk 
6 hr/d 
7 8 9 
↓ ↓ ↓ 
3bResp 	 10 (hyperplasia) 
11 
↓ 
20 	 (CEL, multiple 
organs) 
10 	 (CEL, lung tumors, 
nasal tumors) 
10 	 (CEL, lung tumors, 
hemangiosarcomas) 
10 
↓ 
Nitschke et al. 1981 
Wong et al. 1982 
NTP 1982 
NTP 1982 
12 →  a The number corresponds to entries in Figure 3-1. 
b Used to derive an intermediate inhalation Minimal Risk Level (MRL) of  5x10-3 ppm; dose adjusted for intermittent exposure and divided 
by an uncertainty factor of 100 (10 for extrapolation from animal to humans, 10 for human variability). 
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C-1 BARIUM AND BARIUM COMPOUNDS 
APPENDIX C.  ACRONYMS, ABBREVIATIONS, AND SYMBOLS 
ACGIH American Conference of Governmental Industrial Hygienists 
ACOEM American College of Occupational and Environmental Medicine 
ADI acceptable daily intake 
ADME absorption, distribution, metabolism, and excretion 
AED atomic emission detection 
AFID alkali flame ionization detector 
AFOSH Air Force Office of Safety and Health 
ALT alanine aminotransferase 
AML acute myeloid leukemia 
AOAC Association of Official Analytical Chemists 
AOEC Association of Occupational and Environmental Clinics 
AP alkaline phosphatase 
APHA American Public Health Association 
AST aspartate aminotransferase 
atm atmosphere 
ATSDR Agency for Toxic Substances and Disease Registry 
AWQC Ambient Water Quality Criteria 
BAT best available technology 
BCF bioconcentration factor 
BEI Biological Exposure Index 
BMD benchmark dose 
BMR benchmark response 
BSC Board of Scientific Counselors 
C centigrade 
CAA Clean Air Act 
CAG Cancer Assessment Group of the U.S. Environmental Protection Agency 
CAS Chemical Abstract Services 
CDC Centers for Disease Control and Prevention 
CEL cancer effect level 
CELDS Computer-Environmental Legislative Data System 
CERCLA Comprehensive Environmental Response, Compensation, and Liability Act 
CFR Code of Federal Regulations 
Ci curie 
CI confidence interval 
CL ceiling limit value 
CLP Contract Laboratory Program 
cm centimeter 
CML chronic myeloid leukemia 
CPSC Consumer Products Safety Commission 
CWA Clean Water Act 
DHEW Department of Health, Education, and Welfare 
DHHS Department of Health and Human Services 
DNA deoxyribonucleic acid 
DOD Department of Defense 
DOE Department of Energy 
DOL Department of Labor 
DOT Department of Transportation 
DOT/UN/ Department of Transportation/United Nations/ 
NA/IMCO     North America/Intergovernmental Maritime Dangerous Goods Code 
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DWEL drinking water exposure level 
ECD electron capture detection 
ECG/EKG electrocardiogram 
EEG electroencephalogram 
EEGL Emergency Exposure Guidance Level 
EPA Environmental Protection Agency 
F Fahrenheit 
F1 first-filial generation 
FAO Food and Agricultural Organization of the United Nations 
FDA Food and Drug Administration 
FEMA Federal Emergency Management Agency 
FIFRA Federal Insecticide, Fungicide, and Rodenticide Act 
FPD flame photometric detection 
fpm feet per minute 
FR Federal Register 
FSH follicle stimulating hormone 
g gram 
GC gas chromatography 
gd gestational day 
GLC gas liquid chromatography 
GPC gel permeation chromatography 
HPLC high-performance liquid chromatography 
HRGC high resolution gas chromatography 
HSDB Hazardous Substance Data Bank  
IARC International Agency for Research on Cancer 
IDLH immediately dangerous to life and health 
ILO International Labor Organization 
IRIS Integrated Risk Information System 
Kd adsorption ratio 
kg kilogram 
kkg metric ton 
Koc organic carbon partition coefficient 
Kow octanol-water partition coefficient 
L liter 
LC liquid chromatography 
LC50 lethal concentration, 50% kill 
LCLo lethal concentration, low 
LD50 lethal dose, 50% kill 
LDLo lethal dose, low 
LDH lactic dehydrogenase 
LH luteinizing hormone 
LOAEL lowest-observed-adverse-effect level 
LSE Levels of Significant Exposure 
LT50 lethal time, 50% kill 
m meter 
MA trans,trans-muconic acid 
MAL maximum allowable level 
mCi millicurie 
MCL maximum contaminant level 
MCLG maximum contaminant level goal 
MF modifying factor 
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MFO mixed function oxidase 
mg milligram 
mL milliliter 
mm millimeter 
mmHg millimeters of mercury 
mmol millimole 
mppcf millions of particles per cubic foot 
MRL Minimal Risk Level 
MS mass spectrometry 
NAAQS National Ambient Air Quality Standard 
NAS National Academy of Science 
NATICH National Air Toxics Information Clearinghouse 
NATO North Atlantic Treaty Organization 
NCE normochromatic erythrocytes 
NCEH National Center for Environmental Health 
NCI National Cancer Institute 
ND not detected 
NFPA National Fire Protection Association 
ng nanogram 
NHANES National Health and Nutrition Examination Survey 
NIEHS National Institute of Environmental Health Sciences 
NIOSH National Institute for Occupational Safety and Health 
NIOSHTIC NIOSH's Computerized Information Retrieval System 
NLM National Library of Medicine 
nm nanometer 
nmol nanomole 
NOAEL no-observed-adverse-effect level 
NOES National Occupational Exposure Survey 
NOHS National Occupational Hazard Survey 
NPD nitrogen phosphorus detection 
NPDES National Pollutant Discharge Elimination System 
NPL National Priorities List 
NR not reported 
NRC National Research Council 
NS not specified 
NSPS New Source Performance Standards 
NTIS National Technical Information Service 
NTP National Toxicology Program 
ODW Office of Drinking Water, EPA 
OERR Office of Emergency and Remedial Response, EPA 
OHM/TADS Oil and Hazardous Materials/Technical Assistance Data System 
OPP Office of Pesticide Programs, EPA 
OPPT Office of Pollution Prevention and Toxics, EPA 
OPPTS Office of Prevention, Pesticides and Toxic Substances, EPA 
OR odds ratio 
OSHA Occupational Safety and Health Administration 
OSW Office of Solid Waste, EPA 
OTS Office of Toxic Substances 
OW Office of Water 
OWRS Office of Water Regulations and Standards, EPA 
PAH polycyclic aromatic hydrocarbon 
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PBPD physiologically based pharmacodynamic  
PBPK physiologically based pharmacokinetic 
PCE polychromatic erythrocytes 
PEL permissible exposure limit 
pg picogram 
PHS Public Health Service 
PID photo ionization detector 
pmol picomole 
PMR proportionate mortality ratio 
ppb parts per billion 
ppm parts per million 
ppt parts per trillion 
PSNS pretreatment standards for new sources 
RBC red blood cell 
REL recommended exposure level/limit 
RfC reference concentration 
RfD reference dose 
RNA ribonucleic acid 
RQ reportable quantity 
RTECS Registry of Toxic Effects of Chemical Substances 
SARA Superfund Amendments and Reauthorization Act 
SCE sister chromatid exchange 
SGOT serum glutamic oxaloacetic transaminase 
SGPT serum glutamic pyruvic transaminase 
SIC standard industrial classification 
SIM selected ion monitoring 
SMCL secondary maximum contaminant level 
SMR standardized mortality ratio 
SNARL suggested no adverse response level 
SPEGL Short-Term Public Emergency Guidance Level 
STEL short term exposure limit 
STORET Storage and Retrieval 
TD50 toxic dose, 50% specific toxic effect 
TLV threshold limit value 
TOC total organic carbon 
TPQ threshold planning quantity 
TRI Toxics Release Inventory 
TSCA Toxic Substances Control Act 
TWA time-weighted average 
UF uncertainty factor 
U.S. United States 
USDA United States Department of Agriculture 
USGS United States Geological Survey 
VOC volatile organic compound 
WBC white blood cell 
WHO World Health Organization 
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> greater than 
≥ greater than or equal to 
= equal to 
< less than 
≤ less than or equal to 
% percent 
α alpha 
β beta 
γ gamma 
δ delta 
μm micrometer 
μg microgram 
q1 * cancer slope factor 
– negative 
+ positive 
(+) weakly positive result 
(–) weakly negative result 
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D-1 BARIUM AND BARIUM COMPOUNDS 
APPENDIX D.  INDEX 
absorbed dose.............................................................................................................................................. 72 
adsorbed .................................................................................................................................................... 119 
adsorption.......................................................................................................................................... 107, 117 
aerobic....................................................................................................................................................... 127 
ambient air ............................................................................................ 9, 120, 128, 129, 131, 134, 136, 137 
anaerobic ................................................................................................................................................... 127 
atropine ....................................................................................................................................................... 74 
bioavailability ........................................................................................................................................... 136 
bioconcentration factor ............................................................................................................................. 117 
biomarker .................................................................................................................. 71, 72, 73, 86, 141, 147  
body weight effects ......................................................................................................................... 25, 52, 57 
breast milk................................................................................................................................. 132, 134, 138 
cancer ............................................................................................................ 4, 5, 10, 26, 56, 58, 70, 83, 149 
carcinogen ............................................................................................................................. 11, 83, 149, 151 
carcinogenic .................................................................................................................. 6, 11, 12, 21, 56, 149 
carcinogenicity.................................................................................................................... 5, 11, 56, 83, 151 
carcinomas .................................................................................................................................................. 59 
cardiovascular ........................................................................... 10, 14, 17, 27, 48, 57, 73, 74, 75, 81, 82, 85 
cardiovascular effects................................................................................................................ 24, 28, 57, 82 
cation exchange capacity .................................................................................................. 107, 117, 119, 136 
clearance ..................................................................................................................................................... 61 
death.................................................................................................................. 10, 21, 23, 27, 28, 57, 74, 85  
deoxyribonucleic acid (see DNA)............................................................................................................... 59 
dermal effects.................................................................................................................................. 52, 57, 58 
DNA (see deoxyribonucleic acid)............................................................................................. 59, 60, 72, 83 
drinking water ........................ 1, 3, 6, 7, 9, 10, 11, 14, 15, 16, 17, 18, 26, 27, 28, 48, 49, 50, 51, 52, 53, 54, 
55, 56, 63, 76, 79, 82, 84, 85, 107, 115, 121, 122, 128, 129, 134, 137, 151 
endocrine................................................................................................................................... 23, 57, 68, 69 
fetus....................................................................................................................................................... 69, 84 
fractional absorption ................................................................................................................................... 62 
gastrointestinal effects ........................................................................................................ 10, 24, 49, 57, 80  
general population....................................................................................... 9, 71, 75, 76, 107, 129, 134, 137 
genotoxic............................................................................................................................................... 21, 83 
genotoxicity........................................................................................................................................... 59, 83 
groundwater .......................................................................................... 9, 107, 115, 117, 122, 134, 136, 137 
half-life........................................................................................................................................................ 71 
hematological effects ............................................................................................................................ 24, 49 
hepatic effects ....................................................................................................................................... 24, 50 
hypokalemia.......................................................................................... 10, 28, 50, 68, 73, 74, 77, 80, 86, 87 
immune system ........................................................................................................................................... 84 
immunological .......................................................................................................................... 21, 25, 53, 84 
immunological effects..................................................................................................................... 25, 53, 84 
LD50........................................................................................................................................... 27, 28, 55, 80 
leukemia...................................................................................................................................................... 56 
lymphoreticular ..................................................................................................................................... 53, 84 
Metabolic Effects ............................................................................................................................ 25, 52, 58 
milk ........................................................................................................................................... 127, 134, 138 
musculoskeletal effects ................................................................................................................... 24, 49, 50 
neoplastic .................................................................................................................................................... 83 
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neurobehavioral............................................................................................................................... 15, 69, 85 
nuclear....................................................................................................................................................... 143 
ocular effects......................................................................................................................................... 23, 52 
particulate.......................................................................................... 107, 114, 116, 118, 119, 120, 121, 134 
particulate emissions......................................................................................................................... 114, 121 
pharmacodynamic ....................................................................................................................................... 65 
pharmacokinetic.................................................................................................................. 64, 65, 67, 70, 74 
renal effects............................................................................................................................... 10, 25, 50, 68 
retention ............................................................................................................................ 61, 63, 71, 74, 119 
sequestered.................................................................................................................................................. 72 
serum glutamic-oxaloacetic transaminase (see SGOT) .............................................................................. 50 
serum glutamic pyruvic transaminase (see SGPT) ..................................................................................... 50 
SGOT (see serum glutamic-oxaloacetic transaminase) .............................................................................. 50 
SGPT (see serum glutamic pyruvic transaminase) ..................................................................................... 50 
solubility ................................................................................................................... 9, 61, 89, 118, 119, 120 
surface water ................................................................. 3, 107, 115, 117, 118, 120, 121, 122, 135, 136, 137  
toxicokinetic............................................................................................................ 21, 71, 72, 82, 84, 87, 88 
tumors ................................................................................................................................................... 56, 58 
vapor pressure ............................................................................................................................................. 95 
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